<SEC-DOCUMENT>0001019687-14-002759.txt : 20140717
<SEC-HEADER>0001019687-14-002759.hdr.sgml : 20140717
<ACCEPTANCE-DATETIME>20140717163320
ACCESSION NUMBER:		0001019687-14-002759
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20140717
DATE AS OF CHANGE:		20140717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oculus Innovative Sciences, Inc.
		CENTRAL INDEX KEY:			0001367083
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680423298
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-195554
		FILM NUMBER:		14980685

	BUSINESS ADDRESS:	
		STREET 1:		1129 N. MCDOWELL BLVD.
		CITY:			PETALUMA
		STATE:			CA
		ZIP:			94954
		BUSINESS PHONE:		707-782-0792

	MAIL ADDRESS:	
		STREET 1:		1129 N. MCDOWELL BLVD.
		CITY:			PETALUMA
		STATE:			CA
		ZIP:			94954
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>oculus_s3a2.htm
<DESCRIPTION>FORM S-3 AMENDMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on July 17 , 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No.&nbsp; 333-195554</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington,&nbsp;D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Amendment No. 2 to the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Exact Name of Registrant as Specified in
Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>68-0423298</b></font></td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(State or Other Jurisdiction of</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Incorporation or Organization)</i></P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(I.R.S. Employer</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Identification Number)</i></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1129&nbsp;N.&nbsp;McDowell Blvd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Petaluma, California 94954</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(707)&nbsp;283-0550</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jim Schutz</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1129&nbsp;N.&nbsp;McDowell Blvd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Petaluma, California 94954</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(707)&nbsp;283-0550</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Name, Address, Including Zip Code, and Telephone
Number, Including Area Code, of Agent for Service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amy Trombly, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Trombly Business Law, PC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1434 Spruce Street, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Boulder, CO 80302 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(617)&nbsp;243-0060</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Approximate date of commencement of proposed
sale to the public</I><B>:</B>&nbsp;&nbsp;From time to time after this registration statement becomes effective, as determined
by market conditions and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the only securities being registered on
this Form are being offered pursuant to dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other
than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a registration statement pursuant
to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. to register additional securities or additional classes
of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule&nbsp;12b-2
of the Exchange Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 44%; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Large accelerated filer</font></td>
    <td style="width: 5%; padding-right: 0.8pt"><font style="font: 10pt Wingdings">o</font></td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; width: 45%; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Accelerated filer</font></td>
    <td style="width: 5%; padding-right: 0.8pt"><font style="font: 10pt Wingdings">o</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Wingdings">o</font></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">Smaller reporting company</font></td>
    <td style="padding-right: 0.8pt"><font style="font: 10pt Wingdings">&thorn;</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><font style="font-size: 10pt">(Do not check if a smaller reporting company)</font></td>
    <td style="padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 0.8pt">&nbsp;</td>
    <td style="padding-right: 0.8pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 50%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Title of each class of securities to be registered (1)</font></td>
    <td style="vertical-align: top; width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Proposed maximum <BR>
aggregate offering<BR>
 price (2), (4)</font></td>
    <td style="vertical-align: bottom; width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Amount of <BR>
registration fee (3)</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Common Stock, $0.0001 par value (4)</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Preferred Stock, $0.0001 par value (4)</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Warrants (4)</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Units (4)</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Total</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 10pt">$75,000,000</font></td>
    <td style="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><font style="font-size: 10pt">$9,660 * </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">* </font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Previously paid. </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(1)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Any securities registered hereunder may be sold separately or as units with other securities registered hereunder.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(2)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Such indeterminate number or amount of common stock, preferred stock, warrants and units to purchase any combination of the foregoing securities, as may from time to time be issued at indeterminate prices, with an aggregate initial offering price not to exceed $75,000,000 or the equivalent thereof in one or more foreign currencies, foreign currency units or composite currencies.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(3)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Rule 457(o) permits the registration fee to be calculated on the basis of the maximum offering price of all of the securities listed and, therefore, the table does not specify by each class information as to the amount registered, the proposed maximum offering price per unit, or the proposed maximum aggregate offering price.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(4)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Subject to footnote (1), there is being registered hereunder such indeterminate amount of common stock, preferred stock, warrants, and units as may from time to time be issued by the registrant at indeterminate prices and as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable anti-dilution provisions. In no event will the aggregate initial offering price of all securities issued from time to time pursuant to this registration statement exceed $75,000,000.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)
of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting
pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 100%; text-align: justify"><FONT STYLE="font-size: 10pt; color: red"><B>The information in this prospectus
    is not complete and may be changed. We may not sell these securities until the registration statement filed with Securities
    and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer
    to buy these securities in any state where the offer or sale is not permitted.</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION, DATED
July 17 , 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may, from time to time, offer and sell common
stock, preferred stock or warrants, either separately or in units, in one or more offerings. The preferred stock and warrants may
be convertible into or exercisable or exchangeable for common or preferred stock. We will specify in the accompanying prospectus
supplement more specific information about any such offering. The aggregate initial offering price of all securities sold under
this prospectus will not exceed $75,000,000, including the U.S.&nbsp;dollar equivalent if the public offering of any such securities
is denominated in one or more foreign currencies, foreign currency units or composite currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may offer these securities independently
or together in any combination for sale directly to investors or through underwriters, dealers or agents. We will set forth the
names of any underwriters, dealers or agents and their compensation in the accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus may not be used to sell any
of these securities unless accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our common stock is traded on the NASDAQ
Capital Market under the symbol &ldquo;OCLS.&rdquo; On June 30, 2014, the last reported sale price for our common stock was $3.08
per share. As of June 30, 2014, 189,844 shares of our common stock were held by affiliates. The aggregate market value of our
outstanding voting and non-voting common equity held by non-affiliates on June 30, 2014 was $25,472,527 based on $3.08, the price
at which our common stock was last sold on June 30, 2014. During the twelve calendar months prior to and including the date hereof,
we have sold securities with an aggregate market value of $6,949,491 pursuant to General Instruction I.B.6. of Form S-3. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our securities involves a
high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 5 .</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is July 17 ,
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 95%; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">Page</font></td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: top"><font style="font-size: 10pt">About This Prospectus</font></td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Our Company</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Risk Factors</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Forward-Looking Statements</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Use of Proceeds</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Plan of Distribution</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Description of Common Stock</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">19</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Description of Preferred Stock</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Description of Warrants</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">21</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Description of Units</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Legal Matters</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Experts</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td></tr>
<tr style="vertical-align: top; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Where You Can Find More Information</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">23</font></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td><font style="font-size: 10pt">Incorporation of Certain Documents by Reference</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">23</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You should rely only on the information incorporated
by reference or provided in this prospectus, any prospectus supplement and the registration statement. We have not authorized anyone
else to provide you with different information. If anyone provides you with different or inconsistent information, you should not
rely on it. We are not making an offer to sell these securities in any state where the offer or sale is not permitted. You should
assume that the information in this prospectus and any prospectus supplement, or incorporated by reference, is accurate only as
of the dates of those documents. Our business, financial condition, results of operations and prospects may have changed since
those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This summary highlights information contained
elsewhere in this prospectus or incorporated by reference. This summary does not contain all of the information you should consider
before buying shares of our common stock, preferred stock, warrants, or units or any combination of these securities. You should
read the entire prospectus carefully, especially the risks of investing in our securities that we describe under &ldquo;Risk Factors&rdquo;
and our consolidated financial statements appearing in our annual and periodic reports incorporated in this prospectus by reference,
before deciding to invest in our securities. Unless the context requires otherwise, references to &ldquo;Oculus,&rdquo; &ldquo;the
Company,&rdquo; &ldquo;the Registrant,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to Oculus Innovative
Sciences, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus is part of a registration statement
that we filed with the Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo; registration, or continuous offering,
process. Under this shelf registration process, we may, from time to time, issue and sell any combination of preferred stock, common
stock or warrants, either separately or in units, in one or more offerings with a maximum aggregate offering price of $75,000,000,
including the U.S. dollar equivalent if the public offering of any such securities is denominated in one or more foreign currencies,
foreign currency units or composite currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus provides you with a general
description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain
specific information about the terms of that offering and the offered securities. Any prospectus supplement may also add, update
or change information contained in this prospectus. Any statement that we make in this prospectus will be modified or superseded
by any inconsistent statement made by us in a prospectus supplement. The registration statement we filed with the SEC includes
exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related
exhibits filed with the SEC and any prospectus supplement, together with additional information described under the heading &ldquo;Where
You Can Find More Information,&rdquo; before making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investing in our securities involves a high
degree of risk. The prospectus supplement relating to a particular offering will contain a discussion of risks applicable to an
investment in the securities offered. Prior to making a decision about investing in our securities, you should carefully consider
the specific factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement together with
all of the other information contained in the prospectus supplement or appearing or incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OUR COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are a global healthcare company that
designs, produces, and markets prescription and non-prescription products in over 20 countries. We are pioneering innovative products
for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets. Our primary focus is on the commercialization
of our proprietary technology platform called Microcyn&reg; Technology. This technology is based on electrically charged oxychlorine
small molecules designed to target a wide range of organisms that cause disease (pathogens). These organisms include viruses,
fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant <I>Staphylococcus aureus</I>, or MRSA,
and vancomycin-resistant <I>Enterococcus,</I> or VRE, as well as <I>Clostridium difficile,</I> or C. diff, a highly contagious
bacteria spread by human contact. Several Microcyn&reg; Technology tissue care products are designed to treat infections and enhance
healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds,
and controlling infection is a critical step in wound healing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> To date, we have obtained eight approvals
or clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our Microcyn&reg;-based products as medical
devices under Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States. In December 2013, we announced that
we had received our latest 510(k) device clearance from the FDA for our new Microcyn&reg; Scar Management HydroGel. The Rx product,
under the supervision of a healthcare professional, is intended for the management of old and new hypertrophic and keloid scarring
resulting from burns, general surgical procedures and trauma wounds. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We do not have the necessary regulatory
approvals to market Microcyn&reg; as a drug or as a medical device with an antimicrobial or wound healing indication in the United
States. Outside the United States, our Microcyn&reg; Technology products have a European Conformity mark, known as a Conformit&eacute;
Europ&eacute;enne, or CE Mark device approval in Europe for debriding, irrigating and moistening acute and chronic wounds in comprehensive
wound treatment through potential local antimicrobial effect in the wound bed and creating a moist environment. In February 2014,
we announced receipt of European CE Mark device approval for our Microcyn&reg;-based GramaDerm&reg; Solution and GramaDerm&reg;
Hydrogel. Both products are intended for use in the topical treatment of mild to moderate acne and are designed to complement
other acne treatments. In July 2013, we were granted a Mexican patent for the use of our novel antimicrobial surgical solution
in the treatment and prevention of peritonitis. In India, our technology has a drug license for cleaning and debriding in wound
management. In China, we have obtained a medical device approval by the State Food and Drug Administration for reducing the propagation
of microbes in wounds and creating a moist environment for wound healing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we do not have the necessary regulatory
clearance for an antimicrobial or wound healing indication in the United States, several factors, including our global product
experience, clinical and laboratory testing, physician-led clinical studies based on our technology and scientific papers authored
about our technology, suggest that our Microcyn&reg; Technology may help reduce a wide range of pathogens in acute and chronic
wounds, while curing or improving infection, and concurrently enhancing wound healing through modes of action unrelated to the
treatment of infection. These physician-led clinical studies suggest that our Microcyn&reg; Technology is safe, easy to use and
complementary to many existing treatment methods in wound care. Physician-led clinical studies and usage of our products in the
United States suggest that our 510(k) cleared products may shorten hospital stays, lower aggregate patient care costs and, in certain
cases, reduce the need for systemic antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Common methods of controlling infection,
including topical antiseptics and antibiotics, have proven to be only moderately effective in combating infection in the wound
bed. However, topical antiseptics tend to inhibit the healing process due to their toxicity and may require specialized preparation
or handling. Antibiotics can lead to the emergence of resistant bacteria, such as MRSA and VRE. Systemic antibiotics may be less
effective in controlling infection in patients with disorders affecting circulation, such as diabetes, which are commonly associated
with chronic wounds. As a result, no single treatment is used across all types of wounds and stages of healing and we believe
Microcyn&reg; Technology can fill a niche in the skin care and chronic and acute wound care markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We believe Microcyn&reg; Technology is
a stable, anti-infective therapeutic that treats infections and enhances wound healing through increased blood flow to the wound
bed and reduction of chronic inflammation. Also, we believe Microcyn&reg; Technology provides significant advantages over current
methods of care in the treatment of a wide range of chronic and acute wounds throughout all stages of treatment. These stages
include cleaning, debridement, prevention and treatment of infections and wound healing. We believe that, unlike antibiotics,
antiseptics, growth regulators and other advanced wound care products, Microcyn&reg; Technology is a stable wound care solution
that is as safe as saline, and also treats infection while simultaneously accelerating wound healing. Also, unlike most antibiotics,
we believe Microcyn&reg; Technology does not target specific strains of bacteria, a practice which has been shown to promote the
development of resistant bacteria. In addition, our products are shelf stable, non-toxic, require no special preparation and are
easy to use. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ruthigen, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our formerly wholly-owned subsidiary, Ruthigen,
Inc., was incorporated in the State of Nevada on January 18, 2013, and reincorporated from Nevada to Delaware on September 25,
2013. Ruthigen has established offices in Santa Rosa, California. Ruthigen announced its initial public offering on March 21,
2014. As of March 26, 2014, the closing date of Ruthigen&rsquo;s initial public offering, we held 2,000,000, or 43% of the shares
of Ruthigen common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We entered into three key agreements
with Ruthigen that govern the terms of our relationship with Ruthigen: the &ldquo;Funding Agreement&rdquo;, the &ldquo;License
and Supply Agreement&rdquo; and the &ldquo;Shared Services Agreement.&rdquo; Each of these agreements was entered into in the
overall context of Ruthigen&rsquo;s separation from us (the &ldquo;Separation&rdquo;). The effective date for all three agreements
was the closing date of Ruthigen&rsquo;s initial public offering, which was March 26, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Funding Agreement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On January 31, 2014, we entered into a
new Funding Agreement with Ruthigen to govern the terms of certain additional financing to be provided to Ruthigen by us, pending
the Separation, subject to the terms and conditions set forth in the agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We agreed to continue to fund Ruthigen
for a total of up to $760,000 in order to allow Ruthigen to proceed with its initial public offering. Pursuant to the agreement
any funds advanced to Ruthigen by us were to be repaid at the time of the closing of Ruthigen&rsquo;s initial public offering.
On March 26, 2014, the date the initial public offering closed, we had made aggregate advances of $1,453,000 to Ruthigen. In connection
with the completion of the initial public offering, pursuant to the Funding Agreement, Ruthigen reimbursed us $916,000 of costs
associated with the initial public offering. The remaining $537,000 was subsequently received on April 1, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In addition to the reimbursement terms,
the Funding Agreement provided for the resignation of the Ruthigen Board Members from our Board of Directors. Effective February
21, 2014, one of the Ruthigen Directors, Greg French, resigned from our Board and effective March 26, 2014, the remaining Ruthigen
Directors, Richard Conley and Hojabar Alimi, resigned from our Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>License and Supply Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We initially entered into a License and
Supply Agreement with Ruthigen on June 6, 2013. Pursuant to the terms of the License and Supply Agreement, we agreed to exclusively
license certain of our proprietary technology to Ruthigen to enable Ruthigen&rsquo;s research and development and commercialization
of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada, European Union and Japan, referred
to as the Territory, for certain invasive procedures in humans defined in the License and Supply Agreement. On October 9, 2013,
we entered into Amendment No. 1 to the License and Supply Agreement with Ruthigen, which amended the second milestone event set
forth in Section 7.1 of the License and Supply Agreement. On November 6, 2013, we entered into Amendment No. 2 to the License
and Supply Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and Supply
Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and Supply
Agreement. On January 31, 2014, we entered into Amendment No. 3 to the License and Supply Agreement with Ruthigen to further amend
certain milestone events and the terms of the manufacturing equipment purchases, and to remove sections of the License and Supply
Agreement which related to an exclusive option granted by us to Ruthigen to expand the terms of the License and Supply Agreement
to dermatologic uses. All other terms and conditions of the License and Supply Agreement remain unmodified and in full force and
effect. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Under the terms of the License and Supply
Agreement, we will be prohibited from using the licensed proprietary technology to sell products that compete with Ruthigen&rsquo;s
products within the Territory, and Ruthigen cannot sell any device or product that competes with our products being sold or developed
as of the effective date of the License and Supply Agreement.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Ruthigen will be required to make a total
of up to $8,000,000 in milestone payments to us for the first product only, as follows: upon completion of last patient enrollment
in Ruthigen&rsquo;s Phase 1/2 clinical study; upon completion of last patient enrollment in Ruthigen's first pivotal clinical
study; upon completion of Ruthigen&rsquo;s first meeting with the U.S. Food and Drug Administration following completion of Ruthigen&rsquo;s
first pivotal clinical trial; and upon first patient enrollment in Ruthigen&rsquo;s second pivotal clinical trial. In addition,
as further consideration under the agreement, Ruthigen will be required to make royalty payments to us based on Ruthigen&rsquo;s
annual net sales of the product from the date of first commercial sale to the date that Ruthigen or any of its Affiliates or successors
ceases to commercialize the product, which percentage royalty rate will vary between 3% and 20% and will increase based on various
net sales thresholds and will differ depending on the country in which the sales are made. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Shared Services Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also entered into a shared services agreement
with Ruthigen initially on June 6, 2013 pursuant to which we will provide Ruthigen with general services, including general accounting,
human resources, laboratory personnel and shared R&amp;D resources while Ruthigen plans to establish an independent facility and
systems. On January 31, 2014, we entered into Amendment No. 1 to the shared services agreement with Ruthigen to amend the terms
of certain standard activities we shall provide Ruthigen and the terms related to access to our facilities. All other terms and
conditions of the shared services agreement remain unmodified and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Separation Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Effectiveness and Term </I> &ndash;
On August 2, 2013, we entered into a Separation Agreement with Ruthigen, as amended January 31, 2014, that contains provisions relating
to our ongoing relationship with Ruthigen and more specifically governs our relationship with Ruthigen following the completion
of Ruthigen&rsquo;s initial public offering. The Separation Agreement, as amended, contains certain limitations
on our ability to control various aspects of Ruthigen&rsquo;s business and operations in order for Ruthigen to operate as independently
as possible from us in order to unlock the value proposition of RUT58-60. The Separation Agreement took effect on March 26, 2014
and terminates on the earlier of 8.5 years following the initial public offering or when the parties mutually agree to terminate
it. However, most of the material restrictions and obligations contained in the Separation Agreement lapse when we own less than
19.9% of the outstanding shares of Ruthigen&rsquo;s common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Marketing and Transfer Restrictions
</I> &ndash; The Separation Agreement contains a series of restrictions on our ability to transfer the Ruthigen shares we
own. We are restricted from transferring or selling any of the Ruthigen shares we own without the written consent of Ruthigen&rsquo;s
Board and the lead underwriter in the Ruthigen IPO during the one-year lock up period immediately following Ruthigen&rsquo;s initial
public offering. Following the one-year lock up period, transfers by us of the Ruthigen shares we own must be conducted with the
consent of Ruthigen&rsquo;s board of directors or within the prescribed requirements for such transfers set forth in the Separation
Agreement. These prescribed requirements include that the transfers must be in private placement transactions, that the purchase
price discount may not exceed 15% or 20% of the prevailing market price depending on the type of transferee, the amount of shares
transferred in a given transfer (or series of transfers comprising a single transaction) may not exceed the greater of 5% of Ruthigen&rsquo;s
outstanding shares or $1.5 million in net proceeds to us, as well as certain other requirements set forth in the Separation Agreement.<I>&nbsp;</I>The
parties may also mutually agree to another arrangement permitting us to sell some or all of the Ruthigen shares we hold. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Registration Rights</I> &ndash; The separation
agreement provides us with certain &ldquo;piggy back&rdquo; registration rights if Ruthigen proposes to publicly register any of
its common stock following the completion of Ruthigen&rsquo;s initial public offering, subject to certain conditions and limitations.
The inclusion of the Ruthigen shares we own in such registration will be subject to the same terms that Ruthigen offers its own
securities in such offering and our registration rights will never be never be more than 30% of the value of all securities to
be registered in such offering. In addition, following transfers by us of the Ruthigen shares, we have certain demand registration
rights requiring Ruthigen to register all of the Ruthigen shares we have transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Standstill</I> &ndash; We have agreed that,
subject to the ownership threshold, we shall not, and shall not act in concert with any person to, make or participate in a solicitation
of proxies or powers of attorney or similar rights to vote any of the Ruthigen shares we own or to deposit the Ruthigen shares
we own in a voting trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Voting </I> &ndash; We have agreed
that, subject to the ownership threshold, we shall vote or consent all of the Ruthigen shares we own in the same manner as the
majority of the non-Oculus holders of Ruthigen&rsquo;s common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Equity Plan, Oculus Equity and Corporate
Governance </I> &ndash; We and Ruthigen have agreed on the principal terms of Ruthigen&rsquo;s equity incentive plan, including
the formula for the number of shares reserved under the plan, the vesting schedule of awards under the plan, timing, size and
award type of the initial grants to be made following the closing of Ruthigen&rsquo;s initial public offering, and the formula
for the evergreen refresh provision and other share caps on certain types of awards and future equity plans. The Separation Agreement
clarifies that options for common stock of our Company held by employees and directors of Ruthigen shall continue to vest as long
as the individuals continue in service to Ruthigen. In addition, the Separation Agreement provides that Ruthigen&rsquo;s restated
articles of incorporation and bylaws for purposes of operating as a public company will contain provisions for a staggered Board
of Directors and plurality voting for the election of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Indemnification &ndash; </I> The
Separation Agreement provides that each party will indemnify, defend and hold harmless the other party and its affiliates for
third party claims asserted against the other party, and that we will indemnify, defend and hold harmless Ruthigen and its affiliates
from and against any and all direct losses relating to the WTI loan agreements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I> Directors&rsquo; and Officers&rsquo;
Insurance </I> &ndash; The Separation Agreement provides that, so long as we shall maintain a directors&rsquo; and officers&rsquo;
insurance program covering the past and present officers and directors of our Company, the program shall be standard in our industry
and if there is a change to the program, then we shall provide prior notice.&nbsp; In addition, we have agreed not to exclude
any former Oculus director from any insurance policy coverage if such coverage is made available to our Company&rsquo;s then existing
directors and officers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We incorporated under the laws of
the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, we changed our name to Oculus
Innovative Sciences, Inc. In December 2006, we reincorporated under the laws of the State of Delaware. Our principal
executive offices are located at 1129&nbsp;N.&nbsp;McDowell Blvd., Petaluma, California, 94954, and our telephone number
is (707)&nbsp;283-0550. We have two principal wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V.,
organized in Mexico; and Oculus Innovative Sciences Netherlands, B.V., organized in the Netherlands. Our formerly
wholly-owned subsidiary, Ruthigen, Inc., organized in Delaware, was deconsolidated on March 26, 2014 in connection with the
completion of its initial public offering. Our fiscal year end is March 31. Our website is www.oculusis.com. Information
contained on our website does not constitute part of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors and others should note that we announce
material financial information using our company website (www.oculusis.com), our investor relations website (ir.oculusis.com),
SEC filings, press releases, public conference calls and webcasts. Information about Oculus, our business, and our results of operations
may also be announced by posts on the following social media channels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Oculus corporate blog (http://oculusis.com/dialogue/)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Oculus Facebook page (www.facebook.com/oculusinnovativesciences)</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Dan McFadden&rsquo;s Twitter feed (http://twitter.com/dmcfaddenocls). Mr. McFadden is the Vice President of Public and Investor Relations of our Company.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information that we post on these social
media channels could be deemed to be material information. Therefore, we encourage investors, the media, and others interested
in Oculus to review the information that we post on these social media channels. These social media channels may be updated from
time to time on Oculus&rsquo; investor relations website. The information on or accessible through our websites and social media
channels is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have a history of losses, we expect
to continue to incur losses and we may never</I></B> <B><I>achieve profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We reported net income of $3,735,000
and losses from operations of $6,051,000 for the year ended March 31, 2014. We reported net losses of $5,431,000 and losses
from operations of $3,374,000 for the year ended March 31, 2013. At March&nbsp;31, 2014, our accumulated deficit amounted to
$134,010,000. During the year ended March 31, 2014, net cash used in  operating activities amounted to $4,890,000. At March
31, 2014 our working capital amounted to $1,970,000. We expect to continue incurring losses for the foreseeable future and
may never achieve or sustain profitability. We may need to raise additional capital to pursue product development initiatives
and to penetrate markets for the sale of our products. We believe that we have access to capital resources through possible
public or private equity offerings, debt financings, corporate collaborations or other means. If the economic climate in the
United States does not improve, or further deteriorates, our ability to raise additional capital could be negatively impacted.
If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and
take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet
our obligations. These measures could cause significant delays in our efforts to commercialize our products in the United
States, which are critical to the realization of our business plan and to future operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> We derive a substantial portion of
our revenue from our partnership with Innovacyn and based on new contract negotiations we may lose some or all of that revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> For the fiscal year ended March 31, 2014,
approximately 23% of our total revenues were derived from our agreement with Innovacyn, our animal health care partner. <FONT STYLE="background-color: white">In
April of 2014, Innovacyn, notified us that&nbsp;</FONT>over the next twelve months Innovacyn will transition to a new supplier
of animal care products. We are discussing a transition agreement with Innovacyn. We are actively seeking new distribution channels
and locating a new animal health care partner. We can give no assurances that we will be able to find a new animal health care
partner under terms acceptable to us, if at all. If we are unable to locate new distribution channels or a new animal health care
partner, our results of operations and financial condition may be adversely affected. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our strategy to separate our businesses
into two publicly traded companies may have a negative impact on our business operations, operating results and assets. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On March 26, 2014, our formerly wholly-owned
subsidiary, Ruthigen, Inc. closed its initial public offering. As a result, we now own a minority interest in Ruthigen. There
are various uncertainties and risks relating to this separation that could have, and in some cases have had, a negative impact
on our business operations, operating results or assets, including: (i) the distraction of management and disruption of operations;
(ii) perceived uncertainties as to our future direction may result in increased difficulties in recruiting and retaining employees,
particularly highly qualified employees; (iii) perceived uncertainties as to our future direction may have a negative impact on
our relationships with our customers, suppliers, vendors and partners and may result in the loss of business opportunities; (iv)
the process of completing the separation may be time consuming and expensive and may result in the loss of business opportunities;
and (v) we may not be able to successfully achieve the benefits of any strategic alternative undertaken by us. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The value of the shares we hold in Ruthigen
may fluctuate substantially , which may affect the value of our assets and could negatively affect our stock price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On March 21, 2014, our previously
consolidated, wholly-owned subsidiary, Ruthigen, announced its initial public offering which closed March 26, 2014. On April
10, we had a non-controlling 43% interest in Ruthigen. As such, our interest in Ruthigen is now reported as an asset on our
financial statements rather than as a consolidated subsidiary. Because we own shares in a public company, the value of this
asset may fluctuate and the value stated in our financial reports may change substantially over time. Given that we no longer
control Ruthigen, we have very little means to control the value of the asset. If the value of our holdings in Ruthigen
decreases or fluctuates, it may adversely affect the value of our stock price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The shares we own in Ruthigen are not
liquid and we may never be able to realize cash for the value stated in our financials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> According to the terms of our Separation
Agreement, we are unable to transfer any of the Ruthigen shares we own for one year following the initial public offering of Ruthigen
without the written consent of Ruthigen&rsquo;s Board. After the one-year lock up expires, we have agreed to additional transfer
restrictions that may make it difficult to sell the shares we own in Ruthigen in a timely manner, if at all. Therefore, we may
be unable to realize the value of this asset even after the lock up period expires. Furthermore, we can give no assurance that
a liquid trading market for Ruthigen shares will develop and be sustained in the future and we may be unable to sell the shares
we own in Ruthigen for the amount at which they are valued, if at all. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> Our Company and Ruthigen may be unable
to achieve some or all of the benefits that we expect to achieve through the Separation. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have entered into certain new agreements
with our formerly wholly-owned subsidiary, Ruthigen, Inc. that govern our relationship with Ruthigen following the completion
of Ruthigen&rsquo;s initial public offering. Each of these agreements (the &ldquo;Ancillary Agreements&rdquo;) was entered into
in the overall context of Ruthigen&rsquo;s separation from us (the &ldquo;Separation&rdquo;). The effective date for the Ancillary
Agreements is&nbsp;March 26, 2014, the closing date of Ruthigen&rsquo;s initial public offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The strategic, operating and financial
benefits expected to result from the Separation may be delayed or may never be realized at all. For instance, there can be no
assurance that by separating the businesses that either our Company or Ruthigen will be better positioned to capitalize on
future market opportunities or that either company will be able to increase their respective shareholder value.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I> We expect to lose revenues as a result of transitioning
away from our partner, Innovacyn, and we may not be able to replace those revenues. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In April of 2014, Innovacyn, our animal health care partner
notified us that&nbsp;over the next twelve months Innovacyn will transition to a new supplier of animal care products. We are
discussing a transition agreement with Innovacyn. For the fiscal year ended March 31, 2014, approximately 23% of our total revenues
were derived from our agreement with Innovacyn. During the years ended March 31, 2014 and 2013, we recorded revenue related to
these agreements in the amounts of $3,100,000 and $3,906,000, respectively. We are actively seeking new distribution channels
and locating a new animal health care partner. Our revenue may be adversely impacted during this transition. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to maintain compliance
with the continued listing standards as set forth in the Nasdaq Listing Rules, our common stock could be delisted from The Nasdaq
Capital Market, and if this were to occur, then the price and liquidity of our common stock, and our ability to raise additional
capital may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is currently listed on The
Nasdaq Capital Market. Continued listing of a security on The Nasdaq Capital Market is conditioned upon compliance with certain
continued listing requirements and continued listing standards set forth in the Nasdaq Listing Rules for Nasdaq Capital Market
companies. There can be no assurance we will continue to satisfy the requirements for maintaining a Nasdaq Capital Market listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are not able to maintain compliance
with the continued listing standards as set forth in the Nasdaq Listing Rules for Nasdaq Capital Market companies, our common
stock will be delisted from The Nasdaq Capital Market and an associated decrease in liquidity in the market for our common stock
may occur. In addition, the delisting of our common stock could materially adversely affect our access to the capital markets,
and any limitation on liquidity or reduction in the price of our common stock could materially adversely affect our ability to
raise capital on terms acceptable to us or at all. Delisting from The Nasdaq Capital Market could also result in the potential
loss of confidence by our business partners and suppliers, the loss of institutional investor interest and fewer business development
opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our inability to raise additional capital
on acceptable terms in the future may cause</I></B> <B><I>us to curtail certain operational activities, including regulatory trials,
sales and</I></B> <B><I>marketing, and international operations, in order to reduce costs and sustain the</I></B> <B><I>business,
and such inability would have a material adverse effect on our business and financial</I></B> <B><I>condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect capital outlays and operating expenditures
to increase over the next several years as we work to conduct regulatory trials, commercialize our products and expand our infrastructure.
We may need to raise additional capital in order to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">fund our clinical trials and preclinical studies;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">sustain commercialization of our current products or new products;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">expand our manufacturing capabilities;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">increase our sales and marketing efforts to drive market adoption and address competitive developments;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">acquire or license technologies;&nbsp;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">finance capital expenditures and our general and administrative expenses; and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">develop new products.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our present and future funding requirements
will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">the progress and timing of our clinical trials;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">the level of research and development investment required to maintain and improve our technology position;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">our efforts to acquire or license complementary technologies or acquire complementary businesses;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in product development plans needed to address any difficulties in commercialization;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">competing technological and market developments;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in regulatory policies or laws that affect our operations.</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we raise additional funds by issuing equity
securities, dilution to our stockholders will result. Any equity securities issued also may provide for rights, preferences or
privileges senior to those of holders of our common stock. If we raise additional funds by issuing debt securities, these debt
securities would have rights, preferences and privileges senior to those of holders of our common stock, and the terms of the
debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations
or licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses
on terms that are not favorable to us. A failure to obtain adequate funds may cause us to curtail certain operational activities,
including regulatory trials, sales and marketing, and international operations, in order to reduce costs and sustain our business,
and would have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not have the necessary regulatory
approvals to market Microcyn</I>&reg;<I> as a drug in the</I></B> <B><I>United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have obtained eight 510(k) clearances
in the United States that permit us to sell Microcyn&reg;-based products as medical devices. In December 2013, we announced that
we had received our latest 510(k) device clearance from the FDA for our new Microcyn&reg; Scar Management HydroGel. Before we
are permitted to sell Microcyn&reg; as a drug in the United States, we must, among other things, successfully complete additional
preclinical studies and well-controlled clinical trials, submit a new drug application to the FDA and obtain FDA approval. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The FDA approval process is expensive and
uncertain, requires detailed and comprehensive scientific and other data and generally takes several years. Despite the time and
expense exerted, approval is never guaranteed. Even if we obtain FDA approval to sell Microcyn&reg; as a drug, we may not be able
to successfully commercialize Microcyn as a drug in the United States and may never recover the substantial costs we have invested
in the development of our Microcyn&reg;-based products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Delays or adverse results in clinical
trials could result in increased costs to us</I></B> <B><I>and could delay our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials can be long and expensive,
and the outcome of clinical trials is uncertain and subject to delays. It may take several years to complete clinical trials, if
at all, and a product candidate may fail at any stage of the clinical trial process. The length of time required varies substantially
according to the type, complexity, novelty and intended use of the product candidate. Interim results of a preclinical study or
clinical trial do not necessarily predict final results, and acceptable results in preclinical studies or early clinical trials
may not be repeatable in later subsequent clinical trials. The commencement or completion of any of our clinical trials may be
delayed or halted for a variety of reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">insufficient funds to continue our clinical trials;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in the FDA requirements for approval, including requirements for testing efficacy and safety;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">delay in obtaining or failure to obtain FDA or other regulatory authority approval of a clinical trial protocol;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">patients not enrolling in clinical trials at the rate we expect;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">delays in reaching agreement on acceptable clinical trial agreement terms with prospective sites;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">delays in obtaining institutional review board approval to conduct a study at a prospective site;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">third party clinical investigators not performing our clinical trials on our anticipated schedule or performance is not consistent with the clinical trial protocol and good clinical practices, or the third party organizations not performing data collection and analysis in a timely or accurate manner;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in governmental regulations or administrative actions.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We do not know whether future clinical
trials will demonstrate safety and efficacy sufficiently to result in additional FDA approvals. While a number of physicians have
conducted clinical studies assessing the safety and efficacy of Microcyn&reg; for various indications, the data from these studies
are not sufficient to support approval of Microcyn&reg; as a drug in the United States. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Clinical trials involve a lengthy and
expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of preclinical studies and early
clinical trials of new drugs do not necessarily predict the results of later-stage clinical trials. The design of our clinical
trials is based on many assumptions about the expected effects of our product candidates, and if those assumptions are incorrect,
the trials may not produce statistically significant results. Preliminary results may not be confirmed upon full analysis of the
detailed results of an early clinical trial. Product candidates in later stages of clinical trials may fail to show safety and
efficacy sufficient to support intended use claims despite having progressed through initial clinical testing. The data collected
from clinical trials of our product candidates may not be sufficient to obtain regulatory approval in the United States or elsewhere.
Because of the uncertainties associated with drug development and regulatory approval, we cannot determine if or when we will have
an approved product for commercialization or achieve sales or profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to obtain, or experience significant
delays in obtaining, additional</I></B> <B><I>regulatory clearances or approvals to market our current or future products, we may</I></B>
<B><I>be unable to commercialize these products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The developing, testing, manufacturing, marketing
and selling of medical technology products are subject to extensive regulation by numerous governmental authorities in the United
States and other countries. The process of obtaining regulatory clearance and approval of medical technology products is costly
and time consuming. Even though their underlying product formulations may be the same or similar, our products are subject to different
regulations and approval processes depending upon their intended use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To obtain regulatory approval of our products
as drugs in the United States, we must first show that our products are safe and effective for target indications through preclinical
studies (laboratory and animal testing) and clinical trials (human testing). The FDA generally clears marketing of a medical device
through the 510(k) pre-market clearance process if it is demonstrated the new product has the same intended use and the same or
similar technological characteristics as another legally marketed Class&nbsp;II device, such as a device already cleared by the
FDA through the 510(k) premarket notification process, and otherwise meets the FDA&rsquo;s requirements. Product modifications,
including labeling the product for a new intended use, may require the submission of a new 510(k) clearance and FDA approval before
the modified product can be marketed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The outcomes of clinical trials are inherently
uncertain. In addition, we do not know whether the necessary approvals or clearances will be granted or delayed for future products.
The FDA could request additional information, changes to product formulation(s) or clinical testing that could adversely affect
the time to market and sale of products as drugs. If we do not obtain the requisite regulatory clearances and approvals, we will
be unable to commercialize our products as drugs or devices and may never recover any of the substantial costs we have invested
in the development of Microcyn&reg;.</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Distribution of our products outside the United
States is subject to extensive government regulation. These regulations, including the requirements for approvals or clearance
to market, the time required for regulatory review and the sanctions imposed for violations, vary from country to country. We
do not know whether we will obtain regulatory approvals in such countries or that we will not be required to incur significant
costs in obtaining or maintaining these regulatory approvals. In addition, the export by us of certain of our products that have
not yet been cleared for domestic commercial distribution may be subject to FDA export restrictions. Failure to obtain necessary
regulatory approvals, the restriction, suspension or revocation of existing approvals or any other failure to comply with regulatory
requirements would have a material adverse effect on our future business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have established a nutritional products
division under the name NVN Therapeutics, and if the products we create in our new division are not accepted by the marketplace,
we may cease operations in this division.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We established a nutritional products division
under the name Napa Valley Nutritionals in the beginning of 2012 to expand our product pipeline. The name of the division was
subsequently changed to NVN. This division was originally intended to develop and manufacture medical foods with a primary focus
on the women&rsquo;s healthcare market. However, as a result of recently revised FDA guidance regarding medical foods, we have
ceased production of medical foods and we are redirecting our efforts into the development and manufacture of dietary supplements
for this same women&rsquo;s healthcare market. If we cannot generate sufficient revenues from the sale of such products, we may
cease operations in this nutritional products division. In addition, the introduction of new products by competitors, changes
in medical practices and procedures, and regulatory changes can result in product obsolescence. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If our products do not gain market acceptance,
our business will suffer because we</I></B> <B><I>might not be able to fund future operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A number of factors may affect the market acceptance
of our products or any other products we develop or acquire, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the price of our products relative to other products for the same or similar treatments;&nbsp;&nbsp;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the perception by patients, physicians and other members of the healthcare community of the effectiveness and safety of our products for their indicated applications and treatments;&nbsp;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">changes in practice guidelines and the standard of care for the targeted indication;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">our ability to fund our sales and marketing efforts;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the effectiveness of our sales and marketing efforts or our partners&rsquo; sales and marketing efforts.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to effectively promote and sell
any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive
price and our ability to obtain sufficient third-party coverage or reimbursement, if any. In addition, our efforts to educate the
medical community on the benefits of our product candidates may require significant resources, may be constrained by FDA rules
and policies on product promotion, and may never be successful. If our products do not gain market acceptance, we may not be able
to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding
our sales and marketing efforts for our approved products, which would cause our business to suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If our competitors develop products similar
to Microcyn</I></B>&reg;<B><I>, we may need to modify or</I></B> <B><I>alter our business strategy, which may delay the achievement
of our goals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may develop products with similar
characteristics to Microcyn&reg;. Such similar products marketed by larger competitors can hinder our efforts to penetrate the
market. As a result, we may be forced to modify or alter our business and regulatory strategy and sales and marketing plans, as
a response to changes in the market, competition and technology limitations, among others. Such modifications may pose additional
delays in achieving our goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> We depend on third parties and intend
to continue to license or collaborate with third parties in various potential markets, and events involving these strategic partners
or any future collaboration could delay or prevent us from developing or commercializing products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our business strategy and our short- and
long-term operating results will depend in part on our ability to execute on existing strategic collaborations and to license
or partner with new strategic partners. We believe collaborations allow us to leverage our resources and technologies and to access
markets that are compatible with our own core areas of expertise while avoiding the cost of establishing or maintaining a direct
sales force in each market. We may incur significant costs in the use of third parties to identify and assist in establishing
relationships with potential collaborators. We currently have a small direct sales force which sells our products in the wound
care and women&rsquo;s health markets, and we intend to slowly expand the geographical coverage of our direct sales force.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> To penetrate our target markets, we may
need to enter into additional collaborative agreements to assist in the development and commercialization of products. For example,
depending upon our analysis of the time and expense involved in obtaining FDA approval to sell a product to treat open wounds,
we may choose to license our technology to a third-party as opposed to pursuing commercialization ourselves. Establishing strategic
collaborations is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment
of our financial, regulatory or intellectual property position and our internal capabilities. Our discussions with potential collaborators
may not lead to the establishment of new collaborations on favorable terms and may have the potential to provide collaborators
with access to our key intellectual property filings and next generation formations. We have limited control over the amount and
timing of resources that our current collaborators or any future collaborators devote to our collaborations or potential products.
These collaborators may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities
successfully and in a timely manner. Further, our collaborators may not develop or commercialize products that arise out of our
collaborative arrangements or devote sufficient resources to the development, manufacture, marketing or sale of these products.
By entering into collaboration, we may preclude opportunities to collaborate with other third parties who do not wish to associate
with our existing third party strategic partners. Moreover, in the event of termination of a collaboration agreement, termination
negotiations may result in less favorable terms.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> If we are unable to expand our direct
domestic sales force, we may not be able to successfully sell our products in the United States. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I> &nbsp; </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We currently use a direct sales force to
sell our products in the wound care and women&rsquo;s health markets, while we have established partnerships to commercialize
products in the animal healthcare and dermatology markets. Expanding our sales force is expensive and time consuming, and the
lack of qualified sales personnel could delay or limit the success of our product launch in the United States. Our domestic sales
force, if established, will be competing with the sales operations of our competitors, which are better funded and more experienced.
We may not be able to develop domestic sales capacity on a timely basis, or at all. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> Our dependence on a commission-based
sales force and distributors for sales could limit or prevent us from selling our </I></B> <B><I>products and from realizing
long-term revenue growth.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I> &nbsp; </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We currently depend on a commission-based
sales force and distributors to sell Microcyn&reg; in the United States, Europe and other countries, and intend to continue to
sell our products primarily through a commission-based sales force and distributors in Europe and the United States for the foreseeable
future. If we are unable to expand our direct salesforce, we will continue to rely on a commission-based sales force and distributors
to sell Microcyn&reg;. Our existing distribution agreements are generally short-term in duration, and we may need to pursue alternate
partners if the other parties to these agreements terminate or elect not to renew their agreements. If we are unable to retain
our current commission-based sales force and distributors for any reason, we must replace them with alternate salespeople and
distributors experienced in supplying the wound care market, which could be time-consuming and divert management&rsquo;s attention
from other operational matters. In addition, we will need to attract additional distributors to expand the geographic areas in
which we sell Microcyn&reg;. Distributors may not commit the necessary resources to market and sell our products to the level
of our expectations, which could harm our ability to generate revenues. In addition, some of our distributors may also sell products
that compete with ours. In some countries, regulatory licenses must be held by residents of the country. For example, the regulatory
approval for one of our products in India is owned and held by our Indian distributor. If the licenses are not in our name or
under our control, we might not have the power to ensure their ongoing effectiveness and use by us. If current or future distributors
do not perform adequately, or we are unable to locate distributors in particular geographic areas, we may not realize long-term
revenue growth. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to comply with ongoing regulatory
requirements, or if we experience</I></B> <B><I>unanticipated problems with our products, these products could be subject to</I></B>
<B><I>restrictions or withdrawal from the market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regulatory approvals or clearances that we
currently have and that we may receive in the future are subject to limitations on the indicated uses for which the products may
be marketed, and any future approvals could contain requirements for potentially costly post-marketing follow-up studies. If the
FDA determines that our promotional materials or activities constitute promotion of an unapproved use or we otherwise fail to comply
with FDA regulations, we may be subject to regulatory enforcement actions, including warning letters, injunctions, seizures, civil
fines or criminal penalties. In addition, the manufacturing, labeling, packaging, adverse event reporting, storing, advertising,
promoting, distributing and record-keeping for approved products are subject to extensive regulation. Our manufacturing facilities,
processes and specifications are subject to periodic inspection by the FDA, European and other regulatory authorities and from
time to time, we may receive notices of deficiencies from these agencies as a result of such inspections. Our failure to continue
to meet regulatory standards, or to remedy any deficiencies, could result in restrictions being imposed on our products or manufacturing
processes, fines, suspension or loss of regulatory approvals or clearances, product recalls, termination of distribution, product
seizures or the need to invest substantial resources to comply with various existing and new requirements. In the more egregious
cases, criminal sanctions, civil penalties, disgorgement of profits or closure of our manufacturing facilities are possible. The
subsequent discovery of previously unknown problems with Microcyn&reg;, including adverse events of unanticipated severity or frequency,
may result in restrictions on the marketing of our products, and could include voluntary or mandatory recall or withdrawal of products
from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New government regulations may be enacted and
changes in FDA policies and regulations and, their interpretation and enforcement, could prevent or delay regulatory approval of
our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. Therefore, we do not know whether we will be able to continue
to comply with any regulations or that the costs of such compliance will not have a material adverse effect on our future business,
financial condition, and results of operations. If we are not able to maintain regulatory compliance, we will not be permitted
to market our products and our business would suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may experience difficulties in manufacturing
Microcyn</I></B>&reg;<B><I>, which could prevent us from</I></B> <B><I>commercializing one or more of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The machines used to manufacture our Microcyn&reg;-based
products are complex, use complicated software and must be monitored by highly trained engineers. Slight deviations anywhere in
our manufacturing process, including quality control, labeling and packaging, could lead to a failure to meet the specifications
required by the FDA, the Environmental Protection Agency, European Notified Bodies, Mexican regulatory agencies and other foreign
regulatory bodies, which may result in lot failures or product recalls. If we are unable to obtain quality internal and external
components, mechanical and electrical parts, if our software contains defects or is corrupted, or if we are unable to attract
and retain qualified technicians to manufacture our products, our manufacturing output of Microcyn&reg;, or any other product
candidate based on our platform that we may develop, could fail to meet required standards, our regulatory approvals could be
delayed, denied or revoked, and commercialization of one or more of our Microcyn-based products may be delayed or foregone. Manufacturing
processes that are used to produce the smaller quantities of Microcyn&reg; needed for clinical tests and current commercial sales
may not be successfully scaled up to allow production of significant commercial quantities. Any failure to manufacture our products
to required standards on a commercial scale could result in reduced revenues, delays in generating revenue and increased costs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our competitive position depends on our
ability to protect our intellectual property</I></B> <B><I>and our proprietary technologies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete and to achieve and maintain
profitability depends on our ability to protect our intellectual property and proprietary technologies. We currently rely on a
combination of patents, patent applications, trademarks, trade secret laws, confidentiality agreements, license agreements and
invention assignment agreements to protect our intellectual property rights. We also rely upon unpatented know-how and continuing
technological innovation to develop and maintain our competitive position. These measures may not be adequate to safeguard our
Microcyn&reg; Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We also have agreed to certain prohibitions
on our intellectual property. Pursuant to the License and Supply Agreement, we entered into with our subsidiary, Ruthigen, Inc.,
we agreed to exclusively license certain of our proprietary technology to Ruthigen to enable Ruthigen&rsquo;s research and development
and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada, European Union
and Japan for certain invasive procedures in human treatment as defined in the License and Supply Agreement. Under the terms of
the agreement we are also prohibited from using the licensed proprietary technology to sell products that compete with Ruthigen&rsquo;s
products within the defined territory. Such agreement will take effect as of the closing date of Ruthigen&rsquo;s proposed initial
public offering, if any should occur. In addition, we granted a security interest in our assets, excluding certain intellectual
property under specific circumstances, under a loan and security agreement. If we do not protect our rights adequately, third
parties could use our technology, and our ability to compete in the market would be reduced. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we have filed several U.S.&nbsp;and
foreign patent applications related to our Microcyn-based products, the manufacturing technology for making the products, and their
uses, only five U.S.&nbsp;patents have been issued from these applications to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our pending patent applications and any patent
applications we may file in the future may not result in issued patents, and we do not know whether any of our in-licensed patents
or any additional patents that might ultimately be issued by the U.S.&nbsp;Patent and Trademark Office or foreign regulatory body
will protect our Microcyn&reg; Technology. Any claims that are issued may not be sufficiently broad to prevent third parties from
producing competing substitutes and may be infringed, designed around, or invalidated by third parties. Even issued patents may
later be found to be invalid, or may be modified or revoked in proceedings instituted by third parties before various patent offices
or in courts. For example, our European patent that was initially issued on May 30, 2007 was revoked by the Opposition Division
of the European Patent Office in December 2009 following opposition proceedings instituted by a competitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The degree of future protection for our proprietary
rights is more uncertain in part because legal means afford only limited protection and may not adequately protect our rights,
and we will not be able to ensure that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">we were the first to invent the inventions described in patent applications;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">we were the first to file patent applications for inventions;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">others will not independently develop similar or alternative technologies or duplicate our products without infringing our intellectual property rights;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any patents licensed or issued to us will provide us with any competitive advantages;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">we will develop proprietary technologies that are patentable; or</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the patents of others will not have an adverse effect on our ability to do business.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The policies we use to protect our trade secrets
may not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality and invention
assignment agreements executed by our employees, consultants and advisors may not be enforceable or may not provide meaningful
protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosures. We cannot be
certain that the steps we have taken will prevent the misappropriation and use of our intellectual property in the United States,
or in foreign countries where the laws may not protect our proprietary rights as fully as in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may face intellectual property infringement
claims that could be time-consuming,</I></B> <B><I>costly to defend and could result in our loss of significant rights and, in
the case</I></B> <B><I>of patent infringement claims, the assessment of treble damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On occasion, we may receive notices of claims
of infringement, misappropriation or misuse of other parties&rsquo; proprietary rights. We may have disputes regarding intellectual
property rights with the parties that have licensed those rights to us. We may also initiate claims to defend our intellectual
property. Intellectual property litigation, regardless of its outcome, is expensive and time-consuming, and could divert management&rsquo;s
attention from our business and have a material negative effect on our business, operating results or financial condition. In addition,
the outcome of such litigation may be unpredictable. If there is a successful claim of infringement against us, we may be required
to pay substantial damages (including treble damages if we were to be found to have willfully infringed a third party&rsquo;s patent)
to the party claiming infringement, develop non-infringing technology, stop selling our products or using technology that contains
the allegedly infringing intellectual property or enter into royalty or license agreements that may not be available on acceptable
or commercially practical terms, if at all. Our failure to develop non-infringing technologies or license the proprietary rights
on a timely basis could harm our business. In addition, modifying our products to exclude infringing technologies could require
us to seek re-approval or clearance from various regulatory bodies for our products, which would be costly and time consuming.
Also, we may be unaware of pending patent applications that relate to our technology. Parties making infringement claims on future
issued patents may be able to obtain an injunction that would prevent us from selling our products or using technology that contains
the allegedly infringing intellectual property, which could harm our business.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to generate revenue will
be diminished if we are unable to obtain</I></B> <B><I>acceptable prices or an adequate level of reimbursement from third-party
payors of</I></B> <B><I>health care costs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The continuing efforts of governmental and
other third-party payors, including managed care organizations such as health maintenance organizations, or HMOs, to contain or
reduce costs of health care may affect our future revenue and profitability, and the future revenue and profitability of our potential
customers, suppliers and collaborative or license partners and the availability of capital. For example, in certain foreign markets,
pricing or profitability of prescription pharmaceuticals is subject to government control. In the United States, governmental and
private payors have limited the growth of health care costs through price regulation or controls, competitive pricing programs
and drug rebate programs. Our ability to commercialize our products successfully will depend in part on the extent to which appropriate
coverage and reimbursement levels for the cost of our Microcyn&reg; products and related treatment are obtained from governmental
authorities, private health insurers and other organizations, such as HMOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is significant uncertainty concerning
third-party coverage and reimbursement of newly approved medical products and drugs. Third-party payors are increasingly challenging
the prices charged for medical products and services. Also, the trend toward managed healthcare in the United States and the concurrent
growth of organizations such as HMOs, as well as legislative proposals to reform healthcare or reduce government insurance programs,
may result in lower prices for or rejection of our products. The cost containment measures that health care payors and providers
are instituting and the effect of any healthcare reform could materially and adversely affect our ability to generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, given ongoing federal and state
government initiatives directed at lowering the total cost of health care, the United States Congress and state legislatures will
likely continue to focus on health care reform,&nbsp;lowering the cost of prescription pharmaceuticals and Medicare and Medicaid
payment systems reform. While we cannot predict whether any proposed cost-containment measures will be adopted, the announcement
or adoption of these proposals could reduce the price that we receive for our Microcyn&reg; products in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We could be required to indemnify third
parties for alleged infringement, which could</I></B> <B><I>cause us to incur significant costs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our distribution agreements contain
commitments to indemnify our distributors against liability arising from infringement of third party intellectual property such
as patents. We may be required to indemnify our customers for claims made against them or contribute to license fees they are required
to pay. If we are forced to indemnify for claims or to pay license fees, our business and financial condition could be substantially
harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A significant part of our business is
conducted outside of the United States,</I></B> <B><I>exposing us to additional risks that may not exist in the United States,
which in</I></B> <B><I>turn could cause our business and operating results to suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have material international operations
in Mexico and Europe. During the years ended March&nbsp;31, 2014 and 2013, approximately 58% and 53% of our total revenues, respectively,
were generated from sales outside of the United States. Our business is highly regulated for the use, marketing and manufacturing
of our Microcyn&reg;-based products both domestically and internationally. Our international operations are subject to risks,
including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">local political or economic instability;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in governmental regulation;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in import/export duties;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">trade restrictions;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">lack of experience in foreign markets;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">difficulties and costs of staffing and managing operations in certain foreign countries;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">work stoppages or other changes in labor conditions;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">difficulties in collecting accounts receivables on a timely basis or at all;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">adverse tax consequences or overlapping tax structures.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to continue to market and sell our
products internationally to respond to customer requirements and market opportunities. We currently have international manufacturing
facilities in Mexico and the United States. Establishing operations in any foreign country or region presents risks such as those
described above as well as risks specific to the particular country or region. In addition, until a payment history is established
over time with customers in a new geographic area or region, the likelihood of collecting receivables generated by such operations
could be less than our expectations. As a result, there is a greater risk that the reserves set with respect to the collection
of such receivables may be inadequate. If our operations in any foreign country are unsuccessful, we could incur significant losses
and we may not achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, changes in policies or laws of
the United States or foreign governments resulting in, among other things, changes in regulations and the approval process, higher
taxation, currency conversion limitations, restrictions on fund transfers or the expropriation of private enterprises, could reduce
the anticipated benefits of our international expansion. If we fail to realize the anticipated revenue growth of our future international
operations, our business and operating results could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our sales in international markets subject
us to foreign currency exchange and other</I></B> <B><I>risks and costs which could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A substantial portion of our revenues are derived
from outside the United States; primarily from Mexico and Europe. We anticipate that revenues from international customers will
continue to represent a substantial portion of our revenues for the foreseeable future. Because we generate revenues in foreign
currencies, we are subject to the effects of exchange rate fluctuations. The functional currency of our Mexican subsidiary is the
Mexican Peso and the functional currency of our Netherlands subsidiary is the Euro. For the preparation of our consolidated financial
statements, the financial results of our foreign subsidiaries are translated into U.S.&nbsp;dollars using average exchange rates
during the applicable period. If the U.S.&nbsp;dollar appreciates against the Mexican Peso or the Euro, as applicable, the revenues
we recognize from sales by our subsidiaries will be adversely impacted. Foreign exchange gains or losses as a result of exchange
rate fluctuations in any given period could harm our operating results and negatively impact our revenues. Additionally, if the
effective price of our products were to increase as a result of fluctuations in foreign currency exchange rates, demand for our
products could decline and adversely affect our results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on a number of key customers
who may not consistently purchase our products in the future and if we lose any one of these customers, our revenues may decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Although we have a significant number of
customers in each of the geographic markets that we operate in, we rely on certain key customers for a significant portion of
our revenues. During the year ended March 31, 2014, one customer represented 38%, and another customer represented 23% of net
revenues. During the year ended March&nbsp;31, 2013, one customer represented 25%, and another customer represented 13% , of net
revenues. In the future, a small number of customers may continue to represent a significant portion of our total revenues in
any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period.
The loss of any of these customers could adversely affect our revenues. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Negative economic conditions increase
the risk that we could suffer unrecoverable losses on our customers&rsquo; accounts receivable which would adversely affect our
financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We grant credit to our business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables.&nbsp;We
maintain allowances for potential credit losses. At March 31, 2014, one customer represented 44%, one customer represented 15%,
and one customer represented 12% of the net accounts receivable balance. At March 31, 2013, one customer represented 34%, one
customer represented 26%, and one customer represented 15% of the net accounts receivable balance. While we believe we have a
varied customer base and have experienced strong collections in the past, if current economic conditions disproportionately impact
any one of our key customers, including reductions in their purchasing commitments to us or their ability to pay their obligations,
it could have a material adverse effect on our revenues and liquidity. We have not purchased insurance on our accounts receivable
balances. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> The loss of key members of our senior
management team, any of our directors or our </I></B> <B><I>highly skilled scientists, technicians and salespeople could
adversely affect our business.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends largely on the skills,
experience and performance of key members of our executive management team, including Jim Schutz, our Chief Executive Officer;
and Robert Northey, our Vice President of Research and Development. The efforts of these people will be critical to us as we continue
to develop our products and attempt to commercialize products in the wound and skin care markets. If we were to lose one or more
of these individuals, we might experience difficulties in competing effectively, developing our technologies and implementing our
business strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development programs depend
on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified
scientists and technicians in the future due to the intense competition for qualified personnel among medical technology businesses,
particularly in the San&nbsp;Francisco Bay Area. We also face competition from universities and public and private research institutions
in recruiting and retaining highly qualified personnel. In addition, our success depends on our ability to attract and retain salespeople
with extensive experience in wound care and close relationships with the medical community, including physicians and other medical
staff. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in
the rate of adoption of our products. If we are not able to attract and retain the necessary personnel to accomplish our business
objectives, we may experience constraints that will adversely affect our ability to support our research, development and sales
programs. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The dermatology, wound and skin care
industries are highly competitive and subject to rapid technological</I></B> <B><I>change. If our competitors are better able to
develop and market products that are</I></B> <B><I>less expensive or more effective than any products that we may develop, our</I></B>
<B><I>commercial opportunity will be reduced or eliminated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends, in part, upon our ability
to stay at the forefront of technological change and maintain a competitive position. We compete with large healthcare, pharmaceutical
and biotechnology companies, along with smaller or early-stage companies that have collaborative arrangements with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. Many of our competitors
have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing,
conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Our competitors may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">develop and patent processes or products earlier than we will;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">develop and commercialize products that are less expensive or more efficient than any products that we may develop;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">obtain regulatory approvals for competing products more rapidly than we will;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">improve upon existing technological approaches or develop new or different approaches that render our technology or products obsolete or non-competitive.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, we may not be able to successfully
commercialize any future products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The success of our research and development
efforts may depend on our ability to find</I></B> <B><I>suitable collaborators to fully exploit our capabilities. If we are unable
to</I></B> <B><I>establish collaborations or if these future collaborations are unsuccessful, our</I></B> <B><I>research and development
efforts may be unsuccessful, which could adversely affect</I></B> <B><I>our results of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An important element of our business strategy
will be to enter into collaborative or license arrangements under which we license our Microcyn&reg; Technology to other parties
for development and commercialization. We expect to seek collaborators for our drug candidates and for a number of our potential
products because of the expense, effort and expertise required to conduct additional clinical trials and further develop those
potential product candidates. Because collaboration arrangements are complex to negotiate, we may not be successful in our attempts
to establish these arrangements. If we need third party assistance in identifying and negotiating one or more acceptable arrangements,
it might be costly. Also, we may not have products that are desirable to other parties, or we may be unwilling to license a potential
product because the party interested in it is a competitor. The terms of any arrangements that we establish may not be favorable
to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory
or intellectual property position or for scientific, commercial or other reasons. If we are not able to establish collaborative
agreements, we may not be able to develop and commercialize new products, which would adversely affect our business and our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order for any of these collaboration or
license arrangements to be successful, we must first identify potential collaborators or licensees whose capabilities complement
and integrate well with ours. We may rely on these arrangements for not only financial resources, but also for expertise or economies
of scale that we expect to need in the future relating to clinical trials, manufacturing, sales and marketing, and for licenses
to technology rights. However, it is likely that we will not be able to control the amount and timing or resources that our collaborators
or licensees devote to our programs or potential products. If our collaborators or licensees prove difficult to work with, are
less skilled than we originally expected, or do not devote adequate resources to the program, the relationship will not be successful.
If a business combination involving a collaborator or licensee and a third party were to occur, the effect could be to diminish,
terminate or cause delays in development of a potential product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to comply with broad
and complex federal and state fraud and abuse</I></B> <B><I>laws, including state and federal anti-kickback laws, we could face
substantial</I></B> <B><I>penalties and our products could be excluded from government healthcare programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to various federal and state
laws pertaining to healthcare fraud and abuse, which include, among other things, &ldquo;anti-kickback&rdquo; laws that prohibit
payments to induce the referral of products and services, and &ldquo;false claims&rdquo; statutes that prohibit the fraudulent
billing of federal healthcare programs. Our operations are subject to the Federal Anti-Kickback Statute, a criminal statute that,
subject to certain statutory exceptions, prohibits any person from knowingly and willfully offering, paying, soliciting or receiving
remuneration, directly or indirectly, to induce or reward a person either (i)&nbsp;for referring an individual for the furnishing
of items or services for which payment may be made in whole or in part by a government healthcare program such as Medicare or Medicaid,
or (ii)&nbsp;for purchasing, leasing, ordering or arranging for or recommending the purchasing, leasing or ordering of an item
or service for which payment may be made under a government healthcare program. Because of the breadth of the federal anti-kickback
statute, the Office of Inspector General of the U.S.&nbsp;Department of Health and Human Services, was authorized to adopt regulations
setting forth additional exceptions to the prohibitions of the statute commonly known as &ldquo;safe harbors.&rdquo; If all of
the elements of an applicable safe harbor are fully satisfied, an arrangement will not be subject to prosecution under the federal
anti-kickback statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if there is a change in law, regulation
or administrative or judicial interpretations of these laws, we may have to change our business practices or our existing business
practices could be challenged as unlawful, which could have a negative effect on our business, financial condition and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare fraud and abuse laws are complex,
and even minor, inadvertent irregularities can potentially give rise to claims that a statute or regulation has been violated.
The frequency of suits to enforce these laws has increased significantly in recent years and has increased the risk that a healthcare
company will have to defend a false claim action, pay fines or be excluded from the Medicare, Medicaid or other federal and state
healthcare programs as a result of an investigation arising out of such action. We cannot assure you that we will not become subject
to such litigation. Any violations of these laws, or any action against us for violation of these laws, even if we successfully
defend against it, could harm our reputation, be costly to defend and divert management&rsquo;s attention from other aspects of
our business. Similarly, if the physicians or other providers or entities with which we do business are found to have violated
abuse laws, they may be subject to sanctions, which could also have a negative impact on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our efforts to discover and develop potential
products may not lead to the discovery,</I></B> <B><I>development, commercialization or marketing of actual drug products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are currently engaged in a number of
different approaches to discover and develop new product applications and product candidates. Discovery and development of potential
drug candidates is expensive and time-consuming, and we do not know if our efforts will lead to discovery of any drug candidates
that can be successfully developed and marketed. If our efforts do not lead to the discovery of a suitable drug candidate, we
may be unable to grow our clinical pipeline or we may be unable to enter into agreements with collaborators who are willing to
develop our drug candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to maintain sufficient
product liability insurance to cover claims</I></B> <B><I>against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product liability insurance for the healthcare
industry is generally expensive to the extent it is available at all. We may not be able to maintain such insurance on acceptable
terms or be able to secure increased coverage if the commercialization of our products progresses, nor can we be sure that existing
or future claims against us will be covered by our product liability insurance. Moreover, the existing coverage of our insurance
policy or any rights of indemnification and contribution that we may have may not be sufficient to offset existing or future claims.
A successful claim against us with respect to uninsured liabilities or in excess of insurance coverage and not subject to any indemnification
or contribution could have a material adverse effect on our future business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>If any of our
third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the manufacture, marketing
and sales of our products could be delayed, which could decrease our revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Supplying the market
with our Microcyn&reg; Technology products requires us to manage relationships with an increasing number of collaborative partners,
suppliers and third-party contractors. As a result, our success depends partially on the success of these third parties in performing
their responsibilities to comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they
are fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the resources
and expertise that they apply to these activities. For example, we and our suppliers are required to comply with the FDA&rsquo;s
quality system regulations, which cover the methods and documentation of the design, testing, production, control, quality assurance,
labeling, packaging, storage and shipping of our products. The FDA enforces the quality system regulation through inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In December 2011, we initiated a voluntary
recall of select lot numbers of certain of our Microcyn&reg;-based products due to product labeling. The voluntary recall was
prompted after notification by the FDA that a limited number of our products were improperly labeled. The recall was classified
by the FDA as a Class II recall, which means the probability of serious health consequences was remote. Customer safety and product
quality are critically important to us and to date we have received no complaints regarding customer safety or product quality
issues. The costs of the voluntary recall were nominal and there were no restrictions on our future sales of Microcyn&reg;-based
products, other than revising our product labeling for certain products. The voluntary recall did not materially impact revenues. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If any of our partners
or contractors fail to perform their obligations in an adequate and timely manner, or fail to comply with the FDA&rsquo;s rules
and regulations, including failure to comply with quality systems regulations or a corrective action submitted to the FDA after
notification by the FDA of a deficiency is deemed insufficient, then the manufacture, marketing and sales of our products could
be delayed. Our products could be detained or seized, the FDA could order a recall, or require our partner to replace or offer
refunds for our products. The FDA could also require our partner, and, depending on our agreement with our partner, us, to notify
health professionals and others that the products present unreasonable risks of substantial harm to the public health. If any of
these events occur, the manufacture, marketing and sales of our products could be delayed which could decrease our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>If we fail to
comply with the FDA&rsquo;s rules and regulations and are subject to a FDA recall as part of an FDA enforcement action, the associated
costs could like have a material adverse effect on our business, financial position, results of operations and cash flows.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our Company, our products,
the manufacturing facilities for our products, the distribution of our products, and our promotion and marketing materials are
subject to strict and continual review and periodic inspection by the FDA and other regulatory agencies for compliance with pre-approval
and post-approval regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If we fail to comply
with the FDA&rsquo;s rules and regulations, we could be subject to an enforcement action by the FDA. The FDA could undertake regulatory
actions, including seeking a consent decree, recalling or seizing our products, ordering a total or partial shutdown of production,
delaying future marketing clearances or approvals, and withdrawing or suspending certain of our current products from the market.
A product recall, restriction, or withdrawal could result in substantial and unexpected expenditures, destruction of product inventory,
and lost revenues due to the unavailability of one or more of our products for a period of time, which could reduce profitability
and cash flow. In addition, a product recall or withdrawal could divert significant management attention and financial resources.
If any of our products are subject to an FDA recall, we could incur significant costs and suffer economic losses. Production of
our products could be suspended and we could be required to establish inventory reserves to cover estimated inventory losses for
all work-in-process and finished goods related to products we or our third-party contractors manufacture. A recall of a material
amount of our products could have a significant, unfavorable impact on our future gross margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>If our products
fail to comply with FDA and other governmental regulations, or our products are deemed defective, we may be required to recall
our products and we could suffer adverse public relations that could adversely impact our sales, operating results, and reputation
which would adversely affect our business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We may be exposed
to product recalls, including voluntary recalls or withdrawals, and adverse public relations if our products are alleged to cause
injury or illness, or if we are alleged to have mislabeled or misbranded our products or otherwise violated governmental regulations.
Governmental authorities can also require product recalls or impose restrictions for product design, manufacturing, labeling, clearance,
or other issues. For the same reasons, we may also voluntarily elect to recall, restrict the use of a product or withdraw products
that we consider below our standards, whether for quality, packaging, appearance or otherwise, in order to protect our brand reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Product recalls, product
liability claims (even if unmerited or unsuccessful), or any other events that cause consumers to no longer associate our brand
with high quality and safe products may also result in adverse publicity, hurt the value of our brand, harm our reputation among
our customers and other healthcare professionals who use or recommend the products, lead to a decline in consumer confidence in
and demand for our products, and lead to increased scrutiny by federal and state regulatory agencies of our operations, any of
which could have a material adverse effect on our brand, business, performance, prospects, value, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Declining general economic or business conditions may have
a negative impact on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concerns over inflation, energy costs, geopolitical issues, the
availability and cost of credit, the U.S. mortgage market and a declining real estate market in the United States have contributed
to increased volatility and diminished expectations for the global economy and expectations of slower global economic growth going
forward. These factors, combined with volatile oil prices, declining business and consumer confidence and increased unemployment,
have precipitated a global economic slowdown. If the economic climate in the United States does not improve or further deteriorates,
our business, including our patient population, our suppliers and our third-party payors, could be negatively affected, resulting
in a negative impact on our business.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operating results may fluctuate,
which could cause our stock price to decrease.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fluctuations in our operating results may lead
to fluctuations, including declines, in our share price. Our operating results and our share price may fluctuate from period to
period due to a variety of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">demand by physicians, other medical staff and patients for our Microcyn-based products;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">reimbursement decisions by third-party payors and announcements of those decisions;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">clinical trial results published by others in our industry and publication of results in peer-reviewed journals or the presentation at medical conferences;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">the inclusion or exclusion of our Microcyn-based products in large clinical trials conducted by others;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">actual and anticipated fluctuations in our quarterly financial and operating results;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">developments or disputes concerning our intellectual property or other proprietary rights;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">issues in manufacturing our product candidates or products;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">new or less expensive products and services or new technology introduced or offered by our competitors or by us;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">the development and commercialization of product enhancements;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in the regulatory environment;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">delays in establishing new strategic relationships;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">costs associated with collaborations and new product candidates;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">introduction of technological innovations or new commercial products by us or our competitors;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">litigation or public concern about the safety of our product candidates or products;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">changes in recommendations of securities analysts or lack of analyst coverage;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">failure to meet analyst expectations regarding our operating results;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">additions or departures of key personnel;&nbsp;and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">general market conditions.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Variations in the timing of our future revenues
and expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated
earning shortfalls or losses. In addition, The Nasdaq Capital Market, in general, and the market for life sciences companies,
in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to
the operating performance of those companies.<B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If an active, liquid trading market for
our common stock does not develop, you may</I></B> <B><I>not be able to sell your shares quickly or at or above the price you paid
for it.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although our common stock is listed on The
Nasdaq Capital Market, an active and liquid trading market for our common stock has not yet and may not ever develop or be sustained.
You may not be able to sell your shares quickly or at or above the price you paid for our stock if trading in our stock is not
active.</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I> Anti-takeover provisions in our certificate
of incorporation and by-laws and under Delaware law may make </I></B> <B><I>it more difficult for stockholders to change
our management and may also make a</I></B> <B><I>takeover difficult.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate documents and Delaware law contain
provisions that limit the ability of stockholders to change our management and may also enable our management to resist a takeover.
These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the ability of our board of directors to issue and designate, without stockholder approval, the rights of up to 5,000,000 shares of convertible preferred stock, which rights could be senior to those of common stock;</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td><font style="font-size: 10pt">limitations on persons authorized to call a special meeting of stockholders; and</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">advance notice procedures required for stockholders to make nominations of candidates for election as directors or to bring matters before meetings of stockholders.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to Section 203 of the Delaware
General Corporation Law, which, subject to certain exceptions, prohibits &ldquo;business combinations&rdquo; between a publicly-held
Delaware corporation and an &ldquo;interested stockholder,&rdquo; which is generally defined as a stockholder who became a beneficial
owner of 15% or more of a Delaware corporation&rsquo;s voting stock for a three-year period following the date that such stockholder
became an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These provisions might discourage, delay or
prevent a change of control in our management. These provisions could also discourage proxy contests and make it more difficult
for you and other stockholders to elect directors and cause us to take other corporate actions. In addition, the existence of these
provisions, together with Delaware law, might hinder or delay an attempted takeover other than through negotiations with our board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our stockholders may experience substantial
dilution in the value of their investment</I></B> <B><I>if we issue additional shares of our capital stock or other securities
convertible into common stock.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our certificate of incorporation allows
us to issue up to 14,285,715&nbsp;shares of our common stock and to issue and designate, without stockholder approval, the rights
of up to 5,000,000&nbsp;shares of convertible preferred stock. In the event we issue additional shares of our capital stock, dilution
to our stockholders could result. In addition, if we issue and designate a class of convertible preferred stock, these securities
may provide for rights, preferences or privileges senior to those of holders of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will have broad discretion in how
we use the proceeds, and we may use the proceeds in ways in which you and other stockholders may disagree. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to use the net proceeds from this
offering for working capital and general corporate purposes. Our management will have broad discretion in the application of the
net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the
value of our common stock. The failure by management to apply these funds effectively could result in financial losses that could
have a material adverse effect on our business or cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The market price of our common stock may be volatile, and
the value of your investment could decline significantly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trading price for our common stock has
been, and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors,
including our historical and anticipated operating results, our financial situation, announcements of new products by us or our
competitors, our ability or inability to raise the additional capital we may need and the terms on which we raise it, and general
market and economic conditions. Some of these factors are beyond our control. Broad market fluctuations may lower the market price
of our common stock and affect the volume of trading in our stock, regardless of our financial condition, results of operations,
business or prospects. It is impossible to assure you that the market price of our shares of common stock will not fall in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When used in this prospectus, the words &ldquo;expects,&rdquo;
&ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;intends,&rdquo;
and similar expressions are intended to identify forward-looking statements. These statements are subject to known and unknown
risks and uncertainties that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking
statements. These forward-looking statements speak only as of the date of this prospectus. Given these risks and uncertainties,
you should not place undue reliance on these forward-looking statements. We have discussed many of these risks and uncertainties
in greater detail in any prospectus supplement under the heading &ldquo;Risk Factors.&rdquo; Additional cautionary statements or
discussions of risks and uncertainties that could affect our results or the achievement of the expectations described in forward-looking
statements may also be contained in the documents we incorporate by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These forward-looking statements speak only
as of the date of this prospectus. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change
in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures
we make in our Annual Report on&nbsp;Form&nbsp;10-K,&nbsp;Quarterly Reports on&nbsp;Form&nbsp;10-Q,&nbsp;and Current Reports on&nbsp;Form&nbsp;8-K&nbsp;filed
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless we state otherwise in the accompanying
prospectus supplement, we intend to use the net proceeds from the sale of the securities offered by this prospectus for general
corporate purposes. General corporate purposes may include additions to working capital, research and development, financing of
capital expenditures, and future acquisitions and strategic investment opportunities. Pending the application of net proceeds,
we expect to invest the net proceeds in interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may sell the securities offered by this
prospectus to one or more underwriters or dealers for public offering and sale by them or to investors directly or through agents.
The accompanying prospectus supplement will set forth the terms of the offering and the method of distribution and will identify
any firms acting as underwriters, dealers or agents in connection with the offering, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the name or names of any underwriters, dealers or agents;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the purchase price of the securities and the proceeds to us from the sale;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any underwriting discounts and other items constituting compensation to underwriters, dealers or agents;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any public offering price;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any discounts or concessions allowed or re-allowed or paid to dealers;&nbsp;and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any securities exchange or market on which the securities offered in the prospectus supplement may be listed.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Only those underwriters identified in such
prospectus supplement are deemed to be underwriters in connection with the securities offered in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The distribution of the securities may be effected
from time to time in one or more transactions at a fixed price or prices, which may be changed, or at prices determined as the
applicable prospectus supplement specifies. The securities may be sold through a rights offering, forward contracts or similar
arrangements. In connection with the sale of the securities, underwriters, dealers or agents may be deemed to have received compensation
from us in the form of underwriting discounts or commissions and also may receive commissions from securities purchasers for whom
they may act as agent. Underwriters may sell the securities to or through dealers, and the dealers may receive compensation in
the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act
as agent. Some of the underwriters, dealers or agents who participate in the securities distribution may engage in other transactions
with, and perform other services for, us or our subsidiaries in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will provide in the applicable prospectus
supplement information regarding any underwriting discounts or other compensation that we pay to underwriters or agents in connection
with the securities offering, and any discounts, concessions or commissions which underwriters allow to dealers. Underwriters,
dealers and agents participating in the securities distribution may be deemed to be underwriters, and any discounts and commissions
they receive and any profit they realize on the resale of the securities may be deemed to be underwriting discounts and commissions
under the Securities Act of 1933. Underwriters and their controlling persons, dealers and agents may be entitled, under agreements
entered into with us, to indemnification against and contribution toward specific civil liabilities, including liabilities under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities may or may not be listed on
a national securities exchange. In connection with an offering, the underwriters may purchase and sell securities in the open market.
These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short
sales involve the sale by the underwriters of a greater number of securities than they are required to purchase in an offering.
Stabilizing transactions consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price
of the securities while an offering is in progress. The underwriters also may impose a penalty bid. This occurs when a particular
underwriter repays to the underwriters a portion of the underwriting discount received by it because the underwriters have repurchased
securities sold by or for the account of that underwriter in stabilizing or short-covering transactions. These activities by the
underwriters may stabilize, maintain or otherwise affect the market price of the securities. As a result, the price of the securities
may be higher than the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued
by the underwriters at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This section describes the general terms and
provisions of the shares of our common stock, par value $0.0001 per share. This description is only a summary and is qualified
in its entirety by reference to the description of our common stock incorporated by reference in this prospectus. Our Restated
Certificate of Incorporation, as amended and our Amended and Restated Bylaws, as amended have been filed as exhibits to our periodic
reports filed with the SEC, which are incorporated by reference in this prospectus. You should read our Restated Certificate of
Incorporation, as amended and our Amended and Restated Bylaws, as amended for additional information before you buy any of our
common stock or other securities. See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have 14,285,715 shares of authorized
common stock. As of July 16, 2014, there were 8,466,745 shares of common stock issued and outstanding. Each holder of common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. We have not provided
for cumulative voting for the election of directors in our Restated Certificate of Incorporation, as amended. This means that
the holders of a majority of the shares voted can elect all of the directors then standing for election. Subject to preferences
that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are
entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may
determine from time to time. Upon our liquidation, dissolution or&nbsp;winding-up,&nbsp;the holders of common stock are entitled
to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding preferred
stock. Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or
sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and nonassessable,
and the shares of common stock offered, when issued, will be fully paid and nonassessable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Certain Provisions of Delaware Law and of the Charter and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provisions of Delaware law, our Restated
Certificate of Incorporation, as amended and our Amended and Restated Bylaws, as amended described below may have the effect of
delaying, deferring or discouraging another party from acquiring control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Delaware Law.</I>&nbsp;&nbsp;We are subject
to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general, this
section prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period
of three years following the date that the stockholder became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the transaction is approved by the board of directors prior to the time that the interested stockholder became an interested stockholder;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced;&nbsp;or</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">At or subsequent to such time that the stockholder became an interested stockholder, the business combination is approved by the board of directors and authorized at a meeting of stockholders by at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section&nbsp;203 defines &ldquo;business combination&rdquo; to include
the following:</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;&nbsp;or</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the receipt by the interested stockholder of the benefit, directly or indirectly, of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any
entity or person affiliated with or controlling or controlled by any of these entities or persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Delaware corporation may &ldquo;opt out&rdquo;
of these provisions either with an express provision in its original certificate of incorporation or in an amendment to its certificate
of incorporation or bylaws approved by its stockholders. However, we have not opted out, and do not currently intend to opt out
of, these provisions. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly,
may discourage attempts to acquire us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Charter and Bylaws.</I>&nbsp;&nbsp;Our Restated
Certificate of Incorporation, as amended and Amended and Restated Bylaws, as amended provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">our Amended and Restated Bylaws, as amended may be amended or repealed only by the approval of at least sixty-six and two-thirds percent (66-2/3%) of the total number of directors then in office or the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the shares entitled to vote at an election of directors;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">no action can be taken by stockholders except at an annual or special meeting of the stockholders called in accordance with our Amended and Restated Bylaws, as amended, and stockholders may not act by written consent;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">stockholders may not call special meetings of the stockholders or fill vacancies on the board;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the approval of holders of at least sixty-six and two-thirds percent (66-2/3%) of the shares entitled to vote at an election of directors is required to amend or repeal the provisions of our Restated Certificate of Incorporation, as amended, regarding the inability of stockholders to take action by written consent;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">our board of directors is authorized to issue preferred stock without stockholder approval;&nbsp;and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">we will indemnify officers and directors against losses that they may incur in investigations and legal proceedings resulting from their services to us, which may include services in connection with takeover defense measures.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transfer agent for our common stock is
Computershare Investor Services located at 250 Royall Street, Canton, MA 02021. Its telephone number is 1-888-647-8901.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
<B>Listing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is traded on the Nasdaq Capital
Market under the symbol &ldquo;OCLS.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 8 , 2014, our authorized preferred
stock, par value $0.0001 per share, was 5,000,000&nbsp;shares, none of which were issued and outstanding. We may issue preferred
stock, in series, with such designations, powers, preferences and other rights and qualifications, limitations or restrictions
as our board of directors may authorize, without further action by our stockholders, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the distinctive designation of each series and the number of shares that will constitute the series;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the voting rights, if any, of shares of the series and the terms and conditions of the voting rights;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the dividend rate on the shares of the series, the dates on which dividends are payable, any restriction, limitation or condition upon the payment of dividends, whether dividends will be cumulative, and the dates from and after which dividends shall accumulate;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the prices at which, and the terms and conditions on which, the shares of the series may be redeemed, if the shares are redeemable;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the terms and conditions of a sinking or purchase fund for the purchase or redemption of shares of the series, if such a fund is provided;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any preferential amount payable upon shares of the series in the event of the liquidation, dissolution or winding up of, or upon the distribution of any of our assets;&nbsp;and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the prices or rates of conversion or exchange at which, and the terms and conditions on which, the shares of the series may be converted or exchanged into other securities, if the shares are convertible or exchangeable.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The particular terms of any series of preferred
stock, and the transfer agent and registrar for that series, will be described in a prospectus supplement. All preferred stock
offered, when issued, will be fully paid and nonassessable. &nbsp;Any material United States federal income tax consequences and
other special considerations with respect to any preferred stock offered under this prospectus will also be described in the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may issue warrants for the purchase of preferred
stock, common stock, or any combination thereof. We may issue warrants independently or together with any other securities offered
by any prospectus supplement and may be attached to or separate from the other offered securities. Each series of warrants will
be issued under a separate warrant agreement to be entered into by us with a warrant agent. The warrant agent will act solely as
our agent in connection with the warrants and will not assume any obligation or relationship of agency or trust for or with any
holders or beneficial owners of warrants. Further terms of the warrants and the applicable warrant agreements will be set forth
in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The applicable prospectus supplement relating
to any particular issue of warrants will describe the terms of the warrants, including, as applicable, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the title of the warrants;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the aggregate number of the warrants;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the price or prices at which the warrants will be issued;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the designation, terms and number of shares of preferred stock or common stock purchasable upon exercise of the warrants;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the designation and terms of the offered securities, if any, with which the warrants are issued and the number of the warrants issued with each offered security;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the date, if any, on and after which the warrants and the related preferred stock or common stock will be separately transferable;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the price at which each share of preferred stock or common stock purchasable upon exercise of the warrants may be purchased;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the date on which the right to exercise the warrants shall commence and the date on which that right shall expire;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the minimum or maximum amount of the warrants which may be exercised at any one time;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">information with respect to book-entry procedures, if any;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">a discussion of certain federal income tax considerations; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and the warrant agent may amend or supplement
the warrant agreement for a series of warrants without the consent of the holders of the warrants issued thereunder to effect changes
that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests of
the holders of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As specified in the applicable prospectus supplement,
we may issue units consisting of one or more shares of common stock or preferred stock, warrants or any combination of such securities.
In addition, the prospectus supplement relating to units will describe the terms of any units we issue, including as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the designation and terms of the units and the securities included in the units;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any provision for the issuance, payment, settlement, transfer or exchange of the units;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the date, if any, on and after which the units may be transferable separately;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">whether we will apply to have the units traded on a securities exchange or securities quotation system;</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">any material United States federal income tax consequences; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font: 10pt Symbol">&middot;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">how, for United States federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The validity of any securities offered by this prospectus will be
passed upon for us by Trombly Business Law, PC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of Oculus
Innovative Sciences, Inc. appearing in Oculus Innovative Sciences, Inc.&rsquo;s annual report on&nbsp;Form&nbsp;10-K&nbsp;for the
year ended March&nbsp;31, 2014, filed on June 30, 2014, have been audited by Marcum LLP, an independent registered public accounting
firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements
are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file
with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a web site that contains
reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically
with the SEC. The address of that site on the Internet is http://www.sec.gov. The information on the SEC&rsquo;s website is not
part of this prospectus, and any references to this website or any other website are inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC permits us to &ldquo;incorporate by
reference&rdquo; the information contained in documents we file with the SEC, which means that we can disclose important information
to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by
reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus.
Later information that we file with the SEC will automatically update and supersede the information that is either contained, or
incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents
are filed. We have filed with the SEC, and incorporate by reference the following in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol"> &middot; </FONT></TD>
    <TD STYLE="text-align: justify"> Our Annual Report on Form 10-K for the fiscal year ended March 31, 2014 and filed on June
    30, 2014; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD> &nbsp; </td>
    <TD><FONT STYLE="font: 10pt Symbol"> &middot; </FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> our Current Reports on Form 8-K filed on April 1, 2014,
    April 2, 2014 and June 12, 2014; and </FONT></td></tr>
<tr style="vertical-align: top">
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD> &nbsp; </td>
    <TD><FONT STYLE="font: 10pt Symbol"> &middot; </FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> the description of our common stock contained in our Registration
    Statement on Form 8-A filed on December 15, 2006, including any amendment or report filed for the purpose of updating such
    description; </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, all documents that we file with
the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities and Exchange Act of 1934, as amended, after the date of
the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement
as well as all such documents that we file with the SEC after the date of this prospectus and before the termination of the offering
of our securities shall be deemed incorporated by reference into this prospectus and to be a part of this prospectus from the respective
dates of filing such documents. Unless specifically stated to the contrary, none of the information that we disclose under Items
2.02 or 7.01 of any Current Report on Form 8-K that we may from time to time furnish to the SEC will be incorporated by reference
into, or otherwise included in, this prospectus.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You may request a copy of any or all of the
documents incorporated by reference but not delivered with this prospectus, at no cost, by writing or telephoning us at the following
address and number: Investor Relations, Oculus Innovative Sciences, Inc., 1129 N. McDowell Blvd., Petaluma, California 94954, telephone
(707)&nbsp;283-0550. We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated
by reference in those documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Information Not Required In Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 14. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a statement of estimated expenses
in connection with the issuance and distribution of the securities being registered, other than underwriting discounts and commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%"><font style="font-size: 10pt">SEC Registration Fee</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">9,660</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Transfer Agent and Registrar and Depositary Fees*</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,000</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Printing Expenses*</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,000</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Legal Fees and Expenses*</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,000</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Accounting Fees and Expenses*</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4,000</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Miscellaneous Fees and Expenses*</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: black 1pt solid">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">1,340</font></td>
    <td style="padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">30,000</font></td>
    <td style="padding-bottom: 2.5pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">*&nbsp;Estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 15. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section&nbsp;145 of the Delaware General Corporation
Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses
(including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person
in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason
of such person being or having been a director, officer, employee or agent to the registrant or having served at the request of
the corporation, if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to
the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe
such person&rsquo;s conduct was unlawful; provided that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the
circumstances. The Delaware General Corporation Law provides that Section&nbsp;145 is not exclusive of other rights to which those
seeking indemnification may be entitled under any by-laws, agreement, vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section&nbsp;102(b)(7) of the Delaware General
Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation will not
be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except
for liability (1)&nbsp;for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders; (2)&nbsp;for
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (3)&nbsp;for unlawful
payments of dividends or unlawful stock repurchases, redemptions or other distributions; or (4)&nbsp;for any transaction from which
the director derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article VIII of our Restated Certificate of
Incorporation, as amended (included as Exhibit 3.1(i) to our Annual Report on Form 10-K for the year ended March 31, 2007, filed
June 20, 2007) and Article 6 of our Amended and Restated Bylaws, as amended (included as Exhibit 3.3 to the Registrant&rsquo;s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, filed November 4, 2010) provide for indemnification of
our directors, officers, employees and other agents to the extent and under the circumstances permitted by the Delaware General
Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have also entered into respective indemnification
agreements (the form of which is included as Exhibit 10.1 to our Registration Statement on Form S-1 (File No. 333-135584), as amended,
declared effective on January 24, 2007) with our officers and directors that will require us to, among other things, indemnify
them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent
not prohibited by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></P></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 89%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">3.1</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Restated&nbsp;Certificate of Incorporation&nbsp;of&nbsp;Oculus Innovative Sciences, Inc. (included as Exhibit 3.1 of the Company&rsquo;s Annual Report on Form&nbsp;10-K filed June 20, 2007, and incorporated herein by reference).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">3.2</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc. (included as Exhibit A in the Company&rsquo;s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">3.3</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Amended and Restated Bylaws, as Amended of Oculus Innovative Sciences, Inc., effective November 3, 2010 (included as Exhibit 3.3 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 4, 2010, and incorporated herein by reference).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">3.4</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended (included as Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">4.1</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Specimen Common Stock Certificate (included as Exhibit 4.1 to the Registrant&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">5.1 </font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Opinion of Trombly Business Law, PC.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">23.1</font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Consent of Marcum LLP.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">23.2 </font></td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Consent of Trombly Business Law, PC, included in Exhibit 5.1.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(1)</font></td>
    <td><font style="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(i)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(ii)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (&sect;230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(iii)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(2)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">That, for the purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(3)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(5)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">That, for the purposes of determining liability under the Securities Act of 1933 to any purchaser:</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&nbsp;</td>
    <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">(i)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">If the registrant is relying on Rule 430B (&sect;230.430B of this chapter):</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px; text-align: justify">&nbsp;</td>
    <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">(A)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;(&sect;230.424(b)(3)&nbsp;of this chapter) shall be deemed to be part of this registration as of the date the filed prospectus was deemed part of and included in the registration statement; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px; text-align: justify">&nbsp;</td>
    <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">(B)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) (&sect;230.424(b)(2), (b)(5), or (b)(7) of this chapter) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) (&sect;230.415(a)(1)(i), (vii), or (x) of this chapter) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <i>Provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(6)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 48px"><font style="font-size: 10pt">(i)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&sect;230.424 of this chapter);</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 48px"><font style="font-size: 10pt">(ii)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 48px"><font style="font-size: 10pt">(iii)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&nbsp;</td>
    <td style="width: 48px"><font style="font-size: 10pt">(iv)</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b)&nbsp;The undersigned registrant hereby
undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of
an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated
by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(h)(3)&nbsp;&nbsp;Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on&nbsp;Form&nbsp;S-3&nbsp;and has duly caused this registration statement on&nbsp;Form&nbsp;S-3&nbsp;to be signed on its behalf
by the undersigned, thereunto duly authorized in the City of Petaluma, State of California, on July 17, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><b>OCULUS INNOVATIVE SCIENCES, INC.</b></font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; width: 51%">&nbsp;</td>
    <td style="width: 3%"><font style="font-size: 10pt">By:&nbsp;</font></td>
    <td style="vertical-align: top; width: 46%"><font style="font-size: 10pt">/s/ Jim Schutz</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; border-top: black 1pt solid"><font style="font-size: 10pt">Jim Schutz</font><br>
<font style="font-size: 10pt">President and Chief Executive Officer</font><br>
<font style="font-size: 10pt">(Principal Executive Officer)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><BR CLEAR="ALL">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 25%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Signature</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 58%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Title</b></font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 15%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Date</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ Jim Schutz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jim Schutz&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ Robert E. Miller&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Robert E. Miller</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Sharon Barnari</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jay Birnbaum</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Russell Harrison</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>/s/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jerry McLaughlin</P></td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President, Chief Executive Officer and Director (Principal Executive
        Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer, and Principal Accounting Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P></td>
    <td>&nbsp;</td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014<br>
&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">July 17, 2014</P></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 66pt">* Power of Attorney</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>oculus_s3a1-ex0501.htm
<DESCRIPTION>LEGAL OPINION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 5.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; background-color: white"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">July 17, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Oculus Innovative Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">1129 N. McDowell Blvd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Petaluma, California 94954</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Re: Registration Statement on Form
S-3 Filed on May 15, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">To the Members of the Board of Directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">I have acted
as counsel to Oculus Innovative Sciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the preparation
and filing with the Securities Exchange Commission of a Registration Statement on Form S-3 filed on July 17, 2014 (the &ldquo;Registration
Statement&rdquo;), pursuant to which the Company is registering under the Securities Act of 1933, as amended, the following securities
of the Company having an aggregate initial public offering price not to exceed U.S. $75,000,000 or the equivalent thereof in one
or more foreign currencies,&nbsp;foreign currency units&nbsp;or composite currencies: (a)&nbsp;shares of Common Stock, par value
$0.0001 per share (&ldquo;Common Stock&rdquo;), (b)&nbsp;shares of Preferred Stock, par value $0.0001 per share (&ldquo;Preferred
Stock&rdquo;), in one or more series, (c)&nbsp;warrants to purchase Common Stock, Preferred Stock or any combination thereof (&ldquo;Warrants&rdquo;),
and (d) Units consisting of one or more shares of Common Stock, Preferred Stock or Warrants or any combination thereof (&ldquo;Units&rdquo;).
The Preferred Stock and Warrants may be convertible into or exercisable or exchangeable for Common or Preferred Stock. The Common
Stock, Preferred Stock, Warrants and Units are collectively referred to herein as the &ldquo;Securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The offering or
offerings may be offered from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act.&nbsp;&nbsp;This
opinion is being rendered in connection with the filing of the Registration Statement.&nbsp;&nbsp;All capitalized items used herein
and not otherwise defined shall have the respective meanings given to them in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection
with this opinion, I have examined the Company&rsquo;s Restated Certificate of Incorporation, Amended and Restated Bylaws, as amended,
both as currently in effect, and such other records of the corporate proceedings of the Company and certificates of the Company&rsquo;s
officers as I deemed relevant, as well as the Registration Statement and the exhibits thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In my examination,
I have assumed the genuineness of all signatures, the legal capacity of natural person, the authenticity of all documents submitted
to me as originals, the conformity to original documents of all documents submitted to me as certified or photostatic copies and
the authenticity of such copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the
foregoing, and subject to the limitations set forth below, I am of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">1.&nbsp;With respect
to the Common Stock, when the Board of Directors of the Company or a duly authorized committee of such Board (such Board of Directors
or committee being referred to herein as the &ldquo;Board&rdquo;) has taken all necessary&nbsp;corporate action&nbsp;to approve
the issuance and establish the terms of the offering of shares of the Common Stock and related matters and when such shares have
been issued and sold by the Company in the manner contemplated by the Registration Statement and in accordance with such Board
action, such shares of Common Stock (including any Common Stock duly issued upon conversion, exchange or exercise of any other
Security in accordance with the terms of such Security or the instrument governing such Security providing for such conversion,
exchange or exercise as approved by the Board) will be duly authorized, legally issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">2.&nbsp;With respect
to the Preferred Stock, when the Board has taken all necessary corporate action to approve the issuance and establish the terms
of any particular series of Preferred Stock, the offering thereof and related matters, including the filing of a certificate of
designations conforming to the Delaware General Corporation Law regarding the Preferred Stock with the Secretary of State of the
State of Delaware, and when shares of such series of Preferred Stock have been issued and sold by the Company in the manner contemplated
by the Registration Statement and in accordance with such Board action, such shares of such series of Preferred Stock (including
any Preferred Stock duly issued upon conversion, exchange or exercise of any other Security in accordance with the terms of such
Security or the instrument governing such Security providing for such conversion, exchange or exercise as approved by the Board)
will be duly authorized, legally issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">3.&nbsp;With respect
to the Warrants, when (a)&nbsp;one or more agreements incorporating the terms and other provisions thereof has been duly executed
and delivered by the Company and a warrant agent (a &ldquo;Warrant Agreement&rdquo;), (b)&nbsp;the Board has taken all necessary
corporate action to approve the issuance and establish the terms of the Warrants, the terms of the offering of such Warrants, and
related matters, (c)&nbsp;the Warrant certificates have been duly executed and authenticated or countersigned in accordance with
the terms of the appropriate Warrant Agreement, and (d)&nbsp;the Warrants have been issued and sold in the manner contemplated
by the Registration Statement and in accordance with the applicable Warrant Agreement, the Warrants will be valid and legally binding
obligations of the Company, enforceable against the Company in accordance with their terms, except as may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and similar laws affecting or relating to the rights of
creditors generally, by general principles of equity (regardless of whether considered in a proceeding in equity or at law), and
by requirements of reasonableness, good faith and fair dealing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">4. &nbsp;With
respect to the Units, when (i)&nbsp;the Board of Directors of the Company has taken all necessary corporate action to approve the
issuance and terms of the Units, the terms of the offering thereof and related matters, (ii)&nbsp;the Registration Statement, as
finally amended (including all necessary post-effective amendments), has become effective under the Securities Act, (iii)&nbsp;the
agreement relating to the Units in a form to be included as an exhibit to the Registration Statement has been executed and delivered
and (iv)&nbsp;the Units have been duly executed, countersigned, delivered and sold in the applicable form as contemplated by the
prospectus contained in the Registration Statement and any prospectus supplements relating to the Units, and the Warrants comprising
part of the Units will constitute valid and legally binding obligations of the Company, any Common Stock, or Preferred Stock comprising
part of the Units will be validly issued, fully paid and nonassessable and by reason of the offered Securities comprising the Units
being valid and legally binding obligations of the Company and/or validly issued, fully paid and nonassessable, the Units themselves
will constitute valid and legally binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">My opinion is
limited to the Delaware General Corporation Law and federal securities laws of the United States and I express no opinion with
respect to the laws of any other jurisdiction.&nbsp;&nbsp;No opinion is expressed herein with respect to the qualification of the
Securities under the securities or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">I understand that
you wish to file this opinion as an exhibit to the Registration Statement, and I hereby consent thereto.&nbsp; I further consent
to the reference to my name and firm in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>/s/ Amy Trombly, Esq.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amy Trombly, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_003.jpg" ALT=""></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>oculus_s3a1-ex2301.htm
<DESCRIPTION>CONSENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We consent to
the incorporation by reference in this Registration Statement of Oculus Innovative Sciences, Inc. on Amendment No. 2  of Form
S-3 (File No. 333-195554) of our report dated June 25, 2014 with respect to our audits of the consolidated financial
statements of Oculus Innovative Sciences, Inc. and Subsidiaries as of March 31, 2014 and 2013 and for the years then ended
appearing in the Annual Report on Form 10-K of Oculus Innovative Sciences, Inc. for the year ended March 31, 2014.&nbsp; We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">/s/ Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">July 17, 2014</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!<`KL#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^?4[^TTR
MTNKZ_NK6QT^SMIKV^O[V>.UM+*TM8FFN;NZN97CAM[6U@BDN+BYFD$4$4;R3
M,L0++X:O[5O[+!4%?VD?@&58!@1\8OAWA@1D$$>(\$$8(/<<T[]JD;OV9OVC
ME(!!^`WQ?R"`V0?AWXE7'/8@<@Y!R>!7^0GIVG::MA8XT^RQ]BM@!]E@XQ".
M!^[_`"'8<#H`?U'PU\-L-X@X?.*V)S;$Y6\JKX*C".&P6%Q2KK%T<34<Y_6*
MU'V;@\/RQ4.9-2;;32OYV-QTL(Z25*,^=3;YIRC;E<5I9/I*^O8_U[/^&K?V
M6O\`HY#X"?\`AXOAY_\`-'1_PU;^RU_T<A\!/_#Q?#S_`.:.O\A]=/TXY_T"
MP/(X%M`<`@'G]UUQSMZ^F1BE^P:=_P!`^QY&1_HT'3C'/E<9)^@')ZXK]-?T
M<\LV_P!:\Q?KD^6/\L:</]M3_P"@>'_@V7_R)_KO_P##5O[+7_1R/P$_\/%\
M//\`YHZ/^&K?V6O^CD/@)_X>+X>?_-'7^0__`&?IQ!_XE]D#@=+:#(Y/4B(X
MX7J`?3IS2+8:;@`Z?9`Y(YM8.>__`#S^]R/EZG.<]:7_`!+EEG_159AU7_(G
MRWIY_7;7\KA_;4_^@>'_`(-E_P#(G^O#_P`-6_LM?]'(?`3_`,/%\//_`)HZ
M/^&K?V6O^CD/@)_X>+X>?_-'7^1%_9NG_P#0/L?_``&@_P#C5(=-T\_\P^Q_
M\!X1_**G_P`2Y99_T568?^&;+O\`YL'_`&S/_H'A_P"#9?\`R!_KO?\`#5O[
M+7_1R'P$_P##Q?#S_P":.C_AJW]EK_HY#X"?^'B^'G_S1U_D0_V9I_\`T#[+
M_P`!XO\`XW1_9FG_`/0/LO\`P'B_^-T?\2Y99_T568?^&;+O_FP/[9E_T#Q_
M\&2_^0/]=[_AJW]EK_HY#X"?^'B^'G_S1T']JW]EL<C]I#X"`\8)^,/P\QG/
M'7Q'C/''O7^1#_9FG]M/L?QMH3TSC_EG[_CT[TQM-T]5)%A9!@IP1:P9[CKY
M8X^;D=#SGK2_XERRQ?\`-5YCIKID^7+IW6,3^::>NCW#^VI_]`T-TOXL[ZM+
M^3S/]B#P1\4OAO\`$N'4+OX;_$/P-\0+32;F&TU6Z\$^+-"\66NF7-U&9X+;
M4)]!U"^AL[B>-6E@AN)(Y7A5W5&1=Q[Y77GYP>3R>#ZXQZ!<8(Z]>^*_D3_X
M-+K>"#X*?MI)!#%"K?&OX:EEBC6)2?\`A7-[@G8!NQ@9)SQQC&!7]$?[0O[?
M?[%W[*'BW2?`7[1_[27PJ^#/C'7?#<?C'1_#GCOQ`NE:GJ7A:;4]2T:+7;:W
M:"3?I\FIZ1J-@MP&_P"/FRN4()CPWX-Q-PU7R+BK-N&,N>+SB>6XGV%.=/"2
MEB<1'ZKA<1*I]4P<<3*"A]:M-P52$8QC.;CSNWK4*ZJX>G7GRTU./,U*:48O
MFDDN>7*M5%/6SN['V7O7.-PSG'XCK_GZ>HIU?ES'_P`%GO\`@E-.2(OV\/V<
MYB0Y!B\;1ON`;D`QVAS@C!P200!SG-*W_!:+_@E2&\L_M[?LZK(20JOXZB5F
M/!&U6ME+C:0WR$CD8SG->8\AX@TY<@SKS3RG,-++HE@WMJ[:O;1=;]O1ZUJ7
M_@VF_P`IGZA[UQG<,>N??'\Z=7@/[/\`^TK\!/VJ?!5[\1_V<_BKX-^,7@'3
M_$NI^#KSQ7X(U0:KHUGXIT:UT[4-4T.>X$<834K.TU;2[FXMBI"PWEJ=S!P!
M[RC`(HZD+R,_,<`G(ZY)/Y9R>E>=4A7H5IT,32GAZU)N-6C7A.E6IU%:\*E.
MI"E.$H72E&=.$E>/NVU>B::33335TTTTUW35_P"MB6BF[E!P2!GIR.3D@@>X
M(^OMQ2[AZCDXZCJ>GYTN97M?7[[^EM_E?Y#%HI-P]1^'/I_4BF[QG!P.#SD'
MD8R./Q_+UHN@'T4A90<$@=>I';K_`)]C2!@>X^F>>^,^F0,_GU`S0Y);O^EO
MUZ?UY@XD#J0/KQ32Z@XR,]_8\8_G44S*5`P&#,HSMW@?,!GCC/7&>N#V!K\>
MO^"D7_!3OXM?\$[[+6/'>H?L%_%?XS_`+1/^$,M-2^/_`(4^*WPU\/\`@O2?
M$7C:_31;#1_$.@7/]M^.O#]I'X@N=*\,1^)+_P`.C0;_`,0Z[HVDVUW]MU2S
M@E[,LRW'YUCJ66Y;3I5L9B6H8>E4Q6%PKK5)2C"-&C4Q6(P]*I7G*:4*$:GM
MJNJI4ZKC)$5*D*47.HVH1UDU&4N5+=M14FDMV[62W:/V*WKC.>-P7O\`>/0>
MWXTI(`R2`.O/MUKX^_82_:EA_;9_9*^"7[5,/@6X^&4/QC\.7_B!?`5UXDA\
M73^'#8>)M9\.O:2^);;2=!AU<R'16O%N$T>Q"BX\DPLT7FO]>-@Y(R<=]QPO
M8$`9!&,L>W&?>N?$T,1@<5B<#BZ?L<5@L1B,)B:3<).EB<+5G1K4VZ<Y0ER5
M:=2/-"33LFM&KU&49QC*+O&45).S5U)7B]4GJFGZ,D#J1D,,9QU[_P#Z^/8Y
M!Y!IU?SF?M]?\%U?BI_P3Y\<0^%OB[_P32^,<?ASQ%K7B:S^%WQ+U+XX_#33
M_`GQ-TWPSJYL9M0TO4?"^B^.;O0M3FTY[+Q!_P`(EXDM=-\1VNEZC:3S610S
M21?T)^&-9.O:!H>N-;_8_P"V]&TK6%M3,+@VO]J6,%[]D,R1Q),UOYXA$RQI
MY^PR+&BL$'HYED.;Y5@<MS3&X:C#`9L\1_9V*I8W!8NCBOJRI+$<CP6*Q/)*
MC*M2C4A5]E.,I2@X*<9J,0JTYSG3BWST[<\7&<7'FO;XHQO>SV;.@HI,C(&1
MDC(&>3]/4>])O7.-RY'7D=NO^?\``UY',N7F7:Z5UOIHWMU-!U%("#R"".Q!
MS]?;CZTM6`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1136Z`@XP1^/(^7_@1P._ICFE)V5]-U>[LK
M7U^?;S`<2!C/<X'U_P`BD+*,Y(XY/MT_Q'YUR6O>,?"WAN[\/V/B'Q)H&@WO
MBC68_#GA:QUG7M,TJ_\`$WB&:PU'4[?0O#UG?W,%SK6MSZ9I.IZA#I.G1SZA
M-8Z??W:6[0V<[Q0:_P"./"'A?4/">E>)_%/AGPWJGCO79/"O@C3-;\0:1I&H
M^-/$L6BZOXDE\,^$K'4;JUNO$FO1^'?#^MZ^VC:/%>ZC'HNCZIJAM18Z==SP
MQ>I*R5*4N93<+0F^:,%)SE&U.7,HJ+<G!2C",92J2A&,G$.TW#&<C&<?C06`
M&20`._:O'+#X]?!+4_BE?_`_3_C'\*=0^-&E6;ZIJOPALOB1X-N_BAIVG0V\
M5Y/J5_\`#ZWUJ3Q;:64-I<VUU)<W.CQP+;W%O,T@BD1FZ_4/&WA#2/$OAGP1
MJWBSPUI?C#QK9^(;_P`'^$M1U_2;+Q/XJL/"$>FS>*[[PSH%U=Q:MX@L_#$6
MM:/-XAN=)L[N#1$U;3GU1[5;VV,X_:QDE*E-.4'4BG2K1;I13;JKFI*]-12D
MZD5*GRJ<G52C*4#^M-?7;\CLPZGHP_/Z_P"!_*@N@Y+`#U[=^_X'_)%?*/Q5
M_:>TKP#\6=`^`_A'X=^,_B]\8]:^&/B'XTS>!_!5_P"#-'N-+^%_ACQ%I/A*
M]\17>J>/?$OA;1[B]U/Q1K5GH7A[1+"ZN+[4;U;F2]DTNPB:\;L/@+^T#X'_
M`&A?@G\./CQX4AUKPWX4^)WAJQ\3Z/H_Q`M;3PMXPT>UU&\GT^+3?%.@2WUV
MVA:]#?6TMCJ.C7%RU[8ZBDVE7J17]O/;Q[U,+C*5&GB:F&J1HU?9NE)I<THU
M?;RHR]G&=2M[.M#"XB5*JZ*HU?93<*DG%P$FFVDU>+:DNS5KKMIS1OKU2W/H
M"D!!Y!R/7MW'7\/\Y%94FHV\,A@EN[6*8-"A@DO($F5KEQ%:J8G*N&N9F2&W
M5L-,[!8]S$*71:E92-;K%=VDJW(?[,(KNW?[1L<AC`$E)F$>QPYB#!75@?F5
M@.=RDU=0DTUO[UK-7OI2?36^WGH/^OZ_KR-/(]1U(_$'!_6DW+G&0"<<'@\@
MD9';H>N/3K67'?VDTUU;0W5M)=V04WEK%=P22V?F`O%]IA5S);>8H+H9T3>H
M8J1DFFVE]:ZA$MS8W5I>V\KO'%/:7,5U!YD<I5Q]H@>6,M&Z[60,&1MT94D$
MTN>2U<;:QO>-1)<R7+=NFDV[WCK%3BG*',E)H-;>O)W#`SDYZ8Z_E074`DL!
M@X/U^G6OS\\$_M^^"/'^J?"'4?#_`,+OBA>_"'X\?&#QA\#OA7\=K<^`;SP+
MK7C3P3+\1;74KC7-,L_&TOC'PCX8UO4OA=XMT7PEKNL>'DDU_6(=*TZ:PT^Y
MUS1H[WZ?^$'QR^&/QW\"6'Q+^&/BBT\0^#=3U[Q=X;LM5E2XTMI]:\">+M;\
M"^)K1;/5HK6['V+Q)X=U:TCD,(BO(H([ZUDGL[J"=^S$8#,<)!SKX*M2IQJ*
MG.?)S1IU'.I3="HZ<JOL:\:E&M3="NJ593HUH^R_=N0DXNUI1=TFM=TU=-=]
M-?1H]ER/7W_E_B*"P!`)`)R0/8=3^%8_]JV`DLX?M]CYFJ1F73(_MUL)=0A1
M4<R6,9F)O(PKHS26X=1'(A)PP(9-JE@D]S9M>V2W5E:B^N;8WD'VJVLRA+7-
MS;L_VB&U);B>1$B;(CR`0:Y+S;MR2LU9)4ZCDU?E=OW:O:4HQORJ'.W#GY[4
MV_Z_K;^M=C;R,9R,?_7Q_.DWK_>'7'X_Y[]*\A^"7QG^'G[0WPH\`_&OX3:_
M_P`)/\./B9X<TWQ;X.U]K"^TR34M#U6%;FQN9M+U2WM-3TYIHF5S:7]M;W**
MP+Q(6^;R7XK_`+5.F?#_`.+5A\"?"7PV\=?&7XO2_";7OCMJW@GP!<>#M/O]
M$^%>@^(K/P>NLR7GCKQ+X5T_5M:\2^)KQ]%\*>%]'N+J_P!0NM.OY=2FT:S2
MWN[G:&&Q<JU7#1H35?#JJ\13FG2E05"4(5YU_:\BHQI5)PIU76E2=.4X*HXN
MI&ZNK7NG=I)WT;ELOFDVK7T7F?7&Y<$Y&!P3^./Y_G2>8F,[ASG'?.!D_IS7
MB?P0^-?A'X\?!SX=_&KPM#K&B>&?B9X,T/QSI6D>-+&W\.>+-(TS7K=+BUM/
M%6B->W?]BZM;-*+;4;*2YF%M?H]LTC2(:YCQS\>9?AIXK\?3>-?`6K:-\!_A
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M/\_Y_P#KT@D0G`89_P`FO&/B!^T#\"OA1X5\/>.OBA\:/A)\-/!/BQ[./POX
MP\?_`!,\%>"_"_B:34;#^U+"/0/$7B+6].TC6WO=-SJ-HNF7EW]JL`+VW,EO
MB2K7CWXX_!GX4>$-.^('Q1^+/PN^&O@/69;"'2O'/Q`^(/A#P9X1U635;5[W
M3%TSQ-XBUC3M&U"34[%)+W3TM+^5KNU0W%OOA4R57+6?*U0J-R<HTVJ57WI1
M4G*,7[+WY0Y)N<::JR@XVE&FU)12U[)]G*.G:^NB?2]KZ6W/8`<]**P]"U[2
M?$FDZ3K_`(?U33=>T#6=.M=5T;7=%U*UU71]8TF_@2YL=4TS4["6YL=1L+VU
MDCN;2[M+B:WN(9%EAD>-E<[E4KJZDFFM&I)QDI+22E&2C*,DTTXM1:=TXQ:D
MDSP#]J<C_AFC]HWV^`WQ=)/_`'3SQ+_+^OL*_P`AVP!^P660<&RMQCG.#"@/
MIQGYL_7!.,#_`%XOVI_^3:?VC?\`L@WQ<_\`5>>):_R'M/&;"R'&39VPP<8P
M8E!Z]>.V#DX'3-?T[]')_P"P<6[-_7,GWT7^Z9FEZ6TUZ6OND?/YU\>'_P`-
M7_TJD?T;?L]_"C_@E7\$?^"-7PN_;=_;`_97F_:%_:`^)?QR^-?P@\!>%]-^
M,?Q;^'^I_$36_"_Q4^(VGZ+;7<7A3QQIN@>'/#/@KX>^#)[K7?$EMX7FD4V>
MF:;<K=>(/$6GK<?I[_P22_X)[?\`!*7_`(*6?LT^*/C]XF_X)Z>&_A)?:'\;
M_&WPJM?#'A_]I']IOQ59S:?X7\/^"=9@UF?5-3^)6FRF]O7\63VLMO#:I;)'
M9020-F5RO\8^L_$CXA^(O`7P_P#A9KWC3Q#JWPU^%%YXXU+X;>!;R[#^&O!-
M_P#$G78_$GC[4=#L410E]XNUN*/4=7N[AYIY62*VAEBM84C/]Y'_``:P`?\`
M#N;X@@X)'[8GQ>YP.6'@7X.DG&.#GGMC!`'W0/3\4,%FW#?"V;Y[0XBSZ.:X
M_BY5</4PN?9O1PN`RG'8O&SP>6X7`4\73PE-4L-3BZ\_92<<0^7#RC1BG*,#
M.E7Q%.BZ%#DCA[24J%-SG4IJGS5'4:N^:=FHNVBN^:1^,W[,L_\`P19^*7[?
MGB7]ASXW?\$V=&^%,,W[0?Q7_9W^&'Q<T+]J+]ICQ!H_B#QQX-^).O>`/`FA
M^+_#NH?$#3YM#N_B7/HD6FZ9?:=J-]91^+-3TK0W@B@U*"\C_#W]MWX<^#/@
M_P#MH?M;?";X;:(/#?P^^&/[27QF\!>"?#RZAJNJ)H?A'PGX[US0]`T=-2UN
M]U'6;]-/TRRM;9;S5=1OM0G">;<WD\K/,<O]K'4+W2?VTOVM=7TF\GTS5M'_
M`&S?VD]9TK5+-_)O-+U?2OVB/'&H:5JEC.K(]M?Z=J%K;7ME<QNLEM=V\$\9
M5X\C@O&D/QN^)GC#Q3\2?'GAWXF^,/&WQ`\0ZOXS\7^+-1\#^(S?>)O$GB:\
MFU;6=?NVL?#UO9"XU;4+J>^F:S@@M<SXCC"%<_IF1Y++*\?1S99UF%;+\PX:
MR^C5RW-<[QN84Z.:JI@<7/,,)',<;5CAUB,)5JT*U*-:I.%11Y/94:LJ<>2I
M5C4I2A[&*J0Q$G[2G1A3O3:FE"2I)IR5DT]$U=M<RU\W'IZ''^'Z8I`>?8Y_
M0@?KG^7X]%+X#\?JKO)\/OB$@4;RQ\#>+`J1JN6=G.C;41=S$R-D*N22.,<E
MYR-)+$&!FA<K-"X:*:$L`"LL<H61#@84L%^4;\,NW?\`8PJTZCM3JTJDNL:=
M6A4T[KV6(JMK=6Y8M6=^B.6S25W:UKIQFF]-M8)+=/67DKEM2#GD'!P?8_\`
MUSSZ#.!P*=4(`Y8'<=@3.3[?P]0<$-@GDGC&<F:K7_!\_GV[VZ;:[@%0R<JW
ML.!ZD,3U]]HJ:H)?N-]1_P"A-0U=->7]?D)NSC_BC_Z5#_,_MM_X--E/_"DO
MVS@,`GXU?#<@]O\`DGE[Q^7`SQD\\9K[M_;$_P""7]]^VO\`\%@/V;_CO\7O
M!::Y^R-\!_V7--O-?2_O-(ET;XF?&?1/BU\0-7\'_"_6=%-Q)K5QX?TQ/$&E
M>/\`Q+#)80Z'X@LM*L?"VHW5[I>J:WI-Q\*_\&FO_)%/VS0<'_B]7PXXZ\'X
M=WV#COCKCH<8Z<5_7$J*R[BJY9>3MY(*@')^O(]L>IK^(>/LZS#(?%#C3'99
M6^KXJM+'Y9]8C=5:%#-,HRG"8NKAY1<94L1]7C.%&LFW2=:I**YU"=/ZG!TH
M5<!A8U(\T4H5+/9RIU:THJ2U32DTVNME<_E6_P"#I;P7X/\`"?[`7P0'A?PE
MX6\,_P#&77@JR9O#_A[1]%/V)/@Q\<)4LP^FV-LZVFZ.%C;`^0TD,+F,M!&4
M_4/]D']E_P"`'[1O_!++]E?X9?&3X3^#/&7A3X@_LB?!C2O$T-YH&FVVK3B\
M^'V@NVIV.OV=M;ZQI>O65TD.HZ;K5C>P:G9:G!#?PW"W*AS^<G_!UN,?L#?`
M\<'_`(S%\'$`=!GX+?'4X)Y[G'H<C/I7[,_\$SA_QKR_8BZ$_P##*OP-;&<G
M/_"O-!(/.#GWZDC"]!F,QQF+I>$W!.(HXK$TL12XVXIJPQ%/$XF%:$Z>%RV=
M.4:RKJ?/3G&$X^\XQE&+BDU=U",?K^)O"+3PF'NG&-M9U$U;EZZ_)VU/SS_X
M)6_"S0/^"1'[,'QD^!W[87Q6^'/PDTVY_;1^/6K?!3QG\2_B!X)\,CXP_"5?
M#_PZA\'>.M(@EUA2=3U#1-.67Q)H"P)J.C:K;WZ3V45D]C<3_IU;_MU_L:3_
M``?U;]H"']I[X(R?!30_$Y\&:E\4#\1/#Z^"[7Q?';07)\+)KC72V]WXA:UN
MX+G^Q[0W.HM`XG6%T21EX/\`X*5?`;X-?'C]BK]I+2?B[\-O!OC^'PK\`_C-
MXG\'7OB/P]I>I:UX'\5Z9\.];U+2_%/@G6;RSN-0\)^)=.O[&QN[76M#FL[U
M)K2W221X$:%_YCO^"$/_``3D^`O[;/\`P3E^/NK_`!BCU'Q!XS\2Z_\`&_X(
M_"?6_$MEI7C70/V;+GQU\-/#>G>(/BO\&/`'B.VG\+:+\6=8OM6TS4M7\>SV
MC^+&@\*>'M(T/7M"LK:4S91P>3\593GO'?$N89OA,?3XFRK!YS#`87`5L/B(
MYO1ASXG!>VJ.O1K>QP%3$8B6)=6G&I]9E1IU%6PU"(IU*-2CA*-.$H2H3G2<
MYSYH^SZ3=K--R2CRV:5N9Z:_V&?!_P"-OPD_:!\!:-\4O@C\0_"/Q5^'FNW&
MHVVE>+_!&LVFO:)>7>DWTNG:I9)=VKL8]0TZ_@EM;VQN!%<VLJL)85)&?F3X
MO?\`!3O_`()\?`?QO?\`PX^+G[8'P(\$^/-'NC:ZYX4U#QQI]YJWAVX24PNO
MB6VTE=1/AP6\Z/!>2ZXVG1V,_F074D<J%%_G;_;$\%>,?^#?[_@CSJ?[._P@
M^/&I>-OC=^UE^TUXA34/C!8:(WPSO_`>@:]\/K&?XAZ]\/-#L]=U[4=$DTGP
M'\(_"_@J#6KSQ1?ZG9>+_B%>^,[2YT^WM].TC3OVL_X(\?L6?!_]EW_@GY\`
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M+B!9%\Z)"17@GQ-_X*`_L.?!C6]9\,?%7]K3]GOP)XD\.7MSIOB+P_XB^*GA
M*SUG0-3LLO=Z=K.E_P!IR7VE7]J>+BSOX8+F/CS8PQ`/\Q0U1O\`@DU_P<+^
M'_@]\#;=O"O[+W_!0#4?A=!XK^">B2"S\!:1XB^,FI:MX7TS6_#GA.T%OH7A
MZX\'?%?3+N_\/G3K:!M%\&^+M?\`".FJOA\V6GVW/_\`!VA\#O@[X'\(_LX?
M''PC\+O`7AOXL_$#QE\6=$^(/CK0?"^D:/K_`,0M/TKP-I6K:9'XXO\`3[2W
MG\576FWUL&T_4==DOK^SMI+FPBNDM;B2*O3RS@#*\7Q1PSE.(S',99/QEDZS
M;(LPPU+`4\;3<J6*JU<)FM'$.5"%3!XK`XS`U:N$?+5J^PQ%&*I5)T*<3Q<E
M0K3C"#JX:K[&I3DY*-U*-I0DM4I1G&<5+973:T;_`*F_CY^WQ^QC^R]XFT[P
M5^T-^TQ\(OA+XRU.UMM2L_"GBWQ;I]MXCDTV[G\BUU*?0[8W>I6>F3S!BFHW
MEM;6?EAY3*L2&0>KR_M"?`N'X-I^T3+\7?AQ%\")?#2^,8_C!)XPT-/AU+X9
M\MF36(_%K78TJ2WW1R6X2.X,[7@-CY#72M`/@SQ'_P`$@/V#M4^!OQ+\!^//
M@=X.^*WQ!^(GAW7]5^(7[3'Q1T#2?&?[3'C'XB7VCK)<_$^]^,6J6LGC/2?$
M<.LVL&KZ5I7A?5]!\(^'@&T/0/#^F:`SZ:_\Z_\`P;;?LG_";]JCP;^T-8?M
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M:&75M.@O-/C>Y@+W2I*C-\,_\'"P#?\`!'W]KUL=4^`+<`C_`)NA^";?+@`Y
MR,+P#N`W$=1^'7_!3+X`_"C]AO\`X+8?\$TOB/\`LJ^"?#OP/E^+_C'X:2>+
M_"7PTTG3_!?@=K__`(6GIGPMU^\T?PKX=M=-T;1(?%_@CQ%+I?B[3M-M8--\
M07$$FJ7UK)JFH:K=ZA^XG_!PJI'_``1^_:_4%B`/@(%^8C_FZ+X)X&3N()Z!
MPK$')`9@5/?A\@R[*^)_##,\IQ.-KY9Q+CLDS2A1S*&$6/PE6AQ+1R_%X:O/
M!_[/7BL3AY3H581IMT9^_3C*R,G6J5*..IU%"%2A3JP<J<GR24L/*I&23]^+
MLTFG=II-:6/'/^"5G[9'[*W[)?\`P2'_`&!KO]I;X^_"_P""X\3?#?Q6WANT
M\?>*K#1M6\0"V^)?C/[3+H>B,TFLZM%;R2Q)+/86,\,1EC1B))%4?M#\%/V@
M/@E^T;X-C^('P%^*O@7XO>"9;ZYTUO$7@'Q)IWB*PMM2LIIH+G3[X6,KRZ=?
M0R02^98ZA%;3B-?.6)HGB=OPZ_X(A_L%_L=>,O\`@FS^S?\`%WXD?LX_"/XO
M?$GXL^`M9?QAXO\`C/X)T+XO:J-)TOQSXPT?2_"'AN3XB67B2/P=X#TRRMU2
MQ\$>%4TCPVMU/?:E/87.IWUW>S?DG\3/#=G_`,$0_P#@N_\`"(?`&>]\*?LJ
M_MAQ_"S3O$OPGAEU3_A$-#\*_%CQI;_"KQ%X9M;=[C4!JTO@'XEZ9I/Q(^'N
MJS1IJ_A73?%&I?#_`$^2U\*SW*ZCUXWAO).*.(^-LORS&YQ1XDP6)XHSC#QQ
M='`?V1FBR['X_%YAEV'AAYRS#"8BE1]K+"8C%2Q%+$^PJ3J4L*JU.%-0KU*%
M#"SJ1A[&4</2ERRE[2FYQ45.;?N./-9/ELU?=V/MK_@[*5?^&5_V5R0"W_#2
M6L`$XR%;X6>*MPR,$9554KD`GEN`#7]!/B#]JS]FC]GKPM\)=!^.GQZ^$OPA
MUSQ=\.M+UKPQI/Q&\>>'O"6I^(-(T+2_#]GK.I:/9:S?6L^H66E7>JZ;;7US
M;*\=M<ZC:Q2,K3Q!OY^/^#LH'_AE7]E=6.=O[2&JJ26X)'PJ\598DXP<[B`>
M_)K]E/VU?V%OA?\`M^?L1:Q\&O&/A7P=<?$.[^"%Q!\#?B7KWAC3-9U[X1_%
M*[\&:?<>$O%?AS4YDAU;3[&+Q+IN@GQ9I&EZKID/BWP_!=>'M2N/LET63+$T
MLMJ<">&5/-ZN,H9;5S[C2EBZ^`AAY8O#TJF,R>#Q%.GBKT9^Q4U4J4Y-5)TX
M580G&IR-D746*QSIQC*:I85Q4W)1;5.K[ONZIOOM=J^A]2?!K]JO]FK]H;5O
M$6A_`GX]?"7XPZWX0L-&U3Q7I?PZ\>>'/%NI>'--UZXU"VT2_P!:LM&OKJYT
MZSU:?2=3MM/GN8HX[N:PNTA=C;R[?+M:_P""BO[!'AW6M=\/:[^V/^S9H^N^
M'-?U/PQX@TC4?C!X(M+_`$3Q%I&I2Z/JNB:I;3:NCV>JZ=JL4NF7ME<".>WO
M8VM9HQ*I0_@[_P`&MOQC\/1?!7]H?]D3Q3X)\*>`_C]^S[\2M3UGQ)!!H&C:
M+\0=?\'>,_$/B`75EXPU.WTNPU[Q?-\,/B;:>+_"$&I:S/>3:#H-]X5T"*/3
M]-M-'MF^LOAA^RM^S5^V'_P6"_:@_:BN?@A\+=4\%?L3>'?`7[-&EZ@O@O0+
MC1_B7^V-J5I/\7/BM\4/$\2Z1!I?B?QA\%_!'C_X=_#K0[OQ!;ZUJWAKQ!<Z
MEKEMJ:WD?AY=!\O,^%<GR3B/BK*\QK9U_9V0X%8G"8W"RRIU,:Z\<'_94JGM
MHQPSPV<RQU'ZE+#*I.C2CB9U88E4*DHZTZ]6M0P]6,::J59J-2#Y[4[.2JI6
MUO2Y6I7LGI:W,D?T"6S+)"KHP='^9'4@JZ$`JRE>"KKA@02&!#=ZL5#`"$P<
M]3UR3[]26'S9PI/RC@<`5-7P46VE?>R?7]=?P6M_(ZPHHHJ@"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`J*
M4,0,$`#)((4[CQQ@]3C=@9`SUXJ6F.H?@^AQQG!XP?P]._X5,X\T6M+Z;WMI
MZ=>WR[`?D-_P4*TG1XOVDO\`@FU\1;'X0^.?%^O_``>_:HU'QYX_^(/@/X(>
M-?B)J/P_^"M[^SY^T%X"OY-1\4^$O"FN7UKHMY\0O&7@Q+KPKIMS<ZG=F5-<
M.BR6&ER7D7Y_?M$>/?CAJW_!1G_@G?\`$CXT?LH?M-Z5XMTC]MCXM^!_A-IX
MNOV:)_AW!\*8?V;_`(\>'+;2?A=-9?M07=_K/B7Q.YMOC5\6/B#\1/#?P\N;
MOP;I,7A7PK:75UX$\/\`ACQ?_3P8AG@*!N4XQZ!03Z9PH`P`<`<]*XCQ)\-_
M`?C#7/!7B3Q7X'\)>)_$7PTUZ[\3_#G7]?\`#NDZOK/@+Q)J.A:EX7U#Q%X,
MU34+:>^\,:W>^&=:UGP_=ZIHL]G>W&BZI?Z5+,]E>7,$WT&79]'!+!0J8!5%
M@\MS7+O;0Q%>->I2S..9.5HOEHT8*MF$%6A3YU7P]%0<HRE4A6RE2YE-7^.=
M.;32:4J;A9KKM'KM+;35?@3\2[3]GSP_\2/^";OQN^`TGA7QW^RCJW_!23XM
MW_@>S^'>O^.U^-7B#]L_]HG5?V@/`7Q.\::AK?Q!FU-O%/PE\->/M=^+-[\3
M_!6EGPU)H^D:;;Z]::G>^"_!)\,ZCQ/A;QU\8M3_`."JO["/Q+^-?[)O[47@
MWXR^/?`?[97AK66\6S_LUGP9X8^'EY#\#8/#V@_#&/PK^TWXNNX?A;\%=/:\
MUSXDZ[KNGZ?\2/B%XO\`%U[XLT#P7J,6KZ=X%\!?OOH'[-?[/OA;XB7/Q;\-
M?`OX.>'OBC?7WB'4[SXCZ)\-O!^F>.IM3\6O+)XMU(^*K+1X=934O%DDK/XI
MU"*[2\\1OL;6IKUHHBO=:E\//`VL^,?"OQ!U?P5X4U7QWX&T[Q'HW@KQKJ/A
M[2;WQ5X.TCQBFF1^+],\+^(+JUEU70K#Q4FAZ,GB&UTNZM(=933--348[E;"
MU$?34XDI.FZ7U?%5H_V1G.5NOB,3%8F:S25></:RP\>2I&-2K3GCZEJ=3'SP
M^'E[*C"A"C.51:N[J-YTY\L5>,>1<K2YFK)VT2TBF]6W=?E#^WM\(OA7\9?V
MA_!%A\8?A5^T[X'?X?\`P5NO%'P*_;Q_9&C^*MM\5/AA\1M5\6ZY9^./@Y<:
MA\(+3Q%JDMGXA\/:'X0\3Z-X;\:^!?%?P_\`$=W_`&M8ZJEKK)T*'4/S<\'>
M"-6OOVE/V>--_P""DWP(C^-?QX\7_P#!&SQ2/C?X7T#X+67Q,U3Q-\3[;]H+
M3SI'_"3:%\/M'U'P[8?$B]TJ[73$\31Q6.@:9X^N]2&D:]H<+VUR/ZL'BPK%
M3M(#$%1M(..Q'N2QXR>`.<D^'W/[/7PFO/CGI_[2-QX8N'^->D>$KGX?Z9XW
M7Q7XU@F@\#7DTMY<>$3H</B*+PK+X;N-2D36[G1+C09=.E\216GB.:!M>LK3
M4(5E_%$L+A8X&MAZE2C0R[%X;#3IXFJJU*M7A&TJ%:I#V^"PU>NEB,=A\+6K
MX?V]*C7PF%P55UYUZG24FI)V;J0E+31J+3:<5[K:6D)-<T5HW-6M^#?[-W[$
M\FI_M(?L=^#?VU/@1KGQ$\1>!/\`@F#\$?`?Q!^(&M>$/%_BOPW9?M-?"KXY
M^`?BSX$T76_C5I&FP:=K/CWX?Z-X,M+F+Q+<Z[/I\\FCW.BG6[W^V6TS5L?X
M5_!SQ=\./B/_`,$\O!:_LS_%CPWJG[+O_!1W_@H%?>-?$.C?!+79_!'@3X2?
M'\?M7ZI\&?$'A_QEH^GS:)JWPL\33?%;X;3M+X7N;RP\+S6NI0^*M/T!M#@C
MO/Z;1&``-J[1A2N,#KR0,XVG/"XY..>.?RA_;S_:D^*?[._[1G[%_@C3?CU\
M%_@3\$_VC=3^.'A+XC^-_B_X(T[4+7P%J/PM^#WBOXIZ%XGM/&6O?$KP3X<L
MK7Q'JNFZ)X-NM`UNSD2?[2USIFJP:E<Q0'MP?$69YMF%6$<+A)SE@<75AAYU
ML73PE"6$P/$M?%5J%&E2JJ,J^$S?%?[)"ER5*F#PD%6M.JI9NC3A&[E+XHKF
MNG)\]2@DI2=F[2IKWGMS2=KVM^75C^RQ\4/$'[!>K^"_#O[.O[0/A[_@I=\-
M_@E\7?A?\>_&\6FW/A?2?C5!XF^/'PV^(7[0<B_$O6]6TKX?_'_6_P!I[PQX
M(UBV^`^M07GC!M"M/%&J>'M>?X8Z7?ZO#!^MO_!/WX4^%/`FK_'WX@^`;;XZ
MV&@_&"7X3:[-I/Q6^"GA7]G+P9I7BCPQX-U30+S3/`'P6T'P=\/]9T/7+#1U
M\-:7\3_$FH>%HM"\2ZUIVD6GAS6-9N-$UJ2#)_9?_;S\3^*?V=/@%XN_:/\`
M`M];?'OX_P#BCXPZ-\)OAI\(O"&N1:U\:_`_PN\3^(%T[XV>%_A]XPUZXU+X
M:>"_%'PRL_#?Q$U6S^(GB^&#PI_PE_A[0)M=NM8\0^'--U'V+PM_P4'_`&=_
M'>K?#/1?`]S\0/&.K?&+X;_&/XD_#BQT/X=^(Y9_$"?L^:S!X=^,WP[G2]CL
M6T/XO?#OQ-=6WAGQ'\,?$:Z3XELO$$T6EBVEF&1AFV(SNK1S+`SRMJF\;C)U
M<3A<1+&8?DIUJ5?%4*5>=)QJY=1Q>`G4P<8U,/1PBCCJ$:V*]A7AAJI>R7)+
MF3E:*BI^[*R346X)Z2<9^\]96:;MSJ_Y/_`[X)>*KWXH?LY?%O\`9W^#G[2/
M[*GQ)^,GQMD\0_\`!1;]BWXDZ+XSOOV-9/`NMZ3XMO\`XR_$NRT7XBV/B3X7
M:'XZ\2^)'\*ZM\-M:^"'B6U\0>*[[Q`+'QAX2LV'Q`O?#?@/@?\`9FMM!_8Z
M_8E^#GBK]D3X@6_Q.^!O_!4_P_XG^/ML?V;_`!G?0'X<:1\;?C#>>(?',/B?
M2/"EUI?Q!^&Y^&.I^#T77/#^H:SIFH^'+G2-)^S2RV[Z9;_J=;?MDQ>-OVN?
MV-OB)X`^-.K6'[('[1W[%/[2_P`<-?\`#WCC1O#OA'PKID/P?U/X0ZCX=^)%
M_?\`B+P]I_C;P5=66B>/_$?_``EUOK/B2/18++3+&XN=+L)K.ZN)L;PO^W/#
MXN_;0^%7B71/'OQ8\*_LB?$G]A7X_?M*:@GQ@^'FD^!OAMJ'AGX7>+O@K%X/
M^-W@'Q'J6@6WCJQT;4_!OC+Q9K'B?0?%FK65_::!/X/\57'@_1;#Q%I5[JGN
M3QO$$DXU,MBG0PKS>+E7S2&.PSRF?$.!AE.(Q2PU/%8K%X2.8XC!X*CB_K>(
MI8?!X*,\PJPY696I.\E-V<E2T4'3YIJG/GBOAC&4(IRE&23<YMKFNCXV\<?L
M-'PE^T-\;?A3<>"?V@_"'P>L;?\`8QO/^"?A_9O^$7@KQV?#'@?X":/X/2R^
M$G@[XX>/?"_BJ7]FGQ+X%^-OAWQ!XR\4W'CWQ7X"\*Z_X!\=R:U+XB\20IXH
MT_0NK_9Z_90U_4?CUI(_:-\/?'W4/V@O`_[87[5OC+Q"="^"/@"+X+_%CX-?
M&CQ%\5O[`\2>.?VEM:\(RR_$[]GZ]^!WC?X=>%9/@OJ_CV;XA>'_`(@>#/"?
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M.*IXW!U8\D=HTZ5U%-2^*7+=-<LY\Z32?+:&T+V?*K-,_*C_`()C?$?0OV5O
MV1_^">_[-'B[]FCXX_#OXH_%74;OX$?$Z[_X4TG@W1O"7[0'P[^!]WXY\0>(
MOBI?:[>>'=8\5:1XL\*^`I/#OAKXK^`]*^(WAS6-0T&'3M3UW2[/3)9[;JOV
M[/A'\,_C3^T/IL7Q;^%G[4GPVU_X6_![3M?_`&7_`-NO]D.R^*R?$;PEXZ\2
MZ]XEE^(GP:UN\^&$6NQ:M$5\+?#KQ=X9\*?$KP1XD^%7B"6\UW3M4N-)UK[)
M;:WZEJWQ<^(?[2?[<7QD^`'P3U/X>?"VU_8J^'?P[D^('QW\3?"[3/B?\4+O
MXG_M&Z;XDU[3/A?\-+;7M2TC2?!WP^TCP;X+\.>(OBCXB?\`MK5OB!?ZQIW@
M_1X/!?\`PBK>*-5\U^'?[3W[:'Q2^.7@[]B/Q%>?"GX3?'WP7\+?BM\<?VJ_
MBQX5\%7?B30M,\!V_P"T7XP^$?[.&C_`KP!XB\:Z]8:3?_'+P9X>?XIR^(/B
M5X@\7OX-\&V,6C7_`(3O_&'B.YE\'.$L7#,<1G6%I4\)C7@<5G&.A_:^)5?#
M8?-JCQ]+$MU,!B'.@L%6H8.M@:U/'K$4\TP]+&X:4ZU.6'EJ'+&D_>A>%.-Z
M<;<U-*%M)1U;4I*>DH\DG'2*YOA/Q3\$_P!I9+#5_$'[4G[/7BSXI_&_]HC_
M`((P^)_@/\0]>^&7PCTOQK9>-/VI_"OCN]UKPIX0\?V_@>WE\*>&/'"^&-4\
M+ZSIFMZW)HW@*WU+P_KMEH'B2W?1M*L)UTO]G3Q)XRTF?P>W[.'CF[USQ;_P
M;]>!_@/JJ^(?@QXDTC3M4_:6^'-JFJ>%?AYXBUOQ!H%CI3?$;PI?:7I%UX9&
ML79:RNK#3O[)U$26ULB_KO\`L?\`[3WCSXC_`!E_:\_90^-!\*:M\9_V-?&_
MPRT76/B!X$T;5/#/A#XL?#OXT_#+1?BG\-_&@\':MJOB&?P3XQL;'4M1\)>/
MO#EKXEU_0Y]>\//XI\-W>FZ/XEMO#'AWE_V_?VNM6_9>\8_LNZ%X@\<Z%^SY
M\!?C9XX\;^$?BS^UKXLT;3]=\,?!K6-`\'MXA^&WA"^N?$,J^!_`<WQ8UR#4
MH)_BA\2;75/!?AS1?">M:1<Z?9:QXDTKQ7X7[J><9K]>AE5+*L"L9+#O&T5A
M\1B(4*N'JY?0S7#3P6'I4&^2>6X>G+"8/#0>(K\LL-2HQKP5"$JC!1<G5J2B
MKPDY.,G=2<&I2=M>9M2E*R3NV[-L_)GQ#^SI<>/KC]F^S\:_"K]H'P'^RCXE
M_P"";>L_L^S:%X&_9$/B7Q3\(_VH[^_T'_A<[ZU\*_%?P[\0^(O`7Q`^)_AV
MTTS3?!/QZ\-^$9=)U/Q'X+DL;CQW;:?%IL_B+]-/V[OA9%KO_!)GXJ?!?7/A
ME\1_C)XYU+]DW6/AG\//!OB_P79_&CXL:C\8KCX0:KX7\!WOBI?`FF^)?#B>
M/X-=9&U[QWI<D?A?2M;GOM1CUV&TEM9Y]'X"_M\Z]K7P;_9H3XG^$9_&_P"T
M)^TWXI^.^D_`SPW\,;"T\/V/QV^#7P2\8ZW9Z;^UA9P>)?$$^E_#7X2>/?A0
M_P`,OBJ[:IXGUB"P/Q;\%Z#X<F\0?\)%HOF^C:)_P42^%7B[2OA[I_@3P=\1
M/$GQC^)7QF^,'[/>F?`F\L=(\,>./#7Q=_9_\/\`B+Q5\8?#?CK5]=U6U\%>
M&;#POX>\,_VSI^OOXAN].\7:;XC\'7?A/^UK;Q';3IQXS%9W5Q^#J_V7#ER?
M,WC.3"5Z<L-7K83&8V?UBM6C&G5A3DZ&*PN(Q]1QIUY82OSJCBZ6)@5%4N5I
M2O[2FU=WYFI0C)I='[KC/ECS-)JUXM'QQX,TOQ5X+_;$_9U_:L^(/PT^*OB/
M]GR7_@F%H_[.7A:WA^$7CK7?%7P6^/\`X6^(]QXJ^*^C^*/A=)X?;QQX1F^-
MG@F+P=X6TCQ)8^'KW1?$5[\*&\/:WJVF65_X3E\2>!?L7_L]_';]EWQ9_P`$
MY?BG^T+\*/'!^%OPV_9N_;E\`:%X/T'P_JOQ#UW]CKQ)\=/V@O"'Q5^"WA;7
M?!_@*T\2ZK;?;/V=M(B^"#ZAX;LM7T3X<:CX07X>O?Z?I&NZ:]]^H?A+_@HO
M\'?B7X4_9YU7X5>&OB%XW\?_`+3NI?%?2/AQ\(QI=EX?\7Z5<?`"^U31_CI>
M_$75-6U"+PEX'\.?"[Q%I+>%=7\176N7FEZ]XKU;PKX>\(/K^H>)M*$\&D_\
M%'O@WXKLOAKHG@3PYXZ\5_&?XH?%OXY_`73/@9':Z-HOC#PU\7?V9DU,_'OP
MAXW\1ZGK$?P^T!?A]_9BA/$$?BJ_T7QG;ZOX=U3P->^(-'UVTOPYXW/J=+$X
M*>1SIPK8.I@,5"I.M&M1P>%AG^$4XU:DZ+P<Z;QF9PQ&9<BIXJK@9PJ2?)B8
MS%3I-PDIIM3]HK;-OV4WHD^;X*<E%MM*6E[IE7_@EM\)OB#\'?V4X_#7Q"\)
M:A\-HO$?QZ_:C^*/PW^$^J6]I:ZM\*/@Y\7/VAOB1\1?A=X$U6SLYYXM)O[?
MPEXDLM?NO#,DOG^"7U\>")(;5_#S6=O^D$3`QH21DC)Z#FO`/V:_VA/`O[4/
MP>\-_&KX>6^NV'AS7M7\>>%I])\5:<ND^(_#OB_X6?$/Q3\*/B+X5UJRAN;V
MT^W^%_B!X*\3Z#/=Z=>W^D:E_9JZGI%_?:7<V=Y-]`IC:,#:!D8Z8()!ZXXS
MG!QR.:^5S:MB:^98^MBZ$<-C*F+KRQ&'Y&E0K*2A5I*+<K.FX0A.3G*=2?/5
MFVZO,]H*,80C%\T5%*+VNMT_373LM%9)'@7[4_\`R;3^T;_V0;XN?^J\\2U_
MD/Z<";"R'K9VV?IY0X]03Z]AGOBO]>#]J?\`Y-I_:-_[(-\7/_5>>):_R'M/
M)&GV1''^AVV3U_Y9#'YG`(ZD9`YY']*_1R_W'BW_`+#,F_\`47,OZ_0\+.?C
MP_\`AJ_^E4BTQV@=0#D?PXR<]C@`@;B1VP!R":_OX_X-8#_QKF^(`=AN_P"&
MQ/B_G&`0W_"#?!S`(]2I!(/S;#D`<&OX(_"NH>&],\6>%]4\:>&[KQEX.T[Q
M#H]]XL\&V6O7OA&]\5^&[34+>?6_#=IXKTV"XU/PU<ZUIT5SIT/B'3[>6]TE
MY4OK2)IXD5OZ4_V5O^#AWX2_L4_"6T^!_P"S1_P36T;X>?#>SUW6?$[:7+^U
M'XI\5ZKJ/B3Q`]LVLZ_KOB?Q-\.M3UO7-7O5LK."2]OKV0I:65G:VR0VUO#$
MGWWBYDN=\2\-4\BR+*JV/Q5;'X#'RJK%9?A\+0HX2>+<J=66+Q=&LZU?VT/9
M>SP]2DHJ3J5H22HRY<MJ4Z-=U:M1148SA90G*3<N5WM&$DDE&S;DKOIO;\#_
M`-L!%E_;!_;&7!96_:[_`&I,@'"X_P"%]?$#=AU(W+\H`8988RK*P4C^UW_@
MV@_;$_:9_:>^$7[2WAC]H;XN^(_B_:?!;Q=\,=)^&^I>+K/P]_PD6@^'_$OA
MC7IK[P[/X@T71]*U'Q'86\VB6DVG7/B>;6M8M/-E@_MB6U,5M;?R#_MU?M/_
M`+.O[67CZ;XK_"#]C:R_95^)/B_QOXW\=_&G7=#^-OBWXDZ!\4-:\:7*ZU<:
MA;^"=9T?1?#7@C5V\37FO:_K&I^&K2$ZY/JOV>YM88X(B_\`3)_P:5%QX$_;
MH88R/'?P1Y.UB?\`BE/&P&>@P1TQ@;<'H,GR/%6DL5X4U,3F.5K!X_`?V'1I
MTL<\%B,7@:U/$Y?@,1/#8K!SQ-*-'%4\.U+V.(@YT%35:E%KV2TP#<<P485.
M:$G6D^5S49IPG**E%J%I1NG9Q;BTTGK<^6_VR?\`@K=^WG^R[_P6<^)G@'PK
M\>?$_B?]G[PI^T'\-O!EQ^SKXAT/P%J'@75/`_C#PY\/;+7=`L;T^#E\9Z3?
M?:=>O]:TC6++Q7'?6>K;1.;S2Y+C3+G]=/\`@XO_`&0OV=_%W[`?Q/\`VCKO
MP#X-\-?&WX%:AX"U/P-\0M#T?3-#\2ZK:>+/B7X,\$Z[X#UJ]L(K27Q)HVMZ
M7X@N;NRTS51J"Z?J^GVFH::+)S>2S?G;\;_BA_P1<^!G_!;+XK_%G]J^+]KR
MX^,OA'XM^%]7U37?',7P\U[]C[X<?$>S\$>%I?#/CN#PO\.?#6G_`!AO=&T"
MVAT*Y@O?'%[X^\/Z!XAFN/$>JZ386.A0ZSI.U_P<'?LY?\%4_B'\*[WXQ^+/
MB?\`"/XM_L5?"Z_N_B)K/PN^`/A37/A[=?#K1H)I5T;XH_$S3/%OC+QMK/QG
M'AO1]1CAU?QAX<\16.C^&+,:CXRL?A5X7T,Z_K5G\!0H8>IQ-X1RP5"7`[HY
M-E=7%YQF&%644>)ZL)8.3PF!^JSK4,TK8J'M,*ZN/J8=UH9K&5>G^[HPGW2;
M6'S'G?UJ]2JHTHR55T;7LY<]G#E;4[)/EY;JRNS^-U."W.1V&!R1M`P2!\Q"
M'*DX&``.U3;L8`QV'7&,].YZG@?A@MG`^_?V0O\`@F/^U'^W/X>N==_9PN_@
M/XBN[._UFPO?`GB3X[^"O"?Q1M8=`&G+>ZW<_#R_,OB6+PQ*^J6T-GX@>T.F
MWDOFB*5$\I:]]^+W_!#']OGX!^%9?&GQJ_X9?^%WAF"'47@U/QS^U#\./#$>
MJ7&GZ?-J,VE:'_;DNGQZQK<UO`YM=*LVENKDXCCC0R)(G]$U^+^%L+C99;B<
M_P`KPV84Y^QG@:V)E#%QJ))*#PSH2KRGNK4Z=:+<9R4W"-2</$6&Q#CSQHU)
M0M=3C&\6K73YKVL^FOJDVD_R&!'J.3Q[]2#C)Z@$CDY'-0R\*?J/U9C3(I#)
MY;X<[\-\X52H9"P!Q@Y&Y@PY"E<<'EI)ONG_`(#_`#:OHW=7OO:^Z>CC=-6Z
M.,D_GLG=&#Z7WYH_^ETS^V__`(--/^2+?MF_]EI^&W_JN[^OZXB<1>F4)X[`
M_AVR.QZ<`]#_`"._\&FG_)%OVS?^RT_#;_U7=_7]<BYVH!_=!/X`$=^A/!P#
MU[9R/X+\5?\`DXO%VE_^%.+\],!ENVC?II?L?6Y=_N.'_P`+_"=4_ET_X.N;
MF!/V"_@19O-#'?7G[8'A.6TM9)8UN;I;7X*?'%[J6VMBWGSQVJRQFX>&-HX`
M\8EV>;&K?LE_P3!U33]5_P""=/[$-]I&H6>I61_9?^#5DM[IUS!?6OVO3?!>
MD:;J5F+FW=XQ=Z=J-I<Z=>0G$MK?V\]K<)%<021I\O\`Q*_X()_\$W/C)XNU
M+QS\6/A]\8_B#XIU+4M9U.35O&'[47[1GB*:QDUZ_P#[2U&UT:/5OB7=PZ'I
M;W`A2#3-)CL[&VM;:RM+>".WLK6.'VW]DK_@DO\`L6_L/_$#_A8G[-GA+XF^
M!-8;3->TJYT6X^/?QJ\3>!;^'Q#Y!U&[U'X>^)/'&J>"K_53+`L]IK%UH<NH
MV-U-=75K=17%U/))KF.=<*U^`LGX7PN8YS/,LGS?-,YC5K9)1I8/&5<TH8:E
M+`\ZSBK6PT**H/EQ<J553;;EAHQY4$(5UBZM:4(*G.G3II*JVXJG)M3M[*+;
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M^S-\5/\`A-?'UA!)>R7*?!SQOX2UOP-XVUFPL[6WN?M<GAGQ!?>`O$>L/-)9
M1:;X*TWQ9J4=P\]I!8WWZM?\$N_CKH'[1?\`P3X_9%^)N@:S_;MU+\"_AWX1
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MLAJ,YD^(_P`:.`!NP_PULLN`>H4R*&88"AB2RGYA_2K^R)^P]^R_^P[X#U/X
M>_LS_"S3OA[I6OZE;ZOXPUJ34-7\2^./'VMVPN1!K?COQUXGOM5\5^*]3B:]
MO[B&35]4N(K*;4=1>S@MWOKLS?+?[2'_``1>_8*_:U^)^O?%O]H'P7\6?B+X
MNUV]GOB-3_:,^.\7AK0/M4%E#=67@WP=:?$"#PQX,TFY%A;37.D^&-*TNPN+
MI&NI87N)'<_3Y7QSDF%XJX0S"K',L/D/`^31RG*X1PE+$YGF,G1QZQ6)Q,%B
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MS/-/V;/^"+/[`'[(OQ8\.?&C]GWP!\3/AWX[\.22-%<Z;^T#\<+C0]<M!:7]
MK'I?B_PK>^.Y_#GC'1+?^T;J[M-&\3:9JFGVNHF/4(+>.]BCF7Y_+<TX<P'#
M'&>1RQ^9U<3GU?*Y994CD\(4O99/CZF/H3QC_M7FHU,<ZSH3ITH5XX3E57FQ
M*G*$=)TZTJ^&J*,.6C&HJG[R\KU*<:;C"]-VC!1<^:\7/X7:S;_%7_@O.Z1?
M\%:/^"0+NZ1JGC/X?%VD945<_M*>"L;V8@1HS84,2HS\HPWRU^K_`/P<+R;/
M^"/_`.U_D,1YGP`0CCI)^U/\$4!&Y3G`DR<]L<]&KH/C%_P0B_X)Q?M`?$'Q
M-\4_C+\-_BM\0_'/BN_O+[4];\3_`+27[0&IR0Q7=[=Z@NC:-!<_$22WT#PY
MI]Q?7+:/X=T:.QT;1XW,.G6-M&JBOHCXP_\`!.3X$?&/]B'6OV`M=\0_&K3O
M@;K<O@TW>L)\4]:\:_%I;/P3\6?#7QBL-+3XD_&"#XFZM=Z?>^(/"EEH%XNK
MQZC=V?A&XN]*\.WFAW4>DZCIWHSXDX=@O#*5#$YE7J<%U<+'-(SRN%"%?#1S
M^.>5ZN!G_:=>52=%RGAH8>M"DZ_+"LJM-MTE+H57]?O&$?K2?LVZCE:2H.C'
MG481:C9IMIM[K6R:^:O^"!?BKP]XD_X),?LD66@ZQ9ZK=>$O#WC;P;XH@L9T
MGET'Q3I/Q'\67.HZ+JJ*Q:UU"&TU+3[_`,E\&2SOK.\A#VUU#))^+?\`P4AT
M"3_@HE_P<!_LH_LO?"&:7Q):_LCZ%\+_`!?\?-:T_?'I7@&R\%_$G2/C=XXE
MO-9MK;4(8YM/TS4/AAX5_?11VQ\>>-=+\(37%KJ@U'^S_P!N]:_X(K_LCZ5K
M_B?Q)^SAXJ_:;_8>U'Q[/IC?$6W_`&-OC_XI^$OAGQ[#I,-Q:VUMXA\"ZE:^
M,/`L5RUM=W%M_P`)#H'AK0O%=G#/(--\0V1DE9OKO]CS]@[]F#]A?P;K7@_]
MG'X<CPFWBS56U_QYXRUW7=<\:_$OXBZ[)>7][_:WCWXA^++[5/%7B>Y@N-2O
M6LHM0U`V=A]JN!96L!FE+E#BC(<HSWB3BG*:^8XO,\YH9[1RG+\9@*>&CE=?
MB+VL<=B,PQL<77PV8+!8?$XNE@Z6`P]&-:M/#U\2Z$:56A5'AZLZ5&A.,(TZ
M?LO:34W)U%1LX*$7!<CDU%R<W-))I*3:DOY__P#@[*GC_P"&5?V5RSQQL_[1
MFM7(21T5O)A^%7BCSI]A(9HH6DC$L@5EC,L>]U+H:_J%^'#QS?#[P!-#(LT,
MG@GPE*CQNKI+$^@:<Z2QRH2CHR8975F1E^97P17YW?M,_P#!&G]@[]L#XG:K
M\6?VA_!7Q2^(GBW4)9);>*__`&A?CG:>%_#RSVMC:W5GX-\&:?X]MO"G@VQO
MTTZTEU*R\-Z1IEM?740O+N.6X8R4NG>*/^"=G_!&GX>_"OX)>)?C#=_`CP)\
M9/']SH7PBT+XN_$KXN_%.V_MJTM/#&CZAIGA[5O%EYXY;X<?#GPU%?\`AS^U
MKJ]O?#'PS\(/K%O>ZE>Z4=3DDEX,?C\MS?@[A7AC*7F^/SW*,;G6+JX6&42E
M0Q2S;ZMB,33PM2GC<5B7+`4\!*4Y2P<HXBG*M6MAW24C2$)T\3B:\^2%&I"E
M&+]HD_W:DDY)QBM7.VL]$EJ[V7\X7_!0?Q+K_P#P1@_X+=2?MU>!?!&J>+/A
MA^U1\+?'6M7'PX\*1M;3^)O$OBCP]X<\-?$;X?V\<UY%!<W&N?'#PA\+/C/<
MV\<PFGUG7KI=-LI+B.WAN?ZKO^"=O[,FO?LG?LE?"GX4^.M0@\1?&2ZL]7^)
M7[0_C2.:.YE\<_M$?%;5[OX@_&7Q5=:A"J+J7VWQQKNIV=A=K'##_8NGZ5;V
MMO;6=O;VL7Q/^TCH'@;]O/\`X*2_LQ_L]Z?X;\.^*_!'_!./6;;]LC]H;XC+
M;"YOO"WQ?\7>%QI'[,G[.=AJ_GFVD7QYI6N:E^T'\0-#M;#4H_['^&?PHO\`
M4=8\.2ZAHEAXL_;.-2RC<S9PN<$8)YYZ'D]\'GZ4<5Y]5S#(^%,OQ&%5'-Z>
M28)9QBYU/WV88++GBZ'"7UB+A"5.5/*J];%.-:,ZM2$\#5G)0EADEAZ/LZF(
MDIWI.M-TH](2G:6(46M&O:+E36EG-+34D10H&!@8Z$D^V><GLN.<`9]JDIJJ
M%SC/)+'/J3D_K3J^'BFDDW=VU=K7_%G6%%%%,`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBBDTF`
M4444<JVMY@(1D$>H(_,4W8IR2,D]>W0@@<8XR!]>^:?10XIVNMMOZ_KT`:1A
M3C/`XY)Z<CU-?GA^T_\`LS?'/XM_M-_L=?'WX8>._A+X=TO]D[5?C#XG;PKX
M_P#"_C/6-4\;Z[\7OA1XI^$=];+KGAGQ+I%IX>T?1-%U]-9MF;1]9OK[5;5K
M>0VEJRR']$:@,"8(Y.<\9&3R".2,YX`SGN1TK2AB*V#K.M05/FEA\3AI>UIJ
MK%T<7AZN$Q$7!RAK/#UZM-2YH.#GSQE&<82BFD]'>UXO2VCBU*+U71I/UWNC
M\6_@_P#\$TOBU^SQXC^&7QM\!?%+X<>-?C7X.^-7[;GQ4\3^"]?\.>)OAO\`
M`G4/#W[='B;P7XL\<?#CX;V^@WGCSQ!\,]+^'?B'X;^"=8\*ZM<:/XSD\1SI
MXNCU?3M.NO&3ZKHMOP1_P3C^-GP?\1?LF?$?X=?%CX6>(?B7\)/%W[<OBSXW
MW7CGP9XHTOPEXOUS]OKQ_HWQ2^(GB'X;Z1X9UVXOM#B^''BW1(-,\(>#]<O#
M9^)?#,I35/$F@:I&U[/^S#1#YB<Y&,'!YX(.0,DYW$!>V!GC%+]G3U;KGKW.
M>G''6O5K<2YU7<W6K8:I*K!TZG/@L/:I1<<7RT*BA[-2HT7CL3*A"'(X2J7E
M5K.R,U2IJUH6Y6[6>MW;6_=\D$]-EY'X6^#O^"3_`,3V\!?LO_"/XH_&/X8:
M]\/O@M^Q!^U+^Q3\0;KP3X%\;>&/%GC/0_VC+?0]'M?'/A*?5O'&O:9X3U3P
MSH7@GPK+<Z-JL/B.WU/5[[Q+);7UC8C28(-9_P#@FO\`M%_%3PU\+O`7[0OQ
M=^"%WX/\$?L*?M%?\$__`!9=?"_P3X_TOQ1XS\"_&GP7\*/#>E_&32+C5?$]
MMHW@GQK::A\)]&U'5?AV-,\2^&K>WU#4;/3?%ET'M?LG[>K$H&.H!!&0=P`V
MM@Y]P,\#C@BE\H9/)`R3USRV<D9&1]YNY[=ABM9<69[.<IRKX9U)5L17A-8+
M#J=*MB9XB=>K0E=*A.K]9J*7+3DDHTHPC!48N;]C24>7E;2Y4DVVK1T5[[Z)
M;[MN[/PJ\=?\$P?C'\2_V2/C9^SU=-^Q!\+/B+\3O@OX<^`T_P`9?A1\`O$=
MEJ_B[1M&\2Z!K.H>.O'"IK>@ZWIKZJ/#D5WI_P`)-!US4/#&B^(]9U76+_QC
MXF%KI=M!^E=UX@_:)3]I7X5^&H8O"EW\%;GX'>.]:^-%S'X.\16IT?XIP>(_
M"%I\/)?!'Q&N_$4EGJ,6L03>-(+GX=S^$I+JQT32I_%.K^+]+N?[`\/>(/JG
MR4&"2W#;N6XSS[8P"3@<`9XZ"F&WC[ELYSRQ.`,C=@8SD''T.#D`BO/KYMB\
M9%QQ=+"UH*IC:L*?U>,84:^/I4J5:O2BZM5QE#ZM2J8:'.J>'J.3I0C%NC*N
M2*UC>.D4[)+2#;MV:?7K;2][,_-'Q;^RE\>?A9^UM\4/VM/V1_$OP?,O[2'@
MSX;^$/VC/@S\<(O&FC^&O$'B/X4/K6D^!_C3X%^('@6T\1:UX?\`%VD>#O$5
MWX9\1>"+_P`(WOAOQI9Z=HTT.O\`@[51>ZS-#J'[(WQ]\)?'#PA^V#\/OB7\
M./'/[2,WPF\3?!7X[>'OB#H.K_#WX3_%_P``:G\05^)7@+2/"^K^"K#Q?XG^
M%EY\#=8NM8\-^`==U70/BIJ?B+P5K5_8>.VUCQ')!XHM?TW\A,`<\`CKZXR>
MG<`#TQQW.0Q`CJQ/8DCC@C.<9X!('IG(Z4_[8QS27^SR?U"&65JD\+2=7%9=
M3HJA2P>+JJ<)UZ-&E"A3IW]C57U;"2>(F\)A^0Y(WZ_$IK7123O>*:?+=MM[
MJ[=HV9\-_LJ?LHZM\%_B)^TI^T-\4?$N@^+_`-HC]KCQMX,\4_%'4O!VG:EH
MG@'PMX9^&'@;2OAS\+/AIX(TS5KR[U2\TKPAX5TMIM7\7ZT;77/&7B;6=8U>
MYT_1-..EZ#I</[2O[.?Q)\??''X"_M"?#2?X9^*=0^#/A#XR?#S6?@M\:GU[
M3OAYXUT#XV#P)%J7B/3O%F@:%XVN?!OCGPG%X,%I97UW\.?&EEXE\,>(?$O@
MZX3P[%K;^(+7[J\I>>7].HYPHP<XXQT`R!G/%(84`Q\V`/8X'&!C;TXXP..?
M4UA+,<<\5+&\U.5>IA?JC4J<73CA8X2G@:>'ITHRI^QHT<+3IT*$:%:E4P\:
M<)T*\:T74F**MR_94N;31M\SDW)ZJ3<FW)M6?56;1^+GPK_X)C^//V?-6_9L
M^+'PB\<?#R;XF?`?XA_MH^*;SX27^F>(/!O[/4_P]_;C\4^$O&7Q`^"WPLN=
M-M?&'BGX2>'OAAKGP[\!O\,-<C\/>*M/\K3?$\6H^!;&Q\4V=AX=MZ!\%-;_
M`&6?#OB3X<_&#P]\4?'.D?MK_&_]I#]HG]I7]I7]E[7?BSX`NO@1\3/%6H>&
M=6^'WP_\`:)\)SK'Q\TKPYKO@_2XO`4/Q&\/>(-(O9-0\*ZI>>(WTQ?'MAH.
MG_LP8$)&23CZ9P`!R>I)QR?3(^J-"F,@L"`%RIP<$\DX]`<]N@KNJ<09AB)5
MI8]4L7]8C:O*,8X;$5%#$XG'8;_:J4*LKX3,,2\=052C7C*O&"Q;QE%.BU[.
M"45'W;/96:LHJ+5FK>]!>S>S4/AY6DS\%?V1/V./VG-$\%?LF?'>VL/"'@?X
MA_LO:W^V)\+OA?\`!CXM:,GP_P!1\??L4?'3QW97_P`+O#WQEUOX=^%M;C^%
M?[06D6?@;X;^/O$OBO2OA]X\O_$=[#K6E^/+.?Q7XM\0>(M*]9T_]A/]LKX?
M_"C7O"WP6_:;^$G@WQW\=?VG?C_^T]^U+XEU7X9>/)DUJY^-FKP:AIWPF^"/
MB+P=\1_!WC3X8>%O"/AZ*U\%7_Q$M=0@^*FO6.C6GB30=;\!^(]0N;BU_9$0
M)C(+9QC.<=R2,8&,L3N]>AR.*<(5ZAF&>X.#@9QR`/;]?6ML3Q-F>(Q%:OR8
M&$*TK_5G@Z5:C[&.,QF/H8:HJLOW]'#X[,,7C*/MH<\<56E4E-J%"C07LH\J
MC>>BLFI.,E=15TXK?EC&-W]E62W;^6_V0O@WXL^`7P.\-_"/Q78_`[2CX0O=
M<@\/:5^SYX)\9^!/AY9>']2U&;6D,NC_`!`\=_$?Q3?^+=3US4=;UWQEXHU/
MQ3J%YXJU[5+S7-09M4OM0GG^I4#%%PYZ8.`#R."<D9.2":58PN,,>/SX[9]"
M.O<]B!P7@8&!7AUJE7$5ZN(JJ'/7J3K3E&Z3J5&G-J+=22YVN9\U2;YG)NI-
MR]W1)))+IHOZLOR/`?VI_P#DVG]HW_L@WQ<_]5YXEK_(?TX9L+(?].=M[_\`
M+(8_7!/MZ]#_`*\'[4__`";3^T;_`-D&^+G_`*KSQ+7^0_IPS867_7G;?^BA
M^GK[5_3OT<_]PXM_[#,F_P#47,CP,Y_B8?\`PUO_`$JF6#$<#GD+C`!VAAR&
M`!!RH&T$$,!C'3%(4QU=P#G@.P5<GL"<#(SP2,8QDD`U8IK`]NWIU]_QZ$?3
ML>O])^]:UWNW:^E[WO;57=E=ZM];GBOT3^2?]?UZE60[`S'.U%8L3G&%`9V/
M(Q@=/O$$)C)X7^V+_@TUT'7K/X7_`+:FO7NA:Y8Z)KOQ#^$-GHFM7^D:C8:1
MK5UI'A;Q8=6@T;4;NWAL]7?3/M]B^HBQFF^QF]MX[KRWF7=_$]/")8Y(B%*R
MHZ-N&5(D7##!8;EVY&T,H"AL%6(:OTBT_P#X+!_\%2=*TZPTG2_VXOC'I^F:
M996FF:=86FG_``OCMK*PLK:*TM+6%/\`A7CNL=M!''$K&1Y&`S.UPX\VOA_$
M3AW-N+.',1D&5U<MH?7JN%GB,7F-7'PEAX8'$T,50CAZ6#PN(5=UI4Y4JWMY
MT(TH1INDZSE.,>O!UZ-"JJT_:MP4N2-.$)*3E!Q>LI1E%IMZ--)Z7LKOVO\`
MX++?!/XU^.?^"N?[5/@KP1\%OBEXU\8_%#Q]X6D^&WA;1?A_XGO[KXA6FK_#
M;PA86%]X;F_L:6QU+PW/?6E_:W_B>*:7P[I`TW5GU:^MHM+U(P_VS?&;7?!?
M[`/_``1]D\(?M*>+_#VHM\'/V%-`^`&M2WMT7A^+_P`3=$^`EK\-;3PCX6L]
M;FN]0\1:Q\2/%%BVGZ/IMPVHW5U'J376J2_9+;4;V'^#MO\`@LA_P55DC>.3
M]NOXU[70J2EK\-(9%#!=VR>'X?17,1)`.Z&:,@KN.[&'^,OC+^T'\??VBM9L
M=?\`CY\:OB=\9=7TDRG2;OXC^,-8\2II!N@WVMM'L;ZY?3=)>Y61HYSIUE:"
M2`"'*QJ57X[-/#G/N),+P7E6<8_),!E7"-/#>WGE,\TQ>89I6PN'R_"N5-X_
M"8/#8"-?#X",/^8ITIU:M?FJNEA:<>JGC</AY8J=*G5G/$N3O4Y(QBG*3VC*
M3DWSMW:U249)[GZ"?\$$(GM/^"J_['^28+E+KQ[8S-;S21GRA\)O&*36@='1
MI;1BHCD@<>3*L8WHP1<?N3_P=J()=*_87AD'FQ+KOQSF6.7$L2S#2O`"B=8G
MS&)U4D).$$J`@JRD;3^(?_!",8_X*P?LDGG/]L_$(<=>/A3XQY;!`[9YW'!Z
M`FOV^_X.T3_Q+_V&,D@?VS\=>GMI?@#D8(SG&0,CCTS7%Q';_B._!,DK-\/8
MR4G%)/F6'XBUNWS:7=FWS6;;DW)N3HW_`+)Q5F_XT%NU9.5%6T>BLVKZ;[)(
M_C2QTQD'YN0Q)RP7.3U);DYYYY^]D@D^Z2>,A3^)R>??M^O'2K>GV.J:SJ>F
M:)HUA?:OK6MZIINBZ+I.E6DM_J>L:UJ]Y'IFDZ1I5A;J]SJ&IZIJ%Q!8:?96
MT4MS=W=Q!;6\<D\B1L[6M)U?P[K&L^'/$&F7VB:_X>U;4]`UW0]4MI++5-%U
MK1;R?3M7TG5+.=5GL]1T^_M[BTO+60"2"XAFB<*Z8'[FYP<G34X.IR.:IJI3
M=1TU.4/:*GS\[ASMP=10Y.=2@IN:<'Y*B_==G;GBK]+KV<VK[-N.^_W[?VQ_
M\&F@_P"+*?MFYY_XO5\.!COQ\.[X;1[GIWP23C/%?UMB0]!M.<C!`+`9`&X=
M?8@@8')(`S7\DG_!IJ<?!/\`;-Q_T6KX<'UY'P[OC^>1GV-?TZ_M"?"X?%KX
M5>)_!T?Q'^+'PGN9[3^T;'QS\%O'%SX!^(&B7VCQS7UG-IFO0VFI6\ML\R`7
M^D:OINJ:+JEN/LVI:9=VQ:(_P?XIJ$O$KBB-2JZ-*>;4H5*O).JJ<'@<K4JC
MI4Y1J5.1*_)3DJDU>,7U7UN7O_8</U_=-I7M>TZSM?97T5WIK>UKGL^]@"2I
M``/+$K@DDL"<D,.AR>`/N@D@4]'+,"!U.&SSQMSQ@D+CAB!P2<9)YK^2C]@/
M2OV@?VEO^"5GQK_:W^(/_!0C]M'P?\=?A?J7[4+Z+\2+/XUAO`NFV?P2T[4]
M2\-7'BWX;>(/#FM^`]3T`?V<O_"4`Z/::E>V#W?V35M/NA;SV_Z%_P#!-K_@
MJ.GB7_@EQ^SS^V'_`,%&/B/X*^$.M_$#6O&7@UOBAX@TE/!GA7XCGP]XP\2Z
M%X6\8KIFC:=_8?AZZ\6Z5HC>:ME!IGA[6=8LKB_\,V-EIFL:5I</FYOP9CLK
M_M58?%T<TJ9-Q!3X:QM#"87'4L0\QKX;$8J@\'1Q$*E3'4:M+#5I?[-RUZ,H
M4XU<.H58U%I2KQGR<T'352E[6,I3BX\JLI<SBERV;5N:Z=]'I8_=)!@=,9'0
M=.I/'USG';I2X'H/R%?%OQ1_X*&_L7_!+PY\,/%WQ7_:,^'/@+PG\9O"FF^-
M_A9XE\07FI6NA>./"NL6EG>:3JVA:HFFRV4Z:C:7]I>6=I-<0ZA/;2-/':O!
M'+(GIWQG_:B^"'P`LO!MY\5?'MGX?G^(UY>Z?\.O#^FZ1XB\7^,_B!>Z?I0U
MO4;?P5X%\&Z/X@\8>*#I6D-'J6K2:/HEU#I5K-!)J$MNEQ`7^=6!QS="*P.-
ME/$2K4\.EA,0WB*F%NL3"C^Y2K5,/RR^L1A)NCRR=9TE%LW4HV^*-DDV[JUG
M:S>O6^G?I<]\9SD\*6^8`8)'48!.WK@<Y''`_B)#E*S)QMW?*Q.S(.1E67<!
MD$=&&1Q\I(P:_+[XX_MG?L*?'_\`9$_:"N+K]KZT^'/P>U34M;_9G\=_'#PE
M=>(_"^J?"WXE>*?!MKK+:*NJ:EX>CET+Q1I.BZO9W-ZNH6L-MIMZ\V@ZM<6.
MKI<6D53]G_X]?L5_L$_L&?LP+XK_`&Q+'Q9\!%\(6/A7X:_M)?%;7KZ]3XHM
M%)J-Y]J.M0V-Q;6J,S7-GH.F3NJ6^G6EII5B]XUH'DZGDN*>$52>&S+^T)9G
M'+J>6O)L>G.^">*G)8ITW2^M0<J%/^S52>,E2K?78WH-*4>UAS64H<JAS\WM
M(V^/ETC?X>O-\/,W%OF32_5(8Z#M_/D=?7@@]QWI>/QZ?_6KX&E_X*A?L!0_
M&+PG\`6_:M^$I^+7CO6-(\-^$/"D>KWDBZWXJUU-(DTKPA;:_%8/X8B\871\
M0:)`WA.YUF+Q%:76K:;9WVFVUY>V\$OT;\;/VA_@Y^SGX7TWQC\:_'VB>`-$
MUSQ'IO@[PY_:8O+S5O%?C#66G&D>$O"/AS2+34?$?BSQ1J:6UQ+9:!X=TK4]
M5FAMKB=;0P6\TB\\\MS&C/#TJN68^E5Q<)2P="I@<53JXN,*DJ<I86G/#PGB
M(J<9QDZ2DHRA+G]E9LI3@U)J<&H_$U*+4=$_>:;Y=&GKT/:\#T'Y"C`]!^7U
MXST]<C\^M?.GP3_:M^`7[1.B^,-=^#_Q.\/^+;?X<:LV@?$K398]2\,^)?AM
MKJZ<-7.E?$/PCXML="\5>"+P:8QO1'XFT;3/,MX+B6)I$MK@IXOX8_X*8?L3
M>,?&/PX\"^'?COHU_P"(/C+XGB\(?!IW\*_$&P\/_&#6IK2YOF'PJ\7ZCX2M
M/"7Q$TJ"ULYKF\\1^$=:U?P_:0FWEGU*..]LC<"R_,7*M3669A[3"V^M4U@<
M3SX6]*5:^(A[%2HKV4'43DGS4TZL>:BG72=2"2;G!*2O%\T;22:7NN_O:M+3
MJUU=C[TJ.090\@'C!)QT()_/`'UKXX^+7[?G[)?P,\8>)_`?Q2^-&A^&O$G@
M+2]+UKXD6]OHGB[Q)IWPMTC7M-75]!U'XJ^(/#'AW6O#_P`,K?7-*9-3T=_'
M.IZ#_:&FRQ:A:K+:30S'Z.\`_$#PG\6/`'@KXF^`=:@\1>!/B/X4\/>./!OB
M&V@N[:WUOPOXJTJSUS0-6@MK^WM;^WAU#2[VTND@OK:WNHA-Y5S;Q3(T:Y5L
M+C*%&EB*V#Q=##U[*AB:V%K0P]?FI^U7LJLZ:IU.:G:I'EE[U/\`>14Z=JDJ
M4HMN*E%R6\4TVK.VJ6JL]/5-;II=B=Q)`!Y/)!V@#"G"G@#<1ECS@]0W.)%D
M&!E5!P<\[N-V,$X&#D'(/<>U?S*?\%!])^-_AG_@KG_P3]^`?@/]L[]L+X=?
M"#]N"Y^-FN?%GP+X+^,":?I/AR3X3Z#H>HV&G_"J2\\.ZAJ'@32?$+7C6NNV
M5K>W:6D3/=>&VT34Y%O(?Z4]"T5/#VB:/H4-_K&JQ:)I>G:7'J.OZE=ZWKNH
MQZ=9PVB7FM:S>O)>ZOJMT(A/?ZC=2/<WUW+-<SR-,Y-=^:Y(LKP61XSZ_3Q7
M]N9?/,:5*GAL71J8:A2Q>(P$HUIXB3I5*KQ>#Q$(QHOEE2A"M*485(P6=.HI
MRJP49+V4U3;;33;A&I>-G=*THJS7Q.VQNX5@0NWG(R`#W.?;J#^.>XK\^/V]
MO^"97[+7_!1O0OA[I7[2&A^*KF^^%-_XGN_`/BCP-XIN_"7B?0;7QO#H4/C+
M15O88;RTOM#\3'POX9FU33[VPF1[K0-*NH&@EM5)ZGXE?\%&_P!C#X0^(/$'
MA_XB_'SPQX<_X0WQ7:^`O'?B9])\6:E\.OA[XZOWTR*Q\&_$3XI:/X>U#X<>
M`_%-W<:WH]I%H'BOQ1I&IK>ZIIUG);)=7MM%-T_QL_;N_9'_`&</%'@SP3\<
MOCWX"^&WBWXBZ;;:O\/]"U^ZO_MWCRPO-2@T>T;P6ECI]ZGBBZN-5O=/T^'3
M]$:^U&2YU+2XUM=VJZ<+EX&GQ!EF,P>.RO#YO@\P2K5<OQ6&PN,I8B<:6'<L
M14PTXX>3G".&K2>(BH2A]7K-UJ7U>ISS)NE.,Z<W3G'15(2<6K.7NJ:;TO+W
M5K\5XJST-G]D[]CSX"?L5?"6Q^#?[/O@R+PIX7BU2]\0:WJM_<RZ[XU\<^*=
M2VI?^+_B#XRU`R:[XR\3S6D5GI%MJNM75P^E>'=*T3PSHT6G>'=$TG2[+Z?0
M;5"DY(`Y]?<_CG^=>;7OQ9^'NG^,O`GP[U#QIX<L/'GQ,T3Q#XE\`>#KW48K
M/Q)XPT'PE;:9>>)M5T/2+C9>7=GH5MK6E2ZI)Y*FS2]@\X1NSQKY3X!_;,_9
MF^*/QE\6_L\>`?C'X5\3?&_P%!J5WXU^&-C'K$?BKPK9Z5=Q6=U>:[8WFF6P
MTVR>>:&.PN[J6.VU>-UFTF:]A82UR5GF./JXC'XF.-QM>K&>.QF,JPQ-><H2
MK.G/%UZTX2_=.NG2>(G)4E-*E&<6HT8U'DBE"-HJ/NQBFM+1^%+?;5K5[2=^
M:[^H:*CC8L"3C.3@#/0<=P#U[X]*DKD335UMI^*O^184444P"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`/0Y...O3'O63JVH+IFGWFH?9KN]2QLKN\-EIUK)>ZA=+:P
M>>;6PLHOWMY?7"H8K*SCQ)<W+10H-QS6J>A^AK-U&\MM/M[B]O)8[>SLH'N[
MN>4A8;>VMT::>XD;^".")))97;Y51"_`5LXSE.-W925F[+F3T71ZV;V5K:O?
MN6O]_?\`K[S\^_`__!3W]F3XAS^$+309_B?IES\2?&GQ#^%'PMF\>_";QG\,
MM`^(OQQ^%]WKVF^*O@+H?B_QW8:'X2TWXQ'5_"_B;3-$\%>+-:\.7OB.X\-^
M(6T&34K?0]4N+7Z1_9D_:)\(?M5?!+PG\=O`NC>*_#_ACQ=>^--+M]#\;Z=I
M^F>)M*U/P#XZ\3_#GQ%9:M::3JFMZ9')!XE\)ZLEN]EJU[!<VRV]TD@,XC3\
M2?\`@FG^SWX6^/OPXTSXB_%3XF>(Y/AM^S#_`,%$_P!LS]I7P'\$X?"2>!=,
M@^)5_P#'3XTZO\,_B]\0/%>L6@\<>+/#NG>!?'>M^,O`>@Z,?"?@R]F\1VVI
M^(X/&7]@Z*;3YI_8U:X^'R_\$Q?''PAU?QWIGQ:^*WQG_P""G'PT^)FEZ_XF
M^+$7@C7/#$UO^U3X^^#7AGX@>!-;NAX)\(>$[GXLQ_!C6/!VJGPWH=S=:CJ]
M@VB:M=R>*M735_O<;PWD_/FN#P&)Q5/%Y;C'1E7Q/[W#/EPF:XZE1YH1HQ4<
M1A,#"=;%*-:G@\0H4X>VI5JGLN6-:HO9^TC'WH7:A?FNI4H-J][*]32.[5W<
M_K'$CCJ@.>A*'Y@20!R!N;')`/4XR<\!=T&2"HQU;*KP2.2?106.<L2>,XR?
MYJOV>_$6KZCI'["$Z^*_C'=_%;Q7^SQ^T1-_P5SM_%.I>.;6ZTN]M/@)K4_Q
M`N/C#'YEJGPZ\9>&OVI9;+1_@?)X+B\/:[9>!IM=T[X>2CX>PSM'X-\#?$_Q
MI\$>#?V"?$W[-WBSXNZY^TS\=_\`@D'^U8GC^T^(/BKXG^,K/QA^U+\,OA?\
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M\7?B'\3/VN_CKX=^$>M_L.^&]-_:-\/_``)\%?M-Z#\9_AW\2-%\1:1+K_Q>
M\2>+]2O_`(D>,_#7[4YO-6\2^$O$?ASP+X8L-:\6:99MKFH:%=:#X6T![7[]
M_P""O_A'Q-XS_98\%Z?8IXXF^&>E?M7?LE^*_P!H[_A7MC%JOBVT_9V\-?&W
MPSK/CO7K31KG3=9DU?3_``E?VGASQCXFMUT74_L_AO0-6U;4M/N]*T[48#PS
MR&G0SC!956Q\XT\1C982OBY8.OAX4'!5G5A3>)E&-?$*5'DA"#5&4L9ELW7G
M#%25+1U&H2ERIM14E%-2;O9+;9:WN^D)VORZ_H5\(_BWX<^-'@RV^('A#3/&
M-AX3U*ZNDT.^\<>"/$WP^O\`Q!I5NX-MXFTG0/&6FZ-XA_X137(2M]X?UC4-
M*L$U;3GBU&UA>RN+:XG]'6[1OG#Q%2H*$NH5P0&#JSE=R,"2L@4AE*D#BOYE
M?VA?$OB[Q'^R)_P6@\(M\2_BE\9/V6_"7P_L(/V$_B/XD\3>._%'CS5/CMXK
M^!_CO4/B9\*/AU\1],%MX^^-'@OP5X^G\$Q>!M5U[5?&[+KGB7Q9X%N-?UC3
MO!T=IIOT;\9_V>OV9?B]\`O@!\3%\(Z?\4_VE/VB_A/\"_V3OV>)_%-]XCOO
M#W@_Q/H'A3Q7K'B/Q/8^"8[S2["%/A#X=T_XJ_%CXD?VWI]S=ZA9?#-?#]P#
M*++3)]ZG#^&I^RJ8C'5Z-#$8M8:G"A@98JM1YLIR_-Z2KRQ.*P7LYTL-C:]/
M,57C3EA*^7UX*,_:1]GFJDFW%03:BG=S<8MJK.E*SY9))N%U9NZE&[TU_>,2
M[CD21G)!&WY^H&W`!(;&0,K_`+W'0PPW\%UYOV:YM[C[/)+;3^1/')Y-S&2'
MAG\MV\F9?XH9"DD9)+*"C5^:WB#X:_';X/?#OQK\,KGQ[\)_AQ^P%\-OV>O&
M7@6Q\3_#C3_C5K?[:/@CP!X;^#=[H.F^*_#WBQ[SQ3X9UGXCZ'J-L^O0ZA;>
M"M>U?5YH8GLM.U#Q!*IF_,?]EW]HKX)^"?BA\0_V@OV?=(^(<NG>%/V)/"GP
MD\$?LA>'OA;\8YOB]\=-?\*>.M"DT?\`:#_:-DTKX7:7\/=!^)&C6^IV.DZI
M:^$9OB#XYTWP=XL^(OB/Q'+=ZQ81>!M-QPG#U3&X;&8C#8EXB.&E"-%T,.ZE
M*I*O*DL+AL764Z4,#C:\:K=6A.-6C@X0E6Q68>SG052G4Y7",E9S=VG)*R2]
MYK2\DG:UDG*^D;W/Z9_/9V=%9#(BJYC^\^QRX1C&"#AFC=4?A6,;@$%7"U[:
M_@O8O.L[BVNK<OL$UI+%<0YC8!T$L3O'E,A6`.Y/XE&1C^9SX`ZA\/?C1^T5
M_P`%//@]\7/V@_CO\/[WX^_LY?L=CXC?'J3PK\4OV=[W0_$NL'XC^%?$MG\.
MKOXV^!-+T'X-:/<S>*/!OP[^#_A35=#L+SQIHEK>7^GV_C7QD?&_B2[^@/V>
MS\?/!/[5_P"W+\*OAAX)^"/[,W[1WC+X<_LE?&_P=^SAXBO?$?Q+_9.TOX,6
MU_\`$CX6>(?C-HWB?X8GX=ZM)\8/B!XF\,:]X+\8>'T^'W@"VT>Q^'/PXU22
MY^($&K7^L6.V(X9EA7BJ5;'*G7PV!P&816(PE7#T*V'QM'*JM2I&O4J5)QHX
M:6/K+$XB%"M##4\-2JXNE168X.E&8UKI-1NI2G!I23DG!U(JRM9N?LTTKQ<G
M)VOR2M^\<]_;VL7F7-S;6T1D6)9;B6.!#-)E4@62:1%\U_FV*IW$]$^:BXU"
M"RB-Q>7$%G"A(:6[EBMHE:1RL2O),Z(A?@1JS`M_"N!BOPE\<P^+;+]O;P/>
M?\%+?^%4ZK\%#^P-XZL/`MYX>T#QJ_[-D?QWG^-%T?C+;:3I_BLZW<6'Q*U/
MX(+\,X=`C\2ZA<^)=2L[?Q3#\.69_P"VK2/YI_9!M?BEIFL_\$]I_P#@HK;>
M+6_9ZMOV1?VN;7X:P?M`6/V[P3I7Q.OOVI+&;]G*T^.L&LVD]K!\9(?V!/[`
MTWP)/\4P^MI#;_%VTU6ZD^(EUJ4EY,.&^;"2Q2QT*LHX&GC(T\/15?Z[*IA,
MSQ4L'ELU."Q6,H/+E3Q=)481I?6:,E%+GA4;JKFY>5IN;A=OX6G"*E-6M%2Y
M[JS=[739_1%\8?C?\.?@1X3M_&'Q-U]M%L=2U_1_"7AO3+#1M;\2^+O&WC7Q
M`\D7A_P/\/\`P+X8T_5O&'CWQKK<D-Q)I?A7PIH^K:S<VMI?Z@;2+3]-O[RV
M[+P[XJ@USPIX>\6W-AJGA:TU[1-%US^RO%]@_AOQ!HJ:W86][#I7B31[]TN-
M#U^Q%T+/5M'NW:?3=3BN+!WED@+M_+G\(_`WCB\U?_@F[XI_:<\6?&[X5?LI
MZ`G_``4^TKX0^/&\0^/OAWXV\`Z7XT^(V@+^QPGQ%^(]S8M\0_A;?:M^S%9_
M$32_`VMW/B;P;JVJ:9'HGP]U/6[ZU\7:SX'\6>H_`3Q7\7?%7CC_`()]^,?^
M"B]YXI\3_L]M\"?VY=+\#^,OC!X6M=)\.^,?'>G?'7PCI?[.'Q,_:9\/1Z+I
MGAS3_B5\1_V-K`Z_X`N/$^B:/]J\1:A\1+VTT?2?%&JFWF[\;PC3PL:JIYM1
MQ<L/]?J5YX>/,\1]5EF<:&#RRBZGLL3BN3*Y3Q5.>(57#SQ%N2I0IPJXJ(UU
M)I<DES."UVCS>SOSNWNW]HG'35+2S32_IA$K8`RN&.0>,!"`W!!QT/!Z$,K9
M'`-B,ED4MC)STZ=3C'`[8["OS2_X)16_C^V_9"L8_&MOXKM?#+_'#]IV7X"6
M/CU-;A\;V7[,DW[0?Q%;X"6VOQ^(8HM7@M!\/?[,E\"07P^U6_PR?P9;7++<
M13Q)^E:F3:,*I&!WQ^''''3OTZGK7RF8818''XS`K$4ZOU3$5*"KPM[.JJ;C
M[\4VU!OF49P3FHU*=:"G-4^:6T)*<(RMR\T4[/1J_KOTL]-&G97/!/VJ/^3:
M/VCO^R"_%W_U7GB6O\B'3?\`CPLO^O.V_P#10K_7;_:H(/[,O[19"DD_`7XO
M9&"2-OPZ\2'G&1N^8`#CG!R<@5_D0Z:Y_L^Q^4_\>5J1D@$@PJ1G)[9QZ\=>
MP_I?Z.5_J/%NCTQF3)I)NS^JYC+HGT\O^!X><)N>':3=HU=O\5/\C1HJ/>?[
MO_CZ?XT;S_=_\?3_`!K^E-?Y9?\`@,__`)`\6S[/[O\`@BE><CCIW/;T_'!'
M88_,VD$D;<\\X.>W'7IP![`"DWG^[_X^G^-&\_W?_'T_QHU_EE_X#/\`^0#E
M?9[WV^7<DJ!Y!G&,X.,]@><$C@\$?*01]UN>E/+MV7\W7_$_@.YZD=:B;+'N
MO3HP)XQUP1U*G)&<>82!DD,DFK^ZUOO"7:2OI%;-II-ZVL[)MHL^S^[_`()^
M^O\`P03_`&<_$+_M;?!?]LWQ?\4?V??AC\#/A9X@^(VGZM<?$3XU^"?"_P`0
M-:UQ/!.H^'ETW1?AWJ=_:ZY]@DO?$EI)'XBU![/29[:VO'LY+P+&DW[A?\%]
MO@!IG_!0GPA^S?>?LT_M(?LBZOXD^#_B7Q\WB+PYXT_:2^'/@XZAHWC;2]!A
MMM1T?59]3U#3II]-O-`9+RSO'M9)8KR.6U>0Q31C^#J?3;&X<R7&GV5S*5V-
M)/;6T\A12Q51).CD``G:@/EKN(4#)S$=&TKDC2M,Y;=_QX67!R2-N8N<#(R<
M,<\G.,?G6;<`8[,N,<!QE3XDEA,9E=&KA,OPD<BPN)PU+"36*BJ.(E/,:4\7
M.4,;B%6KR^K:NE[&G3Y'S=L,7"GAIX7ZO-QJ-2J2<ZBES+D]Z-J4DO>BGRIR
M25[ZZ+^L3_@D9_P2@\)?`S]JOP9^TM^VO^TE^QI8:3\$[N'Q=\*_AMX1_:0^
M&WCR[\0?%(I-!X<\4^)+N*\T_2].TWX?RM_PDGA^""YOK^[\9VNAZD@M(]#6
M2Y_F?^.^M1^)_CK\=O$L=X-0B\2?&WXN^(8M1647":C!K/Q$\2ZC;WRW*EDN
M(KJ&Z6X2Y5W%PCB=6D1P:\<;1-(8;3I6F8/S9^P69P<YP,19!&,HP(;<%Z8R
M-#;M0*B[%&U$C7`4`*>%&.1N)4'Y1R,X*XKW\IR',<%G.:9WFF>5,XQ&8X#!
MY=1H?V;1R["Y9AL%B\1C5'"TZ>(Q7NUJV)J5*TISG)SC"4I?`H8SK1E2I4H4
M?91A4E4DW.51R<U3BFVXQT2IJVUK/;5O^W/_`(---W_"E?VS@1C_`(O3\-L<
M9R3\.KWH,X/7.`>?N]:_K'\22`:!KH!Y.C:HR]2Q)L+C[OJ<Y`'7C/.<5_)O
M_P`&FFX_!3]L\;20OQJ^&V,DJ>?AU>$9/.`-R@D$@<CG!K^H/XW?!ZS^.'P^
MU3X<ZEXY^)_P]TS6)+5KWQ'\'O'>H_#KQN+6WE<W&F6WBG2HI;^UTW5()&M-
M4@MO*EG@;$5Q!(B2K_&?BFHOQ*XI4YRI4O[5I.=14Y5'"#P.5-S5)2A*?+%\
MRIQE"51V2G'61]+@%_L6'TU]G)J]MW.JTV]=+\O?1[=#^6O_`((W_P#!/#X!
M?MI_\$R_$5I\8M<^-MJVJ_M%?'VS@M_#/QZ^*NC?#O2[WP]XRLKS0O$%W\"+
MKQ1>_L^^,+O3-3L[+5+RT\?_``L\4Z-KUS9)%XET[5;,/;BO\+?VS?C-^VK_
M`,$`/^"F,'QS3POXOU_]G?1?C#\!]!^*'@_P;I?A'PO\5/"'A#0/#.M^%_$<
M?A+0K9/!VDZMHVGZE;VTL'A"VM-$MM,BT"ZM[*QOC<SS?KY\,_\`@BA^RO\`
M!_X=Z_\`!SX<?$W]LSPA\&/&%[J5[XT^$GAO]KCXL>'/!GBV37+2+3_$,>JI
MX=U'2->LT\2Z?"ECXC?0-=T6XUJV41ZC/.27'W)X&_8U_9F^&?[-UY^R)X"^
M"O@CPI^SAJ7A'Q'X'U3X5:-;7MKH>J>'?%UM<VGBB/5K\7K>(-5UCQ!#=7$N
MK^*;_6+GQ/?7\IU*?5I+]%N!Z>9\9Y/7S'-,=".8YDJO&>4<09)'$8:G@ZF1
M8'!XS#8O,X4JBQ524L5FM+#T<'4HP<\)&.#HXJK6EB/9PA%*A448)J%/EPTZ
M-2TW4]K)IQI\UX1T@W*7-))^^XVLKG\]?_!3GR6_X-LOV</-,6[_`(5+_P`$
MZ7M]Y0LLKR?"TLUN7&?-:V,ZN82SM:^>K#R6?=]A?MN_!G]H7QY^U=^SG\>/
MV`/C+\';3]M?]E/]FK48O%'[.?Q^T7Q&?`/Q(^`/QXUR&RM]6T[Q#IR:=_9&
MJ7'C#X8:GH>I2:/JZ3IY6@R:QJWA8V^CIXE]:;_@AG^QGK'P0B_9T^(?B?\`
M:E^+OP@T)]#B^&WA'XE?M*^/M6TWX,Z7H6L6VJQ:)\*K729M#L_#UM>BUBTF
MYUB]M-7\56?AQ[CP[H?B'2-(O]0L[CWWQ)_P3*^"6L>+/AG\3-$^)'[3_@3X
MS?!WX86'P<^'WQL\+?M#>.M0^)5E\.[7Q9JOC*_\->++WQS/XQ\/_%33_$.K
M:E#%K5O\6/#_`(VMSIVA^'+;2H=*ET>"X/-'B;),/3I1PN-QE65'-..<;_MV
M11Q&78O"\40P,*&#QN`JYFL35PM2%+$8?-(4:M#%0G##XK`UZGLTI4J-63DI
M124J>&A>%;EG%T>=2G":@U&:]V4&UKS.+ZL_.KX!?M%3?'/]F+_@L%X8^,G[
M*,'[)_[:'@GP;XOE_;#^'.F>)(_'?P_\:>+]8_9FDT?X?_$KPGK$+2Z3/:>+
M/AQX0T%;FUB:^ENK6RTK59]:UXZ@+T?('Q>8_P#$(KI#*3E/V7O@A,C`C*20
M_M(?#^2&6-B,!XF19(I0#(&5)$8/AC^]L/\`P3C^"-M\%OB_\&K?Q9\<[>;]
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M&W-)))SYFHVDD?F=_P`%<_`_@SPQ_P`$*/V9;#PWX3\/^'K3P!K?[!6M>";+
M1-*L-*M_!^M27_A))=5\-QVD$9T74IQK&K"?4+,0WER^HWS32RR7<YD]%_:Z
MU3XPZW_P<$_L>^"?#/B[X;>"VTC]@[XV>(_V>]1^-?P]\7_%'X>O\7-8\;36
M/Q';PYX6\)_$[X3W4/Q+NOA;H^H6<'B%?%@.D^$;/6=/ET;46URPDL_OGXJ?
M\$D_V>?C1\`OAC^S)\3/B9^U5XJ^"_PIC$7A_P`)7W[0WBF,:K%87^F7OA!?
M%NK6]I'J_B4?#E-+M=/\`?VC>,WA^QW*IN;GR[J+TKX[?\$W/V?/VD/A;\'_
M`(??%^_^+OB3Q=\`KZUUGX._M&VOQ:\4:!^U%X%\10HT-SXCT[XUZ#)IVOWF
MHZK:E+;6[36(-2T/5V@TZ_OM(EUC2-)U.QSP?%.34,/0P]:>.K1G5\0:5>M+
M`NN\%1XN^J?4<;0HXC'Q]O4H2P;_`+1POM</4J4<96CA\3.K%RK$Z%5N\>56
MC@VH\Z2E/#<ZG%M0M!23CRS]Z-XKFC8_.WXR?L/V/@SXG_MS?M2_MD_MI_"C
MPAIO[6W[".O_`+-?Q-\-?!GX*>-OAU::1X9L+G2_!L/QX70=7^.7QD\4>+;S
MP1%XUTGP_K5W%I0T[1+/7-/%YJVA6=Y=377S=X<\9_MV?L.:M^PG^S%_P49_
M9Q^#G[4/[(W@[]HC]FKX(_LR_MD?L^:_J&@>.OA7\4XM9T;X2_LZ>*/BE\.9
MKZ.YN4O['6DT?69?#^F:7IUUI-YK6F7^H^)]2O=.T?Q7^QUE_P`$R/V>;[P'
M\8O!?Q2UKXS_`+0FL_'KX<3?![XF?%CX\?%G7_'/Q<OOA%<7_P#:<_PM\*^*
M$32;#X;^!+K4PVIZKH/P[T+PO;^(-7=-=\12ZOKUI8:E9Q^#O^"9_P`%O#6M
M_"J3Q%\0OVC/C#\/_@#XMT;QU^S_`/!/XU?&?5_B!\*?@[XN\'S1/\.=?TBS
MO;"V\9>/-3^%D$,4'PRU'XT>,OB;>^"YX;;7-*E7Q19V6NV^6'XJP$<*\+F%
M:>:THPA0ITIY,\#.A#!9%B\JRW$9%C\#F.'QV68NC'$QP5=YF\=AL9EE*4,5
M1<_94'<L/+FYJ2]FW=N7M5)/GJQJR52$X-33:D[T^5QDURM)W7Y-^(?#O[?G
M[-?Q8_;3_:T_X)TZ7\`?^"@W[(O[1GQO^)7B[X]?LV_$6ZU?P'\9O"/Q2^%R
M/\&?CEX/\+>(-;CL++6DT;5?ASJWAS3M&UO1=<2_\-1:7IFA^#-=CBTO7_%'
M[._\$X_B;\&/C!^PK^RQ\0?V=_"FL^`O@CK'P=\*V/PW\">(+^ZU75O!'ASP
MU9OX9M_"-SJ][<WD^L1^')M(GTJTU9[F4:E9V5M>)M2943RR;_@EK\&=*UOX
MNZK\-/C'^UM\%;#]H/Q=XW\<?';PI\*?VA?$.C^$_B=XG^(.LG5O$>L2:5K]
MAXD?X;:Q<V?V?PRFO_!2[^&?B!_#5I:VM[JUWJ"-J9^\/A=\*O`?P4^&_@GX
M1_"GPCHO@3X;?#GPQH_@[P1X.\/P&UTCPYX;T*TCL=.TVRC=IYY/*MXP9KNZ
MN+F_OKHRWU_<W-Y<3S/YG$6>9;FN7X;#T*<JN/H8G!)YBL'5RRMB<%A,EH9?
M"GG&'I8_$9;C\QP]2FJ&"S/!X;!UGEU&-/'JK5KRIT*I4YTY2=VJ;NXP;4DI
MRFZC=.\5.G&W->%24ESRO!I6O^!__!1C)_X+G_\`!#8J"?\`B6?MAYPK,/E\
M&^&BQR%(X'S,<X48;(RI/[A_&O\`:"^%_P``[7X8W'Q+UA],F^,7QJ^&OP!^
M&UA;6XN]0\3?%+XI:K+8^&="T^V:2(,L%E9:SXEUNY\S&F^&?#^NZJRR"R,+
M?%/QU_X)+?L\_M%?'WP[^TS\2?B3^U,_Q>\!:M=:Q\*]<\-?M!^+/#-A\&IK
MV2RN;NR^%FC:9"ECX7TF\NM/MY[[3PE[%J0C6UU0W]B%M5?>?\$G_@5XF^+7
MP/\`C7\3?B[^US\:?&W[.?CW3?B9\($^+O[2'B[QCX8\*^,=)N8;B'58/"<L
M%CH-Q+<F&&WU">:S^V7EC'_9\MR;/,),;C\AS/"<*X;$XW,(1R3(<=E^,ITL
MM7M*V*GC\YS+"0PU:>+5-4)U\=A*&*KU8*I2A3Q-2E1JWH14QA5A4KRC"/[Z
MM&<6ZE[14*<).:4&^;EC)I)I;7:=S\)+W7_`7Q3_`."17_!3OQ=^P/\`!/PM
M\(/V`_B9XC_:<^+_`(D^*/[1GB;QC\3?B3^TCX[U6Q\/0>-/%7PB^$[ZAI=C
M\+/!.LW_`(:T+0O`WB?QYX\U'5])U73I-5C^$$ES:B?5?I3]L;X/>(_B)_P;
MK?L??&;PE>:F_P`8OV*OV3/V(OVUO`7B>.ZEM_$.F:Q\`O@QX`\7^+/$,.K+
M>6M[9ZAIOA6#7?%,MU:7J:G]NT6VEL7:_2V)_0[P7_P1&_8D\">$_B1\)]%C
M^.[_`+./Q+OO%>M7G[*-W\?/'W_#-_ACQ!XNLDT^[UWPO\.["]L&6[T..*UO
M?!ECXAU;Q%H/@KQ#IGA_Q?X;T73O%OA?PWK>D_9?[/?['OPY_9U_9UM/V6M$
MU_XF_$GX16'AB\\!Z?IWQI\<WGQ"UC3OAU<^'HO"=K\.=/U.XM-/^Q>"-#\+
MV\.@>']"M+>.'3M.#IYDLC%Z^@Q_&65PJ8'$954S&O6R_C*GQ#&&84*\JF,P
M%7AS*<CQ^&S'&8C'XBIB\;6CA,PP^*G4I4\'B<%BL-2PU.%&C*$<HX:<E451
M149X9T?=DKQFJU2K&<8P248WE&45=SA.-V^9H_F;_:_^,_C+XLO\%/\`@O1\
M-+74M=^%_P"R%^T'\!/AWH6GZ%?74F@>*_V5/$G@.+1?VRO%FD:4]I=W=YK_
M`(;_`&F/B'>?!PWEM>PV\>G_``:\7K+9:O.-(O$_?O\`X)\:=:^-M+_:._:]
MCNK76#^V?^T'XF^(_@O6[6VBA@N_V?\`X8>'O#WP`_9Y;2[F*.*>ZT#Q-\//
MA=#\7M/DOHUN_P"TOBQK1PT#PNOI>@?L%?L[>&/V)S_P3\T3PG?67[-0^$>L
M_!E/#HUNXF\0+X9UZ*_;4=7'B2:-[D^,)M6U.\\3+XD>![D>)9!JCQ22+M;Z
M<^'?@#PS\+?`G@SX:^"--CT7P;\/O"?AWP1X3TB.6:=-*\-^%=)L]#T73Q/<
M,]Q<-;:996\,ES/))-<R*T\KF5V8^%GO$6`Q^4PRW`8;&4'@<9C,NRRK6<6U
MP@\4LTRS+L3*$W-XJGFBJ8BO&'-AN7$5%S>UM-;4J52%3GG*,N:*G.RDO]H2
M]G.<5LH.GI%2?-HDO=.TC^Z.03DYQT![KT!'S<^I]\U)4<2E%P0!R3@$D>W)
M[XZ_GWJ2OCXJT4K6LEUO\KZ:JYTA1115`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2
M8&0<<C.#Z9ZTM%)JZ:`@*2X/S;B.1R>H!XQG&#QTP>>O%1F.5L?O#RPW8)SM
MY)5<G_:)4G(XP01@BW5:8D%2I9,'!P,[@5(X4<G;G)(`8`'&<"LW36K5N;>_
M7J[+6R5[:6\DTKH+Z6\[GXX6_P"W?^UIKNH?M@>'/"?PN_96O/B%^S+^TC_P
MSCX!^'7B;XY^*_!6I_M&>+]1^#WP\^-?A'1_!GB+Q'X4LM$\/>+_`!7X>^(4
M/AS2_#^KK?Z8/$OA[69+GQ%;Z%')J5I]X:7^V5^S+J/B?5_``^.WPM'Q"\-:
M9X_OO$_A"#QMI%[J.EW/P?2R'QJTJVGLYIK+6]5^#ES?VEG\3]*T*XU+5/`5
MS=6D7BFRTF6[MTE^'_V</V)[F\_:=_:O^-G[17[/.A:5JGC#]LWPU^U;^S9\
M3$\4>!_$?C+PG8^&/@1\.O@5:^'-6O=`N)->\-W]])X2\9>(KCP_876N^#]0
M\,>/A9:AJ\?B"*_LAX/X(_9>_;F\,_M,_`C]H7QO\)?#7C&]^!_QF_;XU7Q1
MH_@#XH_#_P`#>"_$O@_]I'^WKGX+:O\``WX:06?ASPMHUK8VD&G2_'KQ5\4S
MI?QR\2_$7Q;JFO7.N?%/1+5;BS^SQF"X=Q<\13PV)PN#6&P%"M25*IA<+#%8
M^IE&%K/#T:M?$XOZS1^NX?$T:\JCPE7"8K&R@E5HQI>RP4JT5%RBY2<VI+5I
M0562<M$K/V<HM+7F45'1IM_J;HG[<'[(/B32-+\2>'_VGO@9K?AO6OA?XT^-
M^D>(M,^)WA:\T+4/@Y\.]6U#P_X\^*5MK$&HOILG@/P9K>DZIH_B/Q.;E=*T
MK4-.N[2[N$FC=:Z?XE?M._!7X5_LYZ]^UEK_`(XTG5/@3H?PUMOBW:>.O"=]
M9^)=-\6^#-6TNTU3PI?>!KG3)Y+7Q9/X^CU/1;/P-%I<\R^)[S6]&M-/DEDO
MX*_-W]G3]G7]K#]G+Q?^T//H/P*^&/BWX?\`[2/P6U3XLK\-_$GCWPSIG@[X
M,?M;:M>_$'6O%O[.OAL6EKK]U<?LG?$#5=;@\0R7ECI$EQX;^)7B;QSXI3PG
MJ-G\2O$2>"/I#]L3]F#XE?M@_P#!/;6?@#/IGPZ^&?QB\0>%/@)XRC\("[EU
MSX/Z!\6O@KX_^&'QPL_AA<:K;^'_`+3<_"B]\;?#F+X>7FO6?A66_@\&7TVL
MV?AR6YABTMO-KY;DE#-,%0IX^=;*Z^/R^GB<9];P,IT\#7]G/%N=&CAU5I5\
M*U5H3K2C5H-T_;T5..)PT*34ZO))\J4U"=H\LM9J_)JVDT]+)<KZ2:M*_=_"
M#]K;3M;^#GCCXZ_'#Q)\#_AIX7\+?9-1U?PYX&^*UI\7-6^$^DR:-%J)\.?%
M[Q+X9MFT0?$IG=A<>%_!NGZAI]I=NNB:)K7C%A:ZO?>1>/\`]N?]@OPOXO\`
MV?\`X]>*?$GQ-U[Q?\3OV?=4\1_`G5O!'[.O[5/QBNF^!GQ4USP1KFJZZ?#'
MPH^$GCC_`(0B3QIJ?A?P0DS^,M-\/^*KR'1[+3!;I%;W5L/*]`_9E^-L/QT_
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M6D4NGW;K<:QHNGQ7-I&M_:F:P>.9O(/A#^W?^S1\<?&?A'P'\/\`QIXFEUKX
MF^"-=^)OP=OO%OPM^*_P\\)_''X=>%7\/)XB\;?`[QKX_P#!?AKPG\6_#FDI
MXL\,ZG-?>!M8UEKOPKKNB>.--AOO!&MZ1XDOY9OV1_A_X>\1^%?'7@C5/C7I
MO_"K_!FE>&/`/P1T3]HKXL^%?V?KW1_"/A&\\*>&/"6M_".#Q#>?#:^TN\TZ
M>WM-5N]<\*ZR)[R*UUW48K^^L8I*_-7X7?!+_@H=-\2-$^)7B[]D']FCX=_$
M?X8?`'XR?";]E35M(_:T-W^SG^RK<^,?"=NWA_1_"/[._@']EGPSJVN>'_%7
MB+P=\-/#'C[Q-KGC;Q+XBTKP;X?9/`.D>'-/N=6\-ZMY]#`93B*>.K1Q<HQA
M";PL,5B<)@ZM&K.-?ZO2J4JVN:*FXT5C:^$A0IPP\JOU?"5,9]6I%.4URVCJ
MWK92DFKKF:Y;<K?V5*Z3W:CS-?8/Q'L_^"=OB[XU_M<_#'XIZEX"O_BEJGP(
M^#GQ6_:WT_Q9K.MV7A[P7\(?A'JOB+5?@YXX\7^*+Z6W\"_#G6_`VHSZGXVT
MBZL];T7QKH=M%HWCZXCM-.7P_JLA^Q;\2_V*O&7Q$^(,WP%U+XDZE\;?B1\-
M_AC\7_%7B3X^^$OCKX>^,'Q0^!-]_:VA_"+QGX;U?]H'P[H?B/Q+\&+&[_X2
M"WT'3/";?\(]X3\1:UJT^KZ)HGB'QC<7.L?F1X8A^,_[,7[8'Q=E^.G[.'PQ
M^*_A#PC_`,$R_$GC3XY>`?@?XY^(W[1_Q;^.?AN_^-'Q+\1>+=?TGPA\0/@1
M\+-"^*WQB^*_CTZC8>)O`FMZAX6\-Q>&[VT@T#5Y+"PL/"=I[;\)O"WA+XT?
MM^_%/PS\,?B3XA^/?P+\=_L4Z3X?U+]I7X/^(U^%6I?LFV'AWXWOK?PK_9)^
M#7Q2_9T3P!X1T#3=9T;4]9\1ZWX<33I/CMIUAX6T9_B'XWU7PM>>%=!TOVZN
M747A,1%9GF;P_P#85',(5OK=.M@IRH4\+3EAY8>*IQ2ITZ-"I3P%2K2KU,-0
MR_"X98S'TZGU2%-N5W33?M>3X4FHI/EGS-NRO*2YE=)MR:4;W_7;XO\`[2'P
MM^"&L>`?"GC75M<NO'?Q6N_$%G\,_AQX'\'^*_B+\1O'1\':9;:OXPU30_!/
M@K1=<UW_`(1OP=87VE2^+?&.I6NG>$O#,VM>&]/UG7++4O$F@6>H><O^W5^S
M+=?#_P"$?Q$\/_$"]\8Z9\??%OB+X??!SPUX/\$>/?$7Q,\?>/\`P6/%)\<^
M"K/X5VOAK_A8&@>(OAO)X(\76OQ5M?&OASPU;?"6Z\.:U'\3;KP@=,O/*^:]
M?_8V\9_!C]J?]EW]I7X/R?%'XZ^'?A'\)/VC?@9\1?!'Q2^..O?$'XJ/H'QO
M\2_#CXA:%X[^'GB[XU^)WL+^_P##_B7X=S>&?%?AK7/&F@KJ?A'5_#,VB7XD
M\!0Z'K/S/\%OV`?VDO@C\0/V:?VH-1T3P7XQ\>^&OVFO^"@?QH^-WP+\&^(=
M-@7PQX&_;PU&VO=*T[X2>*?$MMX9\+>(OB!\($\(?#Z'QG#JMWX.T'Q2FO?%
M$^%M?N6MO#]OXF\NAEN0SPOM9YDYUEAIUJ<958X;Z[C(1SR4,`Z-2&(JY?"^
M!RJ^-JUJRE_:DX07,J'LZ<ZJDDJ:2YK.SOR1_=>]=64W>53W8I/W5;1,^X_B
MA_P48^!OA;X3^#/B)\-=3M/B;XE^*?Q;U;X$?#GX>:WJ=S\&-9?XM>$SK]W\
M2_#GQ7'Q0T32-<^"%I\&?#GA+Q9XO^+$OQ`\*V>N>%M'T(V-CX:UKQ/K_A;P
M_KE?XK?MRZ7\%?A+\!=6UW5O@S\2OC/^TGXBO/"WPNTKX??%.TT3X#ZO?:79
M:OXH\7>,=1^,_B2#4$TKX._"?P9ISWWCOXA/H%[J^KWT%II?A3P'<>*_%?AO
MP8WPSX?_`."=OQS\-?$OP+^UQKWA/PMXZ\;1_P#!17]I3]LOQU^R_;>(]#N(
MK#X9?M)_LU:/^R[9>$O"7BWQ(=-^'6O_`!;^&>E^#O!?Q:U1-:N=$\(:]K]W
M\0?#GA_QM8M<:+X@U/-^&7_!.KXX_"KX@?!/]I*Z^&/PX\8OX3_:Y_;]^-OB
M']E#2]9\.W+?#WX/_MSGPK<:9HGPV\0>+S9_#:]^,'PTU_X?>&O%GC;1(M;\
M*_#R^OO'_P`6=,\">-+ZTTWP[-XI]59;PK"+4<>JKPT,56<:E>ES9CBHT\;]
M4RN%:/LGA,/2G0P<J^,E2HX?&K%."QE"2?L\U4Q+UY$FYTX];0A>#G/K*4GS
M2M&_N<J;3OK^X?PI\1W_`(P\`>$/%&J^(/A]XIU+7=$@U"\U_P"%6JSZ_P##
MG4[B1Y$>;P?K5U<7-SJNC(!]GAU":3S+F6.69H;4.;:+T=&.T?O$ZMQD<?,>
M.1VZ5\)?\$\_V;O&7[,GP*\1>#/&EMX>\.ZCXY^/W[0WQTTSX6^"]0;4_`7P
M-\,_&SXL>)_B!X:^#_@V[%AI=I+:>%=+UBWN_%)T?3[;PX_Q#UGQC+X8%SX>
METR[N/O%8U`P47.23P#U)/4C/?\`#I7R>/HX>CC\72PE98K"4Z]6.'KPIQI*
MI24HN$HP3E&*M*<&H3E3;H\U*4J,Z4GO"3<8N4;-Q7-%ZV=WW=^E_FKZW,'Q
M-X8T3Q=X?USPKXCTZ'5_#OB71M3\.Z]I5UN:UU31=<LIM+U73;D1M'+]GOK"
M[N;:<QO&XC=F5U?YJ_,&+_@AY_P2?CC2-/V'?A`L<:*D:C_A+"%1`%11GQ)T
M"@`<YP`#7ZP45O@LRS3+5566YIF67*LXRK+`8_&8*-5P3C3=6.$Q6'51TXRE
M&#FIN"E)1<5*2<U*5*K;VE.$VKV<X0G:]KVYH2M>RO:U[*][*WY1_P##C_\`
MX)0_]&/_``A_[Y\5_P#S24?\./\`_@E#_P!&/_"'_OGQ7_\`-)7ZN45V_P"L
MO%'_`$4W$/\`X?,X_P#GF9_5,-_SXH_^":7_`,J/RC_X<?\`_!*'_HQ_X0_]
M\^*__FDH_P"''_\`P2A_Z,?^$/\`WSXK_P#FDK]7**/]9>*/^BFXA_\`#YG'
M_P`\P^J8;_GQ1_\`!-+_`.5'Y1_\./\`_@E#_P!&/_"'_OGQ7_\`-)1_PX^_
MX)0_]&0?"'\O%G_S25^KE%'^LO%'_13<0_\`A\SC_P">8?5,-_SXH_\`@FC_
M`/*C\HC_`,$/O^"4)R?^&(/A%G_N;!_[LM)_PX^_X)1?]&/_``A_/Q;_`/-)
M7ZO44O\`63B?_HI>(/\`P]YQ_P#/07U3#_\`/FE_X)H__*C\HO\`AQ]_P2AX
M_P",'_A",<<?\):?Y^)?KD8Q2-_P1`_X)1!21^Q!\(L@`8'_``EO/^SD>)1U
MSSG@Y&>AQ^KI&<<D8]._UI:?^LO$_P#T4W$*>^F>9Q^7]IC6&PZU]C2;6MW2
MI7TU_P"?2/EK]FC]C3]F+]CK2?%'A_\`9C^#/A3X-Z-XXU>PUWQ;8^%EU3R=
M<UC2K)].L;Z].J:AJ#F2TL'>UA$3QQ!7)V%SOKZBVG&,CZ<@?>S_`"X/3I3Z
M*\JO6Q&*K5,3B\1B,7B:TN:MB<56JXC$59<L8\U6O6J5:U22C"$5*=2348Q5
M[));I**2BE%+9))17DDDDEY"$'C!Z9Z]_P`!BE_S[^_]***RLO/[[_\`#?*P
M_P!1H7[W/WL_U_QI2`>M+1196MKUZOKKO>^_GIT`;MSQVP1].F,?EW[^W%+C
MDYZ'M[\?X#'XTM%'*O/[W_F`F!Q[#`]NWXT8XQQG&/;_`!Q2T4<J_IL!H7`Z
MX.<G'Z=>P]*-O.1CG.?QQZY'7KTX-.HHLM/+;5_CW^=P_K[QI7..@(P>/P_H
M/Y4ZBBBWK]__``X?IL(1D$<<^WYGW/\`DT`8)/K^??\`0=J6BBRO?7[W;[KV
M_`+?U\[B8YS[8]_S_P`?\:4#'YD_GS1119?KN_\`/_AN@!C^>?\`/\_K1]:*
M*+?U^`!1113`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*8R!L;L'!)!(
MY&?0]/49QDJ=IZDE]%`$?EKQ[9Z9[Y]2>F3CTSZ\TGDIC&W.,8SV`P./3@`#
MTP,8J6BH<;VLVK/7S_5?UTT`B,*8X'4$'/<')].Y/..Q([G+A&H&`.I+'W)R
M.?SX].U/HH<$^Z_'\'=+Y)`1F)#C@<8]N./RXZ>W%121MD!02OREN>I#`CC.
M"!R3GC/?=R+-%.4>96NU\W_FK-=&OQ6@%5(P3\R\\DYZ$$@8&#_=V\'UYZD!
MYA7).T-\I``"@GICG``(QP<CG!SD9J>BER*UN:6C;34FK-WULFD]V[.ZNV[:
MNX5&3.=J'(.]5P!M<#:65LJ=S*0,[L[689[4XHWF)DLP&T_-R00V"1_""5SR
M"6Y.X8(`L$9[G\#CU]/K^@I:7LEW=KMVWW=^O1/5;6V5DW<&>6I!^4`__KQZ
M^IS]33?*3@;1\N2#@<$G.?7=G/(P2&;)YJ6BGR?WGNG\NJ\K[MK7SM8"'R5!
M)`(XY.<Y&",8/&>^><<=,THB48(&#@9)ZY&W&1T[$D>I/J:EHHY%K=MI]+M*
GVC25GNFOB^)WU>B`8L84\=L@?0XR/;D#H/Y\/HHJDK)*[=NK`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``B`M4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_)@Q7Y"`
MY1@I(RH;:=I(')`)&X9]0*_-C]IC_@J[^P-^QK\2[GX1_M'_`+0.G?"_X@67
MAS1?&=YH>I^%_&NI+;>&?$)O5T_49M2T3PSJVF1KNT^[DEMWODD@BC>1PJ(^
MS])2QV'@DCD#OC!SDYZ8]_TZ?Y\?_!PE\0O$7P@_X+(Z#\5_!T&B77C#X=_!
MSX$^*_#5KXDTB#7]!EUO2KKQY+IZ:OHUR&MM3LA/M:6UF#128^='"[3]EX=\
M*8#BWB:CDV/E5I1HY;C,13KTDDXSHT'*/+*5.I&TI12G:,FD]+-*_-BI."4W
MM?1[I[M=5>_17UM;6Y_3K_Q$*_\`!'T.R#]M+PJ94B\\QCP9\2?,$&8E,Q4^
M"\B',\*^:1LS/"-P,L8;1'_!?O\`X)+G:Z_M=:03(=H/_"O?BF0P(5L*1X'P
M3R#\NXG(/U_F@^+'QQ_:(^$O_!'7_@GK^T\B:N/BOJ7[3/[0^K_%WQ[XO^%&
MDZQ+XJ\(>(/$WQ(DTV3XAZ9J7A,6S>#I[&^L;;PWI\D<%DEC;Z#'8W@FMUV?
M+]]_P1;\?ZKXU^''AC3OVBO!$&M?&[]ES4?VQ?#'B?5/AQXT\)?"C0O`=]=3
MZC-X?\:^/[>[@\&^!=>FEU"2VL8=7:32KFWDMUB#.L6S]&P7ASP%3IUZ>=9K
MFN"J4LSQU"@I0BE7^IU9PKU*:EA9W<(SC.24VX\[ING[2+@<WUR<=5#F:47:
MVZEHE\75OLU=7O9G]@7_``_Y_P""2X=D_P"&NM*$B;2Z?\*[^*N]-^=A=#X&
MW*'P=FX#<`2,@''<_"S_`(+1?\$U?C?\3/`_PC^&7[2]CXJ^(/Q$\1Z7X0\%
M^'H/`7Q&M)-9\2:T;I;"TBN]3\&6EG:OFUD!N+J\@@4SQQLP:52W^7]=W6FZ
M5J$V@7.K>'IKNQGN[=+;3]4L;BPQ:7]QI\]WIRVS"":PN)K991K42""_CFMC
M),#"H/Z#_P#!)UHI/^"FO["S0-;R1C]I+X<9DMI(Y8B?M=Z?EDB9HW^4CYE9
M@1C'?/UV;^`O#>6<.YOG&`QV:UHX7*\7CU2JT%"G)TL/.M#VLO8-*,N6UO=<
MM>5II,E8Z59QIR@DI..K4NDE:S=M==-=S_5,ADB(4,RQE2Q\N39&ZJ96C!9=
MQ)#.,+)P'8C'S'%3K-"<+YL9:55:-0ZDNK!V1D`.65U1V4J"&5'(R%;'S_\`
MM'>%?CGXO^'"Z'^SM\2](^$?Q(N?&_P]FE\=:WX7L?&MMI'@>#Q?HX^)4>G^
M&M4W:??Z_?\`P_E\0VGA\W0^R6NM/I]Y/@1-G\OO!7C7]L7XJ_M9_M\_LM>&
MOVL-8\-2_`#X:_`S5OA#XIO_`(7?"W6WLO&7Q,\,^)[Z_N/&NGCPVW_"3Z#+
M=Z;%#-I-K):SZ7N$\3RLL3#^9\'E4\=1K8N-:E3I99AY8BLIN7[JE]9IX2%2
M?+"2BI5*M.FN9Q3YF[KEM+U(7Y8IZ-):?BM&UI?].Y^X@9-OWT)<X7#*=Q!Q
MM'."0P((&>>.O%.5XF#%7C8*YC8JRD+(K;2C$'`<-\I4X8-P1FOR?F_X*+7W
MP[\6>-_V=O%_P"_:`^+O[0OP`^&?P7\3_&&S^#?A#PMXHL/%=I\2I(O"TGC[
MP1H-GXBM]5U#0CXBL-4U"30HM-LM0T[3MTDEA%8P_:$]'US_`(*&?#"'1?CS
MX]\%_#_XE_$_X2_LQ>(O$7@[XU?%CP)I^F:QHOAS5?`D#3_%*U\-6%WJ4.O>
M-;7X:6L<MSXSF\.VJK$+2^M[`WU[87$:*>58Z,N=4YKGA2DO=C9TZC:P\U[W
MP8AM^PD^7V[_`(*G:5GKW^6JV7;R1^C>4&#E1DE0<@989R`?48.1U&#Z&F;X
M=P_>)G>$P'7_`%A`8(>?OD$,%X)!!P0:_.C5O^"AGPZE^+_PX^#?@3X6_%3X
MKZU\<_@5:_M#_!3Q'X-L/"I\(_$CX9FST'4)[JTU;6];TBXT-[2T\1Z1*8?%
M%G9PSR7UO#;3O,["'R^'_@K'\*)_@_/\=;WX'?M!Z=\+?"?Q2U+X*?&7Q#J/
MAO2(KGX._$C2_'%AX`UC1]>TH^(WUK7+/2=;U"U&J:OX1BU71X[&Y61;J91,
ML;CE&:U?9JCA<35G5KX?#PA3H3J5)5<7.M3PU*-."G4=3$U,/B:>'AR<U:I0
MK0IJ<J510->_EU_/YGZT^9'N";UW,"5&X98``G:,Y.`P)QG`()QD4"2-AE70
M@`$D,I`!)4'(/0D$#U(('(-?BQJWQN^+GP\_X*I_%3X=>'?^%V_'?X;Z_P#L
M&>!?C=I_P2TCQ!X;U'PQH/CS4OC;XN\+7_B/PW;>+M3TRR\.:?JOAGPIIUGH
MUF+V>*ZU6[N[:/R&>X>WX+]HS]LRQ^.'P[_8P_:`_9A^+?Q;\`VUW_P4)^%W
M[-?Q@\!KJG_"-S:7J5WXGN]$^*?PL^+OA"\74;>'7=`N=-LK7R+>]-F+:^%U
MIAGM]2\]^B>1XNG*A&+<HXC#T,3":@W%1Q,<1*"E?WUS2PN(@I.*A*5&HHN\
M)QIEM_+?^OFK]NI^\V5(/(('7!SVSV]N:B#PAF&]0RA206`*AR50D9R`[`JI
M;&Y@0N2"*_/C0/V_/`NN^,?VO?A_>?"[XD>&_'/[&7A_P[XK\?\`ACQ&GA#3
M]5\0Z#XUTW6-:\&ZQX!$NNO;ZKI'B73-&OY-.U2YGMK4:C!+HUT]MJ*K;O\`
M3_ACQ/K7Q3^%.G>)HM-\6_"/4/&GA634[2VUVWT"7QEX,EU?3[?^S;Z\MO-U
M70[/6+-;EKO[!,ES;S(94NF@E#+7FU\+BL/5P].H_9QKJ+BY*-IQE'FC*FXN
M2G&4;N/(Y7L[-[!9_?\`\,>T-+$"@,T2F9]D09U!DDV,X2/YAO;RT=]J@G8K
MM@JIIQD4*S,R!%#,SEP%54SO+-C"A<'<6(`P<]#7\H7A[_@H7^V%<?L5^(_B
MOH_[0VI^+_VF/#_[7GB+X*>&/#7Q%^"?@[PY^R_XS\"^'_C&O@R6U^)WQ2M_
M!6@>'_!=C=?#RWUO7M1\4VGQ.:]AUVWM-/MM(N7N_LTG[MV?[7NC6_[1"_LL
M7?P]\2W?Q8D_9S?]H?0-3T.3PW=>`_'F@Z9=:7H6HZ7X4\0?:TF74X?$.I0:
M=HHO[&SM+RUDAO!*+832Q=^,X<QV#M*7-%MU&]))6IJG*I-<\87A'VT%*<6T
MF]4E%LGFC_-'I]I;N]EOOHU;OIN?;YN(0`QF@"E58$RJ`5<@(P)X*N64(PX8
MLNTG(R[SH^OF1_>*?ZP??!VE.GWPWRE/O!B`1DXK\L]+_P""I_[/NI?!;P!\
M:M3T/Q'X,M/B+^T+XE_9B\/Z%X^N?#'A#;\5O#%_JFF^)+77/%VIZRG@W1?#
MRW'AZ_AMM=N]9^S:O)"EO;Q33310R<C^U;^U7XDMO@]\.O$^K6'[4'[,UK+^
MUY\*?A%K'B'X>V/PQ\1ZQK=WKGB7PU9Z!'+<Z_J.JZ!J_P`&?BC-XIMM.NO%
M/A3S[VTACNGECLY+"XC@P>1YA&:A.%>G)U)45&<)1DZL9.$J:BVG*:FN1QBI
M2Y_=:3N58_7W=]#]"3R.HX7J.XZBF,X)VY4L"/EW?-R"?N\-G`SC'3GIS7YX
M^)OVZK72?VAOB;^R[X8^`7Q@\<?%OX;?#+0_C#+;^%6\"P>&]6\">(M<U/1=
M%N[+7-8\0VT&EW=Q=:9<PQV&MV-CJ=S<>8;:$V)CNJYS2?\`@IC^SGKWP,_9
MP^,FFQ:Z3^U'KOB/PM\'/AMKD.A^#O%-]XL\%:QXGTOXA:1XA;Q%J-CX8\-6
MGP\U+PGK(UCQ))K!M+E-/^WZ3+?Q7ENDLK),QDXJ-&I7<^7EI<O-&HI4Y5HW
MM*5HNE3J55)J*<*4YIN,6PLUKV[W6VGEW[GZ6B2,X`:,[E9EPX.Y495=EPQW
M*C,JNPR%9E5B"P!?YD2A2[QIYCB.,LR@2.WW40L?G9L':JDDX.!7Y52_\%6/
MV;;'P]XXU;6;F\\/^+?AO^T/X,_9I\8^$M5\0^$8M%LOB)\1O#O_``E/@;6+
MOXHVVMI\,8/A[XF\,))J.F^/]6US[#!<:;<:#-%9:[(EG+W_`(V_;_\``/PQ
M\*^&/%7Q1\!>,/AI>>/OCQ9?L[_#NW\8Z]X4T?PSX\UW4O"<'C/3O&FF?$E=
M</PT3X9W_AUKN71/%&H:JMIJ&N6NH>'K2VC\1M/I[J.3X^-YK`PI6DX.=.TI
M*5KN*5[M..LG%22BFW9)M-M]_N;=M]]?(_1DF,9R4&#@Y*\$+N(/H0H+8_NC
M/3FFK/`X4++&0[M&F'4[W5&=D3!^9A&C.57+!%9B``2/#/@K\5KKXN>%;GQ#
M<?#_`,5?#>XLO$NIZ#%I'B5-$O/[1M=+N9(8O%/AG7/#E[JNA>(?"?B.VB\_
M0=>TV[DLKRU=,F*82PQ_GM\&OB=\?/$'_!5G]JG]GGQ+\;];U[X(?"'X'_!G
MXK>$O`-QX&^'MI+=:G\4W\8Z?J&DZ]XRL?#:^(]8\-Z')9I-I-E)>+>P7:!K
MR\GA*1R73RZM4^L^TJQISPE"6(<:CY964Z5-J*5^:3=:'NMIM<S^S)):^?\`
M7J]#]?5:/<5#+O`!9=PW`,2%)7.0"00"0,D=R*7,8&XE-I!(;*X(`R3GI@`$
MGV%?,'QG^/EK\*O$7P_\"0?#3X@^/-=^)*^-[O3M4T;1[:R\`>&[/P1HZ:WJ
MVI^/?B%K[P>"?!<.I6LGV70?[5NEFUC4/-CM+616D*_)"?\`!5;X*7GP?^`?
MQVTOP#\2]2^'/QT^.&G?LWQZ\]MX;L8?AK\8M0\7CP-'X>^(][J&M0Z9I&F7
M?B>.XT1?$VG3ZCI%[>)]F-U"TUJ99HY=CZU*%6$*DXSGR*4(7BYVDXP33^.7
M)4Y8OWI>SGRQ?*Q.26\DO65M%:^[V5UKLKKN?JIOA;>JR1DQL(Y,,I,;L%*H
MX!RK,'0A6P2&4@?,,JKQDE`Z,P8J5#*2&55)4KDD,$*L0>0&!(P17Y[^)O\`
M@H;\#M&\0?M2^#-$M/%7C#XA?L?:/X;U3XA^%=)LK73;CQ"/$OE01VWP_OM>
MN;32_$JV_B"XM/"FH264D9M?%#3>'%;^T[.YLX_M[P?J]]X@T'0M<U/P]J_A
M?4=5TC3M0OO#>OMIK:UX=N]0L8;R?2-5.ER75B^HZ=+*VGW4EE>W5F\L#F"X
MG1?,;"MA*N'J*6(C.%3V<)QC./))TZD>>G-1=I.$XM2A*UI)W3!-/5._2Z=]
M5NMWLSJ@`A^8@9R!DXR>N.>^`3@9Z5)UZ5!(^S:70L68(@"[L,P/4@':I(P6
M;"@8W,,\^'M^TG\#4\$_$CXDWOQ%\/:?X$^#^M^)/#7Q,\3:J][I&G^"]>\(
MVEG?^)-*UH:K9V=S%=Z;::AI\VV&"=;M;VU6P:YDG1#%)5*R3C2FVY*/+&$I
M.[=HJRBW>3ORJUV[V3'JSW4N@SEE&T`ME@,!B0I.3P&((!/!(('(-*&4DJ""
M1@D`C(!S@D=1G!Q]#7S<W[6?[/"ZIX=TD?$K3&D\4P_#:;3;B/3=?ETA%^,B
M3R?"A-5UE=';2="N?B&EM<?\(M:ZY?:?<ZF(&$,08J&[;3OC!\-O$GQ(\<_"
M'0?%^D:K\1/AQH/@[Q+X_P#"<#R33^%M&\>WVNV'A:_U:8PBSM)-2E\*>(9+
M*T%X+N1M,NVEABV*[;RPN*@DYX;$03BY)RH58IQ4E!R3=.SBIRC%N]E*26[2
M:LSUEI8E,8:2-3,YCB#.H,KB-Y2D8)^=Q%%)(57)$<;N1M1B';E/1A^8K\]_
M!_[?_P`#O%>J>,GN9Y_#/@SP$GQ!3XC^.M=U'PY:P>!)?A_XHTKPC?Z?\4O#
M5M=?\)QX!.K7^M2W_A/4M;TB#2-5L;>XN$U9A(`WM.J?MC?LNZ)96U_J_P`;
M_`=I%=:SXB\.QAK^9KI]>\(Z+:^(_%&F'3XK:6_BNM#T"]M=<U&*6W7[-I%Q
M%J+G[(PFJE@\6]5A<2TVDK4*KU:NE\&[6J[K576I//#^>/\`X$O\SZ?R/4?F
M*,@\9'/&,]?\BOGF+]J?]G*:U:^7XQ>!EL5\-ZYXN^V3:JMM:OX>\-^(U\'Z
MWJ$5Q<1Q0S?8/%+Q^'WM(G>^EU>:"QM[::XGA1XQ^U1^SC+/I=FGQH^'T-[K
M.N0>&-/MKO7K>PF/B:\\32>"['PW?"\:T.C:]JGB^*7PII.EZL]AJ&H>(U.D
MZ?;W.HI]GI2P6+M)2PN)2M[S="JE%.+=VW3LERIO5VLFWH"G!VM..NWO+_,^
MB%:-EW*X9<D;E?*Y4D,,AB,J001V(.>AHW(&V[EW$$@%AN(4X8@$YPK$`D<`
MD`\FOBOQY^V3\/\`P+\<(?V>SI6KZG\1X],\$ZM-I;:GH>A:G>^'?&VJS:;#
MX@\':;XLU/3=:^(]CX3%I>ZKXR@\*M?W^@65I<-?6+,`&T_"_P"V_P#LNZ]X
M?\*>)_\`A:^B>']*\=Z[XJ\->#X?%%KJGAFYU[4?`_BZ[\%ZY-I.F:C8PO-I
MZ:RC7+ZLBK8-IUW8WS7)LUDN(YIY7BI)5:6%Q%2*]Y2IT*DXVL[/FA"2M:_K
M8H^PMZ;@FY=Q!8+N&XJ"`6`SG`+*"<8!(!ZBER,[<C=C.,C./7'7'O7SJO[4
MW[.5S#>2P?&7P%/#8QZ1+<I%KD$AF@\0WFK6&@7-O;HC7.I:=K=UH6M1Z5J&
MFQ75AJ(T^=[>XEB,3NGPN_:<^"_QD\7^._`?PU\86?BG5_A]8^"M3UN;3K2Z
M_L&\T?Q_X>A\5^%=7\/ZQ'`=.U[3M7\/3PW]I?Z1=WMJUKLF+HC*TESP>,IQ
M<JF$Q,(IV<IX>M&*?9RE323U74#Z)\V/(7S$RP=E&]<LL;*DC`9R0CNBN1PK
M,JM@L`55T8$JRL`<$JP(!'4'!.#[&OB?XS?M@_#_`.$WQBB^"MUHVM:_X^U#
MP9X0^(EAX=LKKPKHU_XJT;Q!XPU7P28/AQ;>+[W33\1_%>A7.DP7/C3PUX8N
M+G5]`\,:EH=Z+0WVMZ7#>=+XH_:T^`^C>$]>U[1OB+X-U^XT'P9\1?&UCHZZ
M[;6-Q=:;\+M5TCP[XQO+*_UBW^QZ?#X3US5;;1M9>Z&+"^O;9)45&<HHX3%3
M7-##8B<6DU*-"K)-/9IJFTT^C3:?<3:C\34>FK2_-H^LO,C^;YT^0`O\R_("
M-P+<_*"O()P".1Q3Z^3O#7[7_P``-<F\:6W_``G6GZ3=?#_Q1X>\">(H=7M+
MC3;>+QAXKT"U\4Z3X7T"]:U$'BF_OM'DDU"*UT07=Y?VMM=7VGVTMI'YH]0U
M#X[_``FT_P`(>"O'L_CS0KGP3\2=?\&^%O`?B?2FN-;T7Q9KOQ$UFP\/>"=/
MT:^TBWO8+H^)=;U33]+TVY+I927EW#%)<Q%B1,\-B(-*="M!RNDITJD6VE=V
M4HJ]EJ^RU=EJ"DI;-/T:?Y7/8-RX)W#`SDY&!CKD]!COGIWI`Z$X#J20"`&!
M)#`E3P>C`$CU`)%?.Z_M1?`%?$T_AJX^)OAF"]M];\5^%IM:NOM=EX1/B;P)
MI5SK?CCPG_PFUS;1^$!XE\'Z-:7FH>)=%_MPZCH\%E>B^M[=[*\2#=^''[0/
MPD^*^H_V/X&\86^KZU)X6TCQY9Z3?Z;K&@ZMJ7@7Q#(\>@>,M&T_7M,TN[U?
MPMJCH4M=;T^*XLB[PI+-&]Q")"6'Q$(\TZ%:,;7YI4JBC;OS.-K?/U2ZL]K9
ME!`9@"3A06P2<=!R"3@]!2X&0,G)Z#<<G'7'/:OA[]M+_@H#^S/^P#X;\(>+
M?VD/$OB'PSH?CS6=1T+P]=:'X4UOQ;)=:II^ES:K=I=6NCQR/9P164$CB>[$
M<,DB^2A,AR/<?@5\<?AU^T;\'_`7QS^%&K76O_#+XG>'K3Q+X/U*ZTVXT66_
MT6XN+BW6];3+N&&]L`9K>0E+O:Z"-BX16C:0GEN)="GC9X;$0PM><Z=+$RP]
M2.'JU*3<:E.E7E!4JDZ;34X1G*46FI)"<HIV<HI[V<DG\TWH>W;T`SO4`C.2
MPP1D+G)/3)`STR0.II5=&R5=6`9E)5@<,I*LIP>&5@58'D$$$`BO@2Y_;N\!
MZ=\>?$'P"U3PCXO7Q;X>^,?@[X,74]JV@ZE+-XD\;_#ZP^)?A[Q/I7ABTU.;
MQ++X$'@_48;OQ#XF-I'IVA^1<?;F@DAO37N5I^U)^SO+#&1\8/!#"23PHEM(
MVKS-'?1>._$.H>$_!=]IMQ=QAM5TKQ3XFTN^\/Z'K-B]UI6I:S"--M;V2YFM
MXI7#!8KE2AAL1.-DU*-&I*+4G[LDXP:<6V[-.SL]='9<\/YX_P#@2_S/HG>@
M8*77<59PNX;BBE0S@9R54LH9@,`LH)Y&1G12`SJI;.T,P!;:,M@$C.T<G'0<
MGBOCJ?\`;`^$LGQ*T7PE#K6AS^`M8^$WQC^*<OQ=76=/;P=H$GP.^)'PX^''
MC;P[KJW,4$NEZU;>(OB)96T?VJ3>VHZ9+906\MUNCK+\$?MJ_!O6H?B;<^,-
M;L?A?:?#WXE>(_AU%<^+=173HO%UQX2\(Z=X\UKQ'HUE)IFG:RVFV7AS4[6^
MUF>:P6WLTQY\B+<0+/I_9^(>OU:M>\4U[";?-+FLM(-W?*]-]&WI[S.>'\\?
M_`E_F?;61ZC\Q2;T(!#(002#N!!`ZD'."!CD]N]>)^$/VA/@C\0O%VI^`_`_
MQ)\,>+/%>D64^HZGI.@W,VI-:V,`T5GGEO;6"33RDT?B+1GM!'=N]_'J$4EB
MMPBRM'Y]XX_:3T31_B/XI^#W@KP=XH^*OQ)\%_#^T^(GC7PUX6;P]:S:+HVI
MQ:L_AW3Y[_6+RSL;WQEXE.CW_P#PC7ATJL<\=H]W<SVT/E7%8_5Z_.Z;I585
M$N:2E3G%PCHN>:E&+C%75Y2Y4KJ[72CZI\ZWSCS8<^F],_ZSR>F<_P"M_=?]
M=/D^]Q4F4!ZJ#NV]0#N(R%_WB,''7'.*_/V]_;S^'MOX$^*7Q;M_`GQ(N_AK
M\#'@M?C5XT.CVL-U\.]4C\.:'XA\:Z=)X8N[D:]J-_\`#/2M;TZ;XA6&GVOD
MZ3+!>QQ17-U9W:Q?1/QC^,GA;X+_``?\7?'+Q0+J_P#`_@;PT_B;4Y/#T*ZD
MU_H+26<=K<6B"1+-;&[MKZWOKVXO&-KIEB+C47GCMX))Q<L'BH6<U-J4N2*4
M;N<VHM07*Y-S:G"2A\3C.$E&TDQZ^?XGO(D1ONNC9W8PP.=AVMT/\+<-Z'@X
M-*&5ONLK<9X(/'KQVX-?&7P]_;;^!_C'3=9O5\1NDEO\3/$/PNT"'1Y5^(:?
M$'Q#X7\+Z-XQU^Y^&-W\.H_$4/C71M&T/7;6/59]!M'?0]1L-1TW6TMM5ADA
M/7K^U_\`LTW=]X4L[/XM>&M0'BY/AZ-!U"PCU#4-!6?XL7NNZ7\-;75O$%K9
M2Z+HNH^.-4\,Z_I?A[2M:O\`3M1O=1T34;);9+NVDB!]4Q?_`$"XGK_RXJ]-
M_L;KMOTM?12VEJVDO/3\SZ>R"2`02.",\@XS@^G!!^AS0&5AE2&'J""/S%?+
M\?[8'[-#I<2-\5?#5O9VVG>--9LK^[MM4M--\0:?\/+^'3/'EYX/O9]/CMO%
MR^%=6G^P:S#X;EU2:VNXKN,1.+*Z>'TGX<?&GX<?%J'Q'-X$\4VNL-X/\1+X
M1\66,EKJ&DZQX7\4-IFDZTGA[Q#HNLV>GZGI6JR:3KFE7\-K=6J&>WO89(&E
M`D"*>&Q-.$JE3#UX4X).<YT:D813=DY2E!1BFTTFVE?3?07-%[2B_22?ZGJQ
M91D,RC"[CD@87IN//`]^GO3$"8)#*0I(.T@A2.H)]1WSC'>OS6_:\_X*I_L:
M_L+_`!#\,_";]HOQMXF\+^-?&GA^S\6Z%IV@>`O$OB2TN]$U#6[OP]9W)O-!
MM&\E;G5;&\M6^T$>5-;R23R)`8VE_0FPUJVUK1-/UC3G-S::SH]IJVF%HP6G
MLKZVM[B!CN(C9IX;JW8"78H,B^9M"N5JI@<=2HX;$5,+B*&&QJJ/"8FMAZM.
MABE2E"-66%K5*<:5=4G4@JLJ,ZBIN<%-Q<HITI)Z1:>NMFG9_H=`TB(&=W5(
MXU9Y'9@J(BJ6+NQPJH`"VXD*`"2?23<N<9&1@D9&0#G!Q[X./H:_)36O^"J?
MPOTSPIXYU_\`X5MXYDOO`G@KXR^.M5T*6Y\+S21Z3\!O&NB^!/B:OBK4M.GU
M2+P=/;ZIJ22Z3_PDUKIJ>)-`AU*XMVM;FR13]RP?M,?L^1V$]Y'\5/"(M[+7
M/$?A^[@BG9-0M];\*VL&H>*;/4-$BM1JUM<Z!I]Y9:IK$]QIUO:V>GZA:ZA+
M*+2YBF8_LW&4;)T*]7VCYE*%*=17=[1O34TI6BY6;3MK:VK3:6[2ZZM+\['T
M-D>H_,49'J/S%?/5I^U-^SEJ'B[3O`EA\9/`5]XJU>ZT.RTO2[/68KD:A<^)
M_"4GCSPU':7\*OIDX\0^#(9?$^AR1WIBU;18I;^P>X@C=EL:)^TW^SUXEDTV
M+P_\7_`FL2ZS=^%;32(]/UF"X?5#XXAU"X\'7>GA`3=Z3XGATK4GT/6X-^C:
MD+*<6M_(4(I2PF*BN:6&Q$8V3O*A52L[V=W32L[.VO1[#33U6J[K4]]!!)`(
M)`!(!!(!S@D=@<''K@^E`((R"",D9!R,@D$<=P00?0@BOEGQG^U=\'O"'QKT
M7X!7OB+2W^(NH:9H&LZE87>LZ+HECX6T_P`676J67A>/6KW6KN!/[;\4W.CW
MD>B^'+.WN-=N(4ANC;16E]:336;_`/:V_9]TD:YY_CV34)?#/Q!U[X6>(;3P
M_P"#?'OBW4/#_CWPUX5M_'6L^&M<L?#OAK6-3TJZTWP;=VFOW5]J-K!I)L96
M:WOY3%)'&HX7$R2<<-7DI)2BXT:K4HMM*46H6DFXR2:;3::O=:RYQ6\HJV]Y
M)6_'S/ITD#J0/J0/YTN1G&1G&<=\>N/2O$)/VA_@ZGPRTWXP-XZL(/AYK%KX
M<N]*UA['5XKR^A\77UAIWA=(-`GTY/$2W&OWVIZ?;:79R:.EU=/>6_E0[)5>
ML"[_`&L/V<].^&>K?%O4OBSX7TWX>:#XHNO`VN:YJ4NHV4FD>.+'6T\/7_@[
M4M)N+*+7K3Q3I^LNMIJ/AZ32UU6Q&^[NK2*R5K@$<+BI.T<-B)/FY+1H56^>
M[7)94V^:Z:Y;7NFMT[4M=5JK7T[=_0^BQ)&1D.A&X+D,N-Q.`N<_>)(`'4D]
M*=D9(R,@`D9Y`/0D=<'!Q]*\'MOVC?@K=?$.S^%4?CO3E\<ZMKWBOPMINDS6
MNK06NM>*O`NC1^(/&OA?1];FTZ/0-4\0>%]%F34M=TC3]5N-0TRU+O=01M%(
MJ/\`B%^T7\&?AAJEYHWCOQUI^DZAIGA5_'FO64=EJVJCPQX%BO7L#XT\4G1M
M.U'_`(1[PJ+V.6(^(-8-EI:QVM[?-<C3].U"ZMI6'KR<8QH5I2FKQBJ51N2=
MK.*4&Y;K:^Z[JYLKO1+=]#W:FET#!"ZAR,A"PW$9QD+G.,\9QC/%?/*_M0_`
M:7Q6G@F#XH^&O[<FU^3P;!=@77_",?\`"8)X=D\7MX13Q88!X5N/$Y\+PSZ\
MFAQZY]M.GP2R^2&7:WFGPW_;E_9V^)'@V]^(.A^-='L_!,FH^%M-\+W-]?6S
MZ[XQG\>S"W\"W>A>!;1[KQ?;0>-)G#^&+>^T>TO=7MUEOK>R^Q12W2Z?4L9:
M_P!4Q5K1=_JU>UI:1U]EIS/:]O1"4HMV33?9-7_,^T2Z`@%U!+;0"P!+8SM`
MSDMCG'7'.*0,C$[64D`9VMG`)8`G!Z$A@#W(('(-><?#_P")W@;XG:/J.M^!
MM?LM:M]"U[5/"?B"&*WN[34/#GBS0?*77_#NNZ5?P6FI:5K>F>?;/<:?J%I;
MW(M[BVN8UDMKJ"63X1_:1_X*S?L5_LJ?M`:+^S%\:O&_BO1_BSKUOX)N=,TF
MQ\`>(?$&E31_$#5+G1_"YEURPMGT>"YO-0MMIMY)?M-K'-;2S)Y<P$91R[&8
MVI/#8?!XK$5J<*E:=&AAJU>K"E12E5JSITZ<YQITXSBZE245"FI1<Y14DVVT
MM6TEYZ?G8_34%#T8'YF7A\_,N=R\'[RX.X=1@YZ&CS(^!YB<X`&]<GA\8YYX
MC?\`[X?^ZV.<O]4FL],N;R&%]1GAL[BYAT\206]Q=^2BW$<*O*D$4.HRQO%%
M!%(T4>]XV+"/,H^(?@_^WO\`"7XMZ/H/BV.PN_"/A'7?"\/B2Z\1:WXE\&W;
M>'YM5URY\/\`A7PSX[T?P_J&H>(-`U_Q3<VNMS^$[&XM)#J$FDW\!F6["0OE
M2P59MNC1JU;/E?LJ4YV>]I<D96V=KVO9]4Q)I[-.V]FG^3/T#W+ZC\Q2_P!.
MM>`V?[3'P"U'4-+T?3_BEX6U#5=;T7P;XAT;3[&>ZO;[5]"^(&MS>'/!^KZ;
M;VUK+-?6.M:U;7-C%<VR2QVSVUS-?M:V]O-,E3Q]^TY\$_`?P:O?COK/B^RO
MOAO!>6.C6VM:5'/>C7?$FK^*8?`FA^%M%LRD4NI:YKGC.YMO#=CIX5$6]N$F
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MG;V-3:3:3^#JXR2[\K[.R<HK1R2?FTOU/ID.C#*NI&,Y#`C'/.0<8X//L:%=
M&`*LK`D@%6!!(X(!!P2#P<=*\?NOCG\([#X9Z?\`&6\^('AJW^%VJ>&?#WB_
M1O&GVX/I^J>&O%5EIE_X9U#3UB22ZO$\06FM:1)I%M!:O?7YU2PBM[5[BZ@C
M?CC^U;\!QYL?_";PC6(?&=QX`D\(C0?$C>.I/&EKX9L?&9TJ'P<-'_X2::1O
M!%]IWBV*ZATJ2PN?#EY:ZI!=R6DJR,1PN)E?EPV(E9\KM0JNTE>ZNJ=KJSTO
MT?87-'^:/WK_`#/I'>F`=RX(+`[A@J,98<\@9&2.!D>M*&4D@,"0`2`02`>A
M(]#@X/?M7Q=>_MM_L_2>//`'P]\.^._#?B;5OB+X;T#QYI]U;Z[I6D:#I7@W
MQ5KVN>&_#FM:WJ>J36@M]4\0^(_#NO:-H/AV"W7Q'-JF@ZO;WT-N=.NGCZ3X
M2_M6_![XT?$#Q;X%^'OB+2=8N/!UUK6E!GU?3+.Z\1ZSX<UQ-&\3W?A#PP]R
M_B#6_#WAG4YAIOB#QHMF-+M-4DB@24I.MPY+"XJ*<I8;$1C%7E*5"M%15W&[
M;II)7BTVVDFG=K<?-'^:/WK_`#/JZBBBL!E<MB)F/]W!.0!@*,]3CMUX'O7^
M=%_P<R[9/^"HVNAE1T;]GSX+,%G@2>W=4N/&<G[SSK>XM&C!F0,)E93\VT9"
M-7^C!L8@@L.0`,=CP,C((Z#C(/OD5_//_P`%'O\`@@3H'_!0W]IR;]I+5?VG
M/$7PHNKCX<^#?`<G@[2?AKH/BO3TE\+-JV_6HM5OM<T>^CN;F/4(HXXT1$14
ME5AM*@_?^%G$6`X5XO69YQ-_V?\`V9C,/.IR3FW.O3E!4HJG&<U*6RER<JYN
M9R5F<N*ISJ8>,(+FDI0;5TK);ZMI::[,_P`\^35=3U"$Z7JWB7Q1<Z+>;+2^
M@_X2/4=2$6FE=C6FG:7?:Q8Z3:6=G&6?3=.BBBM4F"FYCE0;*_H$?_@M/\+]
M+^)?[,OQ`TKX6?M#ZKX=_9U_9/3]E>?]GW7/BMX+M?@K\?[*TT>[L+?7/C7X
M=`US3O$=F#/)/'HUQHFI"".&,Q;;V"RE@_3\_P#!I1X//!_;G\<=>I^"N@-_
MXZ?'H'YGCJ.G*K_P:4>#@"#^W1XW(RC;!\$/#B;VC=9(PT@\>F6-1(H9C"R2
M,!LW!6-?O.<<>^#V>K#/'K$3E3]I%JKA,PKTX1KPA2JN5*B\-*K[D8V4:].<
M'352G.,HWEPK#XA)VIO=.UX/X7=:-O9ZV^^^Q^7/PHO_`!)\1/\`@AY^W_\`
M%S1_AAHVDZTG[9_@;3_A@_@[X0Z3=S>`?A;XVU[X::CXQ^'WPXU9O#>K^,H/
MAUI3ZG>&5VU"XALC)=);:=I4#ND_Q_\`\$Z/A#\3_@Y_P4^_X)VZ=\5O!?B#
MP'JOC?XO?![XA^&]'\1V-UI^I3>#O$=WJX\/ZC/IDUM#)HPU&&RGFM[&Y6.1
MXE^U%5,^P?T::9_P:T:CHEA!I6B?\%+OCSHFE6[MY&E:)X&GTK2;<-'M>:'1
MX?BO)I'VJ<16D%S,;$-/;P1[V+P0;?6OV<?^#;>Q^`7[47P1_:<U7]MOXB_%
M+7?@YX\\-^//[)\6?#JREO\`Q.WAA_,TKP]J/BO4O&NOZK#I%@9KV#3Q:1P"
MSLWM[>.V'DF23P'QUP9EV#XPP>79Y2Q=/.\LQ]'+E_8&:X*6'E7P<*$,)"M6
MQ>*C2A*46I<U!PGS.TZ?O2DUAJ_/3;I-*$H-M..RDVWOKHUIOI]W].+K</O\
MDH#^\V^=N(64H%A=!&P*QK(/WR`@N"P!&X@_GM\$OV-_BK\*OVO?CS^U9JWQ
ME\+>)4_:'TOP)I'C7X=Z=\.+G2(M)M/AGHOB/3/"3^'_`!-=>+M2D^URR:VL
MFLS2:':1WB1NOD@JDE?H?:QM'"%;8#D86,`1Q@'[B`*AVJ0=NX%L8W,3S4VU
MP,;AG.1UX'/'&/;^=?S1A\5BJ.%Q>%A*5.&8TY87%I)-2P\<0L534M6[>VI4
MY+E=[VOI<]C[:>EN7?6R=X]OGYVZGPSX(_91\?>#?VTOC%^UDWQ3T/4M'^,7
MPW\!?"[4/AA'X+U&PC\-Z#\-Y/%-]X>U31?$+^++VRFUZ]U+Q.PU^:[\+F"]
MT^QMK>"*`Q(J^&I_P3N\>^"_A[^TS\!?@Y\;[#P=\!/VI?%GQ/\`%_B"RU_P
MC>>*_B)\))OC:\MQ\7-(^%OB"[\01Z9J>E^)+J]UF^\-MXUTV_N/`^JZU>:E
M9KJWEQVK_JU@X//)`]L8Z_GSVHVG&,]L=_3_`'B/TKICF.-OS2JN_)AZ/+9<
MKA@KK#2:NTY03]QO6/X$2OI;7=:;].MUH_F?F3X)_P""?#?"CX]?LP_$_P"$
MOCW1_"OP[_94_9@N_P!D[X>_"G4O!MWJIN?A[/;^&8(M6U/Q18>*]%$GB&"X
M\&Z->%WT&:VFBGO(C%'=.]V?&[S_`()9>,;[]D_]H+]EB?X\>'$T[]H#]IKQ
MO^TIK'C6V^$:-J>@ZKXW^)VE?%.]T/3])N_&<MA.UKK>C6FGVVL.8KF+3KBX
M/DRN$1?V7","""./7/\`A3R&Z#&/0CWSZ?A^O6M:6=9KAJU/$8?$SA4HXO+<
M?%Q49/ZQE%7&U\&VY-7:JYAB)J+]V4FW/:-G#;WEU;U=NW:^^Q^<6L?LB_&Z
MQ_:N7]KGP'\8/`.G^-;C]EGP/^S1K?A/Q-\/=8U;POK,7AKQ[XP^(&H>,8KN
MU\66NJZ+=QZOXC@BT'1++?I=O8MJT%TKSWBW:^%7'_!*B;3?AC\-?`OA/XXS
MV?BCP_\`MH']NSXE^._%G@E/%M[\2OC7)J=G?7$&FZ7-XEM;7P5X&2VDGTF+
M0+0Z@]M':Z?=P744[7;7'[)8.><$<X&/4Y]/S_K44T7F*4Q&T;*ZNCK]\-M&
M-PSM'!)PI)8)C&#E4\WQ].-*+J2DZ5*&'B^2&E&C+%RHQ;NFX4WC\2X)O24Y
M.SM#EJZ[?C]_W_<?C5K/P,TO]LK]L[X5_'V+X=?''X.:?\"/#OQ9^$W[0,WC
MCP__`,(7X>_:=\'Z7XQT+7OA/\+=4TF]U35[OQKX%T?XB6=]\6O#VOLP@T>T
MM;[PZ5>/Q?((_P!;O$.G^([W0]6@\.:II^DZ_/970TC5-5L+K5=-LM7>'R[.
MYO\`2;/4-(EU+3[?<_FV+ZC`)9!&\;IY48'2&V&8V&TR1<(\FZ0J"HC?`+84
MM&JYP,%@202S$S(C+D,<C+8RS.<%L@DMW]APO1>`*RQ&,J8OZK[1-+`05+#Q
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MU?"?B;38[#6K2X(74(;^W5[:7G+W_@D?;V7[/MU\`?AU\3?#OPN\*ZI^T_X.
M_:>;POHOP^O-7^&'@+4?`.M^'O$OASX9?"/X?S>,M,M?"'PZN=>T)M2U^Q-[
M+-=7>JZE-8PV:O''7[144Y9QF%:3J5*LE-U?;-VBG*KS*I[1VT<N=*7,US76
M]DHK:Y^?6G?L@_$S2OVP?B1^UU:_&3PT=3\?_L_>&/@!_P`(1<_#;4I]+TO3
M_">MZEXFTSQ4NIOX]EGO=1DU_6-1EN--O;2>"?2I8--DNE,3RO\`+_@3_@DA
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MTW3H+J&Z\/\`!O\`P2N@^&WP_P!2^'GP^\:?#+1?ASXL^-WC+XQ_$']FC7?@
M=I'CO]D/7-*\4^#_``=X9M?A+X;^"GB[Q'?V7@+P5H&N^%9?B9IMQX7O+*[E
M^(7B'Q%JD\`L]06RC_8+!QC(Z8S@Y_GUIH4@Y)R?\]S6?]J8^$)4X59<E6I"
M52*V?*Y-.5YW;CSR:DO>N_XFQ$4[[/Y_IY>1\9?L;?L>>&/V/?`'BWP)X5U&
M.71?%_Q)\3_$B'PEX?@U+0/AI\,U\46=A;W'P\^#W@_4-:\02^"/AE83V#ZM
M8>%[75I+.+Q%JFK:M!!:K>"V@\>T#]BCXR^$_P!L/XX?MA^'OCOX'3Q#\;?`
M'@;X97/@35O@W=ZAX<\->&?A]K5Q?:!?VVIVOQ'TF_U/Q&;34M2CU.[DM;.Q
MO9/LX%I$$4U^EH5@>HQW'/(_*@H<\8'IU/YYS4QQ^.I5J]2G4IU/K5#V%=5X
M>TC*'M(5+6=VM:<'>,D[1M>SES::7T?S?3\/Z1^04O\`P3B^/FL_%GP1\:/B
M+^V9J'QIU[PUXJ^(^NZA\,_BG\+SKOP!BMOB#=:!:Z5<^#_A-;^/;;1-!\2_
M"OPSI>I:5X!U/4&UJW-]K$^KZI"VH%[DZ_@[_@EWINF?L0?'S]A?QY\5)/&G
M@#XL^(/BAXF\&>+]/\(V_A#Q5\-]=\?^-)OB?H.MP0:=J]UI5_JOPY^)$>F>
M)?"]Q!%:*)=/A@N4>W+QO^LVQO\`9_E_("E*L<9(R/R[_P#UNU:5<ZS58=45
M*G*-.4)4X4*<*=I0DYPDK*%G3;:@U[W+.47*2?NS*$9M<UM+J^KT:5UZ:?Y'
MYD7'_!,;X9W7C_\`9-^)<OC;QA/XL_9L\/ZKI'C?4+F:&7_AJ"_U#4X_'RZQ
M\=./,\031?'47'QQ$9E94\;W=U+`D%M.T1_2VU@>$MOY`"11LQ5YVA@011":
M;&^4DB2XW.2P:Y93C:<VU!&.>.<_TQ_/M3JYZN+Q.+5*6)G*4Z=-TX*;YG"#
MJ3J<B=V[<\Y-*]HIJ*M%1C%1@H74;6;O^"7Y)%.]MOM*(F%.&)(:."13\I`X
MG@G4$-M96"8#JI<,H*GX5\:_L(>$?$?A[XGZ9I?Q+^+NAZO\2_'OQ"^*]U?0
M^,;2WTFV^(_Q`^'=A\/[C7)M#TKP_I]KJ.FZ#:Z;I6H:!H]V&;2M2T]KO3;Z
MQ:\O1=?>ISC@X/\`GV-,96;;R,@$'KSG'T]*BG5KT9\]*JX6LTENFM;IZ[O]
M>[*/S-F_8.\;ZCX5^"?@/4OC3')HGP2F^#&H>#_&5MX2M4^*/A:_^&&C:)8>
M)(-)U7[2GA'Q)'\0+_29;Y]6\;>#]6U+PI!J4\.EVU]>V6F:C:>N_!K]CFS^
M"WQU\<_%OP_\1?'NIZ#XO^#O@OX7Q^"/$>NQZO'::MX;\>?$KQOJGC.^UE=/
MLM2UW6M1?QRME9ZKKLVJ:U;SW'B*_NKZXEU>0G[612H.2"2<\?0#^E/^E=-3
M,L?6INE.M+D4>5)N\6G+G>BW][7HKMOE3;<@_,O]H'_@G5H7Q2^'GCVV\/\`
MCGQ1J7QEU_X._$/X)>$?BC\3=5T[7]=\.>$?BIXD\,ZWXDM]:\4Z7X6T_P`:
M>.+7P]_PCRQ^#;#QMK'B6QT*WO+^TM;%HKN13[-X?_8U\&Z7\1?"_P`:;W7O
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M@_Q!_P`)#X9FO_[3\$Z@?#FH:+J%QJ#KK/P^_P"$2U=K&_GTV"_$4%JP^T</
MZC_/X4H#9Y(([C_(ISS#&RA./UF;YHRB[RWO=N]HK1O5KJTF[M`J,$TU;1IK
M1]+?Y?B^Y\F_$7]D;P)\6/$$VL^/=;\:>(-+D\6?#'QU:>!;[7;*[\&>%_&'
MPHU"RU;POXA^'D5[HMSXF^&%V^J:?:WVMQ^!/$NB1^)E6>RUL2VNHZHEUC>$
MOV+OA]X*UGP5?Z?X@\>W^F_#S7/C;KG@_0[_`%KP^NEZ6?VAM;UKQ!\3=%8V
M/A;3];.CS:MX@U2[\.-'KPUK0K>X.DPZRVDVUG81_9FT>@'N.#28;L>>/7H,
M^I/K7/#'YA"'L55DH.Z4KWC&ZLY6=VFXWC=6;4FK[LU_K^OZ9^>&E_\`!-+]
MF_1?#_P_\.Z;I5]!;_">\\.2_#&^DT7X976I^$M+\*Z7K&E:3X:U&\E^'@;X
MB^'5L/$&MZ:;7XFQ^,M1MK;5-0?3M4L9[^[N9_0(?V0=-\):IXDUCX0_$SXB
M?"^^\;'X,6?B^UT&Y\)0^'+K2/@U%%IEFNA>&;?PC#I7A:\\6^'+1="\4P>&
MX=&T2]M[EKBWTJRNEN&G^SL/ZC_/X4QHV8YW`'&,C/J3VQZ_I5O%X^K[M?&2
MJ0WY9.33DG=-J3:=G>6J;4M4TQ_/]?T1\G?&/]D'X>_'6\UQOB%J_C76?"_B
MFW\'0:W\.Y-:TVX\%V=YX-U>YU33_$O@F+5=&U#7OA=XMN99X8M?\1?"_7O!
M]_X@MM-TJ743<ZKIMC?P><:I_P`$\OA!JTWBI9O$_P`5XM)\4^%_VB?!<VA6
MWBO0I=,L?"O[4^L^%_$'QDT2P?5/"FHZIY&J^(/!VAZ[H]S?ZE?7>D7%I'!;
MSB']V?OL+A0"1D$G/;.2>GXXHPXXW#VX[=NQIT\=C8-P5:2II+ELW:]UT:=G
M9*[LFTOBV(E!323MH[ZZ]+'P7JO_``3V^#FN7JZAJ>K>.+NXLOB-X4^+F@1Z
MEJ'AO7[;PW\1?"OPMU#X*R>(+2R\2^$]?TS6+7Q/\-[^30]>\,^*K#Q#X<MY
MW;5O#NG:#J*PR0^N^/?V7O!GCSX6^"_A'+JNM^'O"W@7QE\*_'NB_P#"+6?@
M_0;AO$7P9^(&B?%3P(9;"W\)R^%;/2[+QWX;T;5+[2M$\+Z1:7EI;R:?LCM)
M6A;Z7P_J/\_A2C=W(/\`GZ"E5Q6+J2IR>(DW2<G&]W9R:=UHK/1;"A34+VMK
M:]O*_P#F?$EY^PC\&M7NYX]=A\4:UX/G^)OQ#^,0^&>J>(EG\%+\1/BKX6\1
M^"_'6NR&TT^P\2/'J_A[Q5XC@M=)_MYM'T'4/$6KWVFV3B:.&+M?A%^R=X$^
M#NO>%?%&EZOXP\5^(O`OP8\-_L^^"]:\7:Y#?3^'OA1X2O+:XTG0DMK#3],M
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MH2J594X3JRYJDH4I2=*G*4F^:4(1E*[<FR94H2=VU?3U=O\`MV_WZ'PWXN_8
M)^$OCGQ=\1_%GBO5OB!KL7Q2^*/@GXR^+_"Y\466E>']0\=_#CP?H7@3P=-;
M7&GZ$GBG2](LO#.AVVFWNF:=XGM;*^B$BW%E<+=71DR)/^"=_P`%9]*TNPGO
M?&[7?A#P5X"^'/PVUB#6],LM2^'?@CX:?$K1OB[X0\/^&HK#1+/2I8['QUX=
MT2[NM4UJROM7U;0].M_#E_<"PC<W/WYA_4?Y_"C#^H_S^%=$<=BXJ,8UY)1^
M%)V4=$G;W5:Z2B[?%%*,KQ21G["']W[GWOKWUU]3\\-1_P"":WP)US19M%\1
M:K\2M?M)O#GQB\-RKJ?B?2&NI;;XW_%3P5\;O&=P+F#PS"L%]%\3?`/AW7]!
MF874>DI9)9();4+;KHW'_!.WX.ZCXN?X@:[K?C/Q'XY?Q?XY\:MXB\2P?#CQ
M")]4^*?A'PSX!^)]E/X9U/X;S^!YM&\:>$/!OAK3;RUN/"LES:S:>]W;744L
M\K2??V']1_G\*,/ZC_/X4_[0QG_01/9K?6S=VM(K1O5ZK77=!["']W[F?)-C
M^RO!X.TWQE:_"GXB^./A]J'C[XI?#?XC>(]7LI?#MY-':>")O"EOJ_A/1;.X
M\/O9VNA^,?#'A:/PIK%A?)<V4-G?W4]G#"Q9).B\1_LS^&]4^*][\;/"_BOQ
M[\,_B'K'A"P\`>)-3\#:UIBZ/XI\*Z%?SW_A:#7/"/BO1/%?A:;4?"L][?-H
M6N66DZ=K5I#>WUB+LVMT8U^ECNXP0/7/_P"HT?-CJ-WKVZ_3T]JYI5\3*I5K
M2K-SK0E";EJVIJSYKII]'MNDU9J+6_ZGPWK7["WPOUSPY\3O`EQ?>/HOAM\;
MM2T[6_C-\.F\;37OA[XI:U#8:+8:_J/BW4+ZPN?%,-Q\0+;P]I6G?$XZ!KNF
M0>-=+ANH-0MGEU2_D?WKXJ?!3PU\6_AQJ/PR\0?VOIF@W-YHE[8S>%]5/A[4
M]&G\)Z_:>(?"QTM]/BBTXV.DW^FV,/\`8=_8W6BZMH<;:%XAL]3LKB[BG]K'
M09Z]Z3G)YX[#\O;Z]ZMXO%2]C>JU["7-!QT?-RJ/,N5)\UE%<TN:3C%1YN5*
M*1\/Z1^PA\*/#_C-OB?X>O\`Q-X8^+!\;>)_'R?$'PM<:5H\D&O^,?`&A_#/
MQ$MCX&;3;KX;Z7I6K^$_#6@KJUCIOA2UFU3Q+97'C"ZN_P"W;^\NKGSC4_V`
M%@TOX4_#[P+XUL?!7PM^"NL_#S5OA8+;1;R[^(W@2+P5J;:AXCTN+Q/)K`TC
MQE9_$:1I/MB^+O#]U;^$[6ZO+?PYI]O<2P7MM^E%-(;/!`'^?8ULLPQB?,J\
M^;^9O72Z6N]DFU%7<8IM**N[S**G'E=K:?AJ?#6D?L$?"CP_8>"M,\/>)/B?
MX>L/A+H7Q0\/?`U=&\6VT%_\%++XOA8/%MWX.U:^T;5-2U75[32O/\-^&-3\
M<7?BZ?P_X;NIM-M(VDQ>-Z_\"O@%I'P"T77="T#Q1XP\5P>(?$$WB/5=4\<7
M'A&^UV]U>YL=)TV^U/5-7\,^"_!]YXGU35+?1[:?4M<\9OXD\0+<`V]IJJ:>
M_P!E3Z%P_J/\_A49C<DDL,$YP,X_SR?\],:N*Q=91A/$-TG*]:G*[55)2Y4]
M%=J<G.[;NW)OWI2;4*4(WNUM96TZW?3MITZ=D?&7[0?_``3Y_8N_:K\5Z'X^
M_:/_`&:_A;\:/&?AK0X/#&A>(_'6A'5]5TSP]9ZG<ZW;:5:3FY@$$<6KWMQ>
M1MM;RY'8*`@15^N[73(K/3;;2K2!;6VLK%--L8HUC>*TL[:&."W@6-P(Y(O*
MMX4:-P%*90X4M6EY3]`PQS@<\>W_`->I,/ZC_/X5%;$8^NJ%*KCJM3"8-26!
MPTIU9T\*JKC*NJ4)SE3IJK*%.4E3A!-P7-S-)K1QBOAMKO\`I?1:^MSXRA_8
MB^%EM\!?B5^SU'JOCUO!_P`5M6\::WXMUV7Q-;Q^/+B\\?\`BJ[\9^)XK?QC
M:Z5'J5I;WFNWEP]JC)>QZ=9RK;6\)2)16=>?L0?#M_'/BSXF:=XA\?Z7X_\`
M&6J_$*YU7Q38:]I4=S!I_P`5?#7ASPCXWTW3-*ET.31+:QO].\*>'=5@C>SD
MN+#7M&BUBQN%O+B6,_<##((_SUJ/8?4?K_A6\,;BXQ:]O)7W2M9KW=&I1=U[
MD=-O=C9*RM+C%ZO?^O)]W_3/@O1/^">GP.\/6NB:3HDGC;3?#7AW5/@[J.E^
M#[3Q8P\/P6GP-^%U_P#!SP-H;O<Z;<:KJ6D'P)J5Y9^)X]5O9KWQ)J\D&N?V
MAI=[:Q,.]^$'['G@+X%:'X<\/_#76O%?AW3O"\'@W2+0Z<G@+3M8UGPCX`TZ
MYTOPMX*\8>)-+\!:=K?C30;*PFAM&O/$]WJ7BJ>.TMQ=>(KDB66;ZY52#DXZ
M?X4XYQQUJ:N-QE2+IO$3<&[M.3:;=KMJUFW97D^9NRUT5G9+1;?UY+\$?(/Q
M._8N^$'Q7\;^,O&OB6#78Y/B7;?":#XG:'IVH6L.A^/F^!NNZGXC^%LVM6]W
MIEY>V+>&=2UW6/-E\/:CI5WJ]I-:V>H7$]M9P1(K?LL6NC6_Q?LO"'CWQGIE
MM\?OB[_PM7XI2ZGJ2:E?HE]HGA[PUXB\+_#RZB@T^;P;I^M^&?"6@:`9VN-2
MFMK..Y<.9=BR?7>']1_G\*C:)F).5YQVST`'<>U$,7BH4X4_;-QA%12LK:.Z
M=K;IV:>K5HZVC&*S=&,FWI=W\M]'K^G_``3YX\5?LQ_#+Q%IOB4^'=)3X1>+
M_%>@V?AC4OBI\&K/0O!'Q;B\-6>IZ;J:>&+#QX-%U#5+7P^\FD:?#/I;"6R>
M*(BWMK-PCCY<^*W_``39\(^.?A#J'PS\,_%OXJ^%]3B\.:CX;\,^(I-0\,BS
MT:UUGQEI7C75KM]"\->$_#5C+K&JZGIB'7O%%DNF^,O%*LL'B;Q+JMLBQ+^E
MZ@@`''``&,]O6G4Z.88[#-SHUZBES<UXR:>MU=N7,Y/EDXOWE>+DDTFU+1*V
MG96^[[NVA\&:U^QSK7B_XT^`?B1XT\<Z-K6B>`M3^)=M>6T7AB6/7_BE\+_B
M-\/?$/@67X+?%:.]U6_\)^(/"]G<Z[8^*M7\4#03XL\2ZQX.\+VAN-%THZI;
M76IXD_8&^`6K:=XXTGPKX</P>T+XG?!R;X#_`!#\*_!R'1/`7A/Q/\-;F\UV
M[?16\-:7HW_"/:-?VY\3^(K*R\3Z+H]IXBL]-UO4+>._)E4I]OTC`D$*<'L?
MQK-8K%IIJORN*2B[.T;.Z=KV]UV:]W1I./+96-]'U/B5/V$_@@MW:V1TS7I/
MA_!\5A\;$^%EQXBDN?`=I\1QX1G\&P:Q::7=P7MXFGV>G7,E_;^&X-2LM!B\
M0)%KZVDE_#;+%S&G?\$Z/@59IX!D>X\<W6L?"'1/A=X;^$GB>?Q+`?$/@'P_
M\&_$+^)OA_H^FWD>F0P:[::7>2S65^?&EIXBFUK3I;BVO'A28*OWYLE_YZ4Y
M4;^-MP[#W]>G^>^:IX[,HQE;&.::=X+F7,Y+EDVWO*4=)RES2G%6FYK0.2*U
M3C=;67_`_P"`NECQ7X0?!+PU\&K;QL="EU;5-8^)7Q%UGXI^/O$.O:D+W5?$
M?C/Q'9Z;::GJL\-O;V>DZ5!!:Z;9:1I>BZ+866EZ?H^FZ?:PQMY3-7BGQ@_X
M)X_L4_M"?%G3/CK\;_V:/A7\2OBYI$'A6#3?B!XIT)K_`,3Z>G@C4&U7PI'8
M:@+J+[/;:'J4UU>V4`A(6YN9G=V5VC;[8VKZ#\J8Z%OND+QCN.YST]CT^N?;
M*AC,SP]9XC#XNIAJM2G4H3G1JU:4O8UHQA5@Y4IP;A*%.$73OR248J47%)(L
MI:2M;S2:_)_YF/<:=+<P7-LL]Q9&XM9[83V,_ERVWVF,+)=1+-'*GVFWPL=D
MS"1;>,($5`H4?'>B_L&_"'P_\&O#'P2T;5/'^D:'X4O?"UU!XHTOQ%I^F^-O
M$MAX.U[7?$GAWPQX^UK3M'M;?QYX5TK5?$>LSV^C>*]-U5(SJ$[BXDNF>[D^
MV5CD!RSCKVSW_P`_3Z5,.`!Z`4Z%?$X9N%.M)QDU4<UI><9>ZGWY;MQ3323T
ML]0<8Q?NM._5)_JD?!OA;_@G[\)_!\_P4O-$\3_$VSU+]G9A;_!O68-;\*6V
ML^"O#MVNJP^*_!%O>6_@Q'UCPE\2+76FA\?V&N/?27Y\/^')=$ET.>P69O9/
M&?[.?AWX@_#W1/A_XPU_QIX@;PS\0/"/Q.\.^.K[7;%/B)HGC?P'XQL/&WA'
MQ#IWB2UT2WM%N-#OK"/1!:7N@WEEK/A5[GPOKL-]I.H:@;GZ/IHW=R#_`)^@
MJJN)Q56<)RKR<H7MS:O5W=FDG:]VU>S<I.UY2Y@^,=#_`&(_AGX:U[X?>*M$
MU?Q?I_B7X>_&;X@_M`IJUI=>'+-O&7Q5^)OA/7?`GC'7/&5IIWAO3[*\M-7\
M)^)];TJ/1-)MM&TJS>XBOE@>YM82>QTW]F;P9K6C^(X?C5X9\%_&S6O%?BV3
MQAJTGCKPSI'B/P_;7.FRW5CX)T;1M!\0Z?J=GI>C^#/#<_\`9VEBW@$T5]>^
M(=6MUM[K6Y53Z?HISQF+FTY5G=1Y4]>91NW927+)1N_AO;1=DD'PSJ_[#OA+
M7_$_COQ=XB^*?QLUB_\`'VA^(_"DMA-XI\*):>"/"/B>6U^W^$?A9J=OX%@\
M4?#GPG##8V=N?#OA_P`0)HFMV*7,7B32-6N;MI%\VT;]A#Q1X8T'XT>#=-^*
M.G^-/`'QK^)WBWQQXE\!?$?P[.-%M]#U[X>^#_!>@^'-(U+X>W_@75M$3PM<
M^&)KV1=,\NU\1V-S:V$L>A&Q1I/TKD0OC!`QGJ,]<>WM2*C+G!7G';'3/M[U
MK#'XR$5%5Y))II+2*:DY1:5E9IMM-.Z;=FKOFSE2C-\SM?\`':VUCX;TS]@S
MX-7GP=\,?#3XBZ/IOCCQIHWP\^%_P^UGX]V_AKPQX+^-/BD_",>'9?"/B74?
M%_A73K">"6QUKPMIGB73?#\2/HFE7"PV;6U_)!<7EYK+^Q'\,(_B%<_&I=8\
M9CXZW?Q"7XF7'Q=.I:0GB2XUB/X6V'P8A\.2V.GZ+IN@2^`X?A_I-CIT?A8Z
M5!#)>M<:Y>75UKMY?W\_V>49@<L,]!Q_^KWIOEO@C=GTR2<'UY[DDG]*PAC<
M=[6;E6DH.4K.[?-&5G)-/F3C)_%!KDE97@THVM4X)):*W3]5II;H]UKJ?G]8
M_P#!-[]G/1M%OO#6A:?XIT?PMX@\'^!/`OC[PY:>(8[BT^)NB_#;XA>,_BOX
M4O\`Q==ZEIEYJ*>(H?'WQ&\<ZSJFLZ)>:1<ZG_PDVJP3L8VM?)[[X??L5_"+
MX9^,O`'B_P`-#Q+(OPF'QCC^%7AK5-6M;SP[X!'QZU2PUKXFMI2QZ?;:UJ5K
MK%QI=E966D^(-8U73=*B26YL;:*YE$\?V)Y;>H_7_"C8?4?K_A6\L=BI)J6(
MJ24MTY7O=.+;]V[;B^7FOS<EH)J"44<D.R_#_P"1^=N^N^I+1117&,****`"
MBBB@`J%_O_\``5_FU%%`#X_N#ZM_Z$:?110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M```L`0```0```"P!```!````4&%I;G0N3D54('8T+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'$`
M]0,!(@`"$0$#$0'_Q``?``$``00"`P$`````````````!P8("0H%"P(#!`'_
MQ`!*$``!!`$#`P("!0@$"0T````"`0,$!08`!P@1$B$)$PH4%2(Q.4$6,CAW
M>+2UMB-18747&"4U-C=V>;<D,SI"4F)Q<G2!D;/!_\0`'`$!``(#`0$!````
M``````````0%`@,&!P$(_\0`+A$``@("`00!`@8!!0$``````0(``P0%$082
M$R$Q!T$4%2(C,E%Q)#-"86.Q_]H`#`,!``(1`Q$`/P#?XTTTTB----(C3332
M(TTTTB----(A%1?*:_%Z?:OX?C_XZI_)<IH<1K7;7(+)BOB-]!%73ZNONEX!
MB.R*J[(?<)4$&FA(R)4\?BD5)*W$W,ZK!27MSASBIVS7FA7+KB/UZ]\9@T5J
MFCO#^:X[W3$%4(1Z%VZY_9]0XN#<,'&KMV6U=0U>OPP'L56/`LR7)%6+3R/]
MR]U!]A`S>C(JQWL7R,5JI'S;9Z4GUZ0?RL;W_%`>/N0/<KG*=R<3Q(QBS[#Y
MJV=44CT=6T=E<2"/JC8C!B(X\V!ET1'GT:93[2<1.JZH@KK>/,5)*"BK-OZA
MQ%0+/*>ZSOG`5415"E@NM1H;G;]9LI$V4/GZ[77JB5_BNWV*X>!E45K?SKY*
MY+MIA+,M9KQ_GO29[_<\X9KY)!(`7K^8FJP==9CMDX\XVRTV*D;CIB``*>5(
MC-4013\5541-5K:W>;-3=NMM^4XA')U^G<5,$]$+D[2Q1<Q_LXR8O!)`9AP9
ML\N/2>**?,_KBW('/OU[2D'M'OGCO+D_U]I!J;'C<&C^<YUF66.KY.,EH5#5
M]5ZKV?1]$,%EUD>O:(2/>541%,B+SK[DX[[)+T^9VUQ*P=7[9%G3Q+&27XDI
M2)C3SJ]5527J7DE55557KKF;?=_!:J0L!JT<N[3STK<?B/V\P^GX",,3:[OL
M'M]U%[E1%Z+UU\4;<R\L2[J[;/,E84$-';..Q3N+U7\U8\HB<$NG151?LZ]/
M"HNJ`ZWZ94VM4^OUFWRP>+;;,1]]EM8..3?D-7F7=X_]'Y$D^7;%01;=17QR
MJAQC5\>OXJ&K7CCY`'!_^_=%VFQ"@$7L,K6<.E1PZQTH`2O@*0)]09-;'0(4
MII43L('625!55!1-$)*UQZT2ZJ(E@G:JNHZVXH=>Q7HS[L9Y11?*"KK)*B+U
M5$5$55Z*NH"W/WX3#L;<B2,<NZO,<@<&CQ2LEL";4^XL"2,Q[$UHU;<&)[GS
M3ZH*(V#:(2IU34SX%1/XSAU!2R7/?FPZ]GYYWJG1V?(ZR9QCY7H)2WGB#_NJ
MG]>K+0;316=09.GZ:HIIQ\'7KD;:K%I.-3BY.18BX-%F/V(M60]5=]CIVJ_C
M%3,.&4G5D4Y`QDORW9FLL[*#8_>SHJ\V,&Y)**S(H/)!;D`^CS6&FFFN_E?&
MFFFD1IIII$::::1&FFFD1IIII$::::1&FFFD1IIII$::::1&FFFD1J,L]W'B
MXH42EJH;F0YG<=P4N-PB3WW4140YLYQ.HP*R/W(3\M[M'HG8TAN*(KX[F9ZY
MB4*%5TD8+7-,D>*OQ>F0O^>E*/\`239G;U)FMKQ7YB8^2(*`/8BJ9HB^&W.W
M;6)L/W5W(2\SF\09&1Y$^/>Z](-$58,!"ZK$JXB_T42*WVBC8H1(ID2IQNTV
MN?L=A9T]H'%5U2J=OMRH>O5UV<%:*%(*W;&Y#W(AY2A"+K0?T(\RJJNNL9.0
M.5)/@H!(:]E]%F(]K2I]$_+G]*_<SC,5VUE/V368;BSF\DRQ>CD2+VK]`XV)
M+U&+30CZ@3H(J"Y8/(4ETD51]L50=3`X;3($XX0-MMBI$1$@``BG55)55!04
M1.JJJ]$3ROCJJ<'DV44N(U3]Q>3`B16N@@*_6?E/GX:BQ&!_I),EXN@-,MH1
MD2_@B*J17&I,HW1=;L<O&5C>&JJ.0,.8>5FQN&5\MOY+(:+N%DQZ$E2R2-J*
MJ,HG.O:F"68'3O&HTF(VRW-_%MX-A>YF?A6S=KFMWM6C$$CO)=@O936P7@9$
M69/[U[BFA?TKP/T@+Q^W16/1(Y]\<`<\LP^9S,W<N1<3'*C;JH+*9C3I,2[D
MW%BXQ6."78?OV?:7SKS9=4*/7!(,#'M>5M"0M>@-KYE^:2]Q,EL,B52]P:."
MX[38['7KU0/E(KJ29G_8/YR6XRZB=Q,#U[4E6NK:^IB,0*R)'@PHS8M,1HK0
M,LM`"((B(`*(G1!1/ZUZ=5ZKYUXV5K74\8YMI.C08K:=3?E/-LMI_4G<:CW$
MOV"`]2)5Z(BKJ0^D6]#E]4YZYBJ.]L4N<748X`!*^#N`R`./U/EM;R1W*J`]
MHP%Y4A,2LUD\#OX[[V/Q_+WV\GX"`>O1)/N?/48_24,=(E+4U]7&'RC,&(Q&
M#K^)*C0#W$OVJ1=25555555=47NGNMAVT&+S,JRZR9AQF`,(D,5$I]I-45]B
M!7QD7W)$E\^@"`(O;U[C5`15U;EO'S=V^VT?9HZ2JNLTRRQ4F:BHK(I-))D%
M]1H3]S_E8(3I`@HL-/=!5)LRZ==0UB.S6ZVX61L\A.1UI00(=-'=ML9V^NQD
M'28RPWU>8ESV6Y+,<)3;8H2^\CQH?:X?<:"(^2]4?5[7^7(Z2^EN+B[[?XX\
M>SV.)2HZ>Z2Q``+=AM,P>/'=Z:^YZ<*FTW7,H![%Y87&+I;.$S-NS8V,QYJJ
ML8_BLUR1Q536>7`8D=UC`!0>1R956,U^0YBMKR4WI@.5JG%*KVEP%]%,J./9
MO!&@6;L<^G=>3W'6G>OMHZTT!%T!$[=9`Z@9(55<$TE.8,&*,HE7JI2!8;1X
ME7\55U"55_%5U9/MKD]MR3W`@Y%-@_1&U^WCARL8A`1+'S.]8>.$.1-MF#9+
M45Y`X$`'!(3<5312\'J^E$Z)T3[$\)J[^C6)CO@[+<8-V3FX6=<%_.\U2F;U
M'L%9FV.ZM4@,F-9<PQM?5VA$QL=35^TZS1NW<6U4V*E=E:<^"L\UXM1`%6.I
M'HN%!>UO9+OP3R#&FFFO;)1QIIII$::::1&FFFD1IIII$::::1&FFFD1IIII
M$::::1&FFFD1KT29#46._*?-&V8[+C[IEX0&V@)PR+[?`B*JOV^$77OUQEW%
M*=3VD,1[RE5\R.(>/KD]&=:0?*HGUN[IY5/M^W6C)-BX][5`&Q:K#6/?'>%/
M;\>_GCXGU0"P!^"0#_CF1#MC3/Y#;6VZU^T2V-X3U?C,9_ZR4V+17R;81A"Z
MHV];&W\[)<#HKC2QT7QU194R3(JO%*2??7$@8T"O8-YTU12,R3PVRRVGUW7W
MW%%IEH$4W'3`!3JNN/P^;6I0U=='E1_=JX,2LDQD<`78TF'&:8=8=:4NYLQ(
M/L5/**)"JH2+J@<M;B91GM/37$B,SC&)06LKL6I+[01K"U=D/QZ@'B,D`X]=
M\M+E.M.JH>\<9SPK8ZX=,BGI[INI<*_&LVNPL0-DWVH%LVF<Q?)R\HE@?'C\
MV7.I(XJJ%2$<*)/[3DY3&Q7%-8Y"*I!6FH`+6@]CEN``>/;-W'[F>O$,;L\T
MGQMPL^A=CXF3V(XL^G?'QZ":]6)LIHT[7;N4UVN/.&*_*HJ-,HBHJZF[PB=5
MZ"G_`+=$_P#S5NN=<JMBMO6G1ML[J9LYH2$:NA<2[L3=3P+"1ZWYCVW#5.B(
M\38HO3N5$U:M=<E]^=^SML/X][86N-138!B9G69_Y,.NC3A,6Y<6&75!<<;$
MW([@')<1.A*RB]$3C,_ZI]`=#TMK<396=6]5919GUG3U3;G=;78]G<1=^"6Q
M,925(0Y#U445+V@JB`2=7J-EL&\STC"PT`XNR3^'QZ*N0!V]Y4OZX)[06=O?
MR1+M=TM^,8P)B='"SJ6YL`"6QL;.6#%/2?554^;=0O=DRR7M1JOB"<AQ?SD%
M.Y-8_P"?N[NQR&NW\>V'HK.[1P_8L]V,LB'%H:IASZKRX[5."D2*'15)AQP7
MI9D*$'0E1-2-@_!;'*5IG,.2&X<C-Y%>)39%=.LCK\6AN]?<??E.ONM.2U(^
MAN/&L;W#5?=1SJO6L+GE+10B#:[BGM^N>7L5/D&)-+7I7X51*B*VC\F>#;3#
MXLJG?W(0LO(G7Y@E7HOA_56XZVZI6O*^IFZ'TVZ?S&'X'HS17+M^N]S6Q!3#
MHQL07+A66@JMEM=>1DHQ/%N*OQ?X>/@XI*ZG'.UR:_5F?D#P:Z@^N79W[>\`
M^PI*H0/:O/?@^QVSO%6GE;J;OY1'R?/";*1,RK(G$E24E*G7Y/':]Y3=]PG%
M]MGVP5Q54$1&T1-4M)E9SRJ==RC,BE[8<9J%U;!($YXJZXSR-#575DV:DK9Q
MJ@U`?Z$N@N@O8@DXI(GJ_P`#U1B[[6]/,?/H^6Y+'+YFEPU'2/':N4O1QB#4
M4H+[MK.`^T!`&%`B%/=]T4ZZEW'<;S+D+/K[S-*B1@^RU6XU(QO;YP/E+3*T
MCD*PYV3QVNU(M8WV"Y'I^@HY]5714$1%SUFENS$Q.D=5TZ.G-&[+?B]!X=PL
MWVY[F7C=_4?;5-8V#@,1YK=<U[Y681XK#9R:A\NR%1GSKLHY60!VOLW4KCT<
M!?\`3ZJA@HLM`':+0.RO^0'R9*FR##=JQ-RVOJ1H,4?C1Z'`Z@&?ED#%JPB5
MF><=1'L*SD*<MGN3O1DT[NO7KJ?]>F/'8B,,QHK3;$>.V#+++0H#;338H(``
M"B"(B*(B(B(B)T_J37NU^P>F],-#I\/7&Q;+*:^Z]ZT6JIKW)>WPU*`M5*L2
ME-:^JZE51\<SBLJ\Y%]EO'`8@*">6"J.U>X_\FX`+-]R2?\`+3335]-$::::
M1&FFFD1IIII$::::1&FFFD1IIII$::\2(112)4$112(B5!1$3RJJJ]$1$3RJ
MJO1/_GI;GN-R_P"+6T4EV'N9R`VFPF6PV3K\6_S>BA2&6P_/)UDIBN-]G_6$
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M-^W7%;_Z?=)]1JYV.EUUV07\J9%F'1:RW<<=[):CUVDCD,'1N0?[`,G8VRS,
M8CQ7VJH':45V4%?7H%2"/^N#Z^/[D`U,39W;=0>Q7C1F!7`(J"\UA4!^<KJ+
MT1)%C*L'2[U7HON*;B=/*+YZ:IBAS[D3:1K6OP3:_&\$F6-C-EVM[N!>16IK
M1ONDW'>9I8/11*/$!H6X[W<VJ@JBJH1:OJQ;+,5SBFC9%AU_39/0RR=")<44
M^-9UT@F2['19EQ#=8<5L_JF@&O:OA?/C41;A9=QP#(AQ+<;,]N:K*708-*6\
MRJLHKDVWE7Y<S8.PA23`U$O:)WN%>A=OA%UP&P^DNR1:/R+J!--3CK:BX.DU
MFKT`L6Y45BV?1@9>35:0O9Y:56SM=@I7F6%6XJ_5^(QC>SE2;,BVW*X*D$`5
M/;6A4$$]K$@D`D'CU:-D.U.*S)#=WREY$GF;K9BZ&%45@E70B[U0_9;IJIQZ
M=()21&_S!!Y$1"%!7HDAXYEN43*UO$^+>S4?$L?3HP6=9=6I15+`JG:<J)5]
MB6-I($>CK9R50'O'<GG4W[?,\9KF\L*W;J7MADF14[8.V4>CLJ7)+6O:[D0#
MD$W(GR&`[E1!-31.J]$+579)OELI@]_^2.5[I;?XMD8!&5:"[RBFJ;-MN6"'
M$(H4N4R\V$@%0F2(!$Q5%%534#2_1G*P[[+SGXFELR#QF;'6C(VW568A[>Y+
MNJ-VU^32K\$$8F+2R<_MV+\C;?O%=`OC?(">ZZK>RG#0^O:X>.$1B/MY+'!^
MX,C;`N-5;`O&<ZW3O9FZ.X`JCK5E="GT-3.*O<K=#2_6B0FVRZ>V:@3H^40N
MBKJZ`0$$00%`$41!$4011$3HB(B?@B>$3HB)_;XZ1*&_NQ[E_7XJSNYMS(R2
MV>CQZRCBYC0RK.?(EFH1F(D2-.==?>?/J+3;8D9EX%%74N:]AZ=Z5T?2V*^-
MI\):#:QMRLJQGOS<VX@=U^;F7%\C)M8CDO;8Q'VX'`E+DY>1EN'R+"_:.VM0
M`J5K]DK1>%51_2@"--?/+EQ8$63.FR&8D.&P]*ERI#@LL1HT=LG7WWG35`;:
M::`G'#-4$`$B)41%U$%7R,V!NVY3M5O3M=.;@IW2S8SG'%1A.BKU<ZV(]$Z(
MJ_C]G]FNBD:3/IJ@L(W2VWW+">YM[G6*9JW5FVW8GC%Y7W(P3=[O:"44!]]&
M2<4#[$<4>Y!+IU[5U^9ONIMKMH,`MPL[Q3"AM#-JM+)[VNI4G.-(BN!%6>^P
MCY`BHIHWW***BJB)YTB5]IJ+8&^&S=K=UF-U6Z>W]ID%T"'4TU;EM'/LK$2'
MO%8D2)->?>ZC];H`*73STU*!$("1F2"(HI$1*@B(HG55)5Z(B(GE55?">572
M)Y::MCW%YI<2]H[):;<OD7M!A=JA-`5?>YU0Q)8&^?MM`;*S",#-SZB"2(2%
MX5$U)&WF^6S6[489>V6Z.!YVP?7M+%\GJ+<R[>O549B2G'NB=%ZK[?3POG2)
M*FFFFD1IIII$::::1&FFFD33M]0'U&N3'J&>H9`](3T[<\G;98U12'_\9_D)
MC?<5Y35%9[?Y2U>.V4=SOK&:U'VJZ1*9)F:];N@PT\TPVX;F7_8GT'_3EV=Q
MIB%D>RL+?#-ID5O\K-R=YY]AGF495:DVGSEI-<NI,F)&=DO*;G9"CL"*$B+W
M$BFNJM\&?<L;G\KN=6[&<35L]S;C%,4LPL9((_+E+DE]>RLD?64ZI/"KKS$(
MG40E1U>U33ZJ:[#S2)J\>H=\-EQJW'P7(]U>"27O%'E!B4"9D6$VFWF27E3C
M.0V];'=DQ:6QK6II!5!-,$88F5`QBCNF!FR^`JVML7PZ'K4[T[U;EY;Z:_.F
M7(D\BMJOINKPW-KHFV;O)QQ"45=<XID:*@?-Y!4HTKD::B$_/BMNE(0G6#>=
MW)-=;!R1Q`N/GQ;N%2-M@&F;RK=W!,E*/5BHDKN;80U^5)2&F41%6=)FV$A[
MJ*IVN^X7]:(G8C;Z[SX+QWV@W#WMW+MF:3!MM<7M,JR*Q?,0%J#61S>5MM25
M$5^2X@1V`ZIW.N`/CKUUI6\8[[F5\2]R!W+S[-]T]P^./IH;4Y-(QZCP/;>U
MDX_:[GO@ZG^1[:ZBDT=@_(A(,NY-[YB-7C(8BQXPF?OKDS^+5W*R?!/28RRJ
MQN8]`#/-SL!QB^D1S,#=HGYK[TVO/M5$)B=V`VZ)>%0$Z>=3O\,;A&)8?Z/'
M&:;C"0_F\T8R?+<J*(':XN22\@FP9*3"5$[Y*1*Z%W*G5.Q0Z?CI$N>V\]#S
MTO=M\3:Q&KXG;>7<48B19%GE\>5E-[,/L(7);UO=2)DT)3Q&;A.L.M=IEU;0
M$$4'"AZI7H*;';,ILWR+]/\`QC>+:C=+_&&V=Q;*\/V>OLJGT,[",@RM@,KO
M9]5&D29];&JZY@RDRH\J-6QV75)]M$\KN)::1(@SW8[;#=_:MO:#=C#ZK<+`
M9$"DC6..Y9'&VAV!4B1W8#\X)/N?,26)$=N0CKBJ?OC[BKW>==<=MIPRX_S?
MBC+OBG983&G\?JS.;>VC;7O2):8JJ+@97K%<Y7(\C1UT:QD>\$54]M4;`"%6
M^X2[-#77L;7?],3RW_:&R_X5,Z1-^':G:/;;8_"Z[;O:;#J/`\)J')#M;C>.
MPFJ^JAN2W%>DFQ%906P)YU5-Q43J1+U76#+X@_@YQRW:X$<G]^;S;C'F=[\*
MV^^G<?W0C178^50W,?/W8D;Z1B/Q7W8ZMFZTC+QN,BCBDK9*B:V$]8JO6X^Z
MSYE_J@O_`/ZTTB<=Z0/#3CUQPX;<;<QVQVXQZAW!SC83;BPSS.8T4UR'++.V
MQZ!:V<NSL)#K\IT9-A(>D"R3Q--=R`V@B*(EIWQ#7#CC9F7IT<TN2%[M1B\C
M?/$-HF[N@W/:AI&RZ%-Q^;6PJGMMV%;DJQ%BON,"P1JVK:H)"O365CT_/T'.
M)7[/FU7\GU6K0O7Q^YZY\_J+MOXO3Z1,'?PE'$'CIN5P%@\DMP-K<;S+>NDY
M%YJU1;@9'%^E;^C'$FZ%ZB6IF2R=.$4)Z6\Z"L$"]Y(2^436Z!K54^#R^Z3<
M_:/W9_=\8UM5Z1..MZFNOJJSH[B(Q85-S`F5=G`D@CD:;7SX[D69$?;7HALR
M([KC3H+U0@,A7PNNM@^)AX=\?]A?4,X3X1LG@D':S%-WX=?&SBAPPWJ:KL_;
MS&HKE?2'&,&&I#L.6\T\8AU-"15\IUUV6&NOO^*Z^\V]-C_RP_Y^Q[2)NX<7
M>)O'CBQAL>GV"VKQ;;2'=TU`EW^3L$8S]RY7UX!%?M)*J3\Z0".NDK\AQQTB
M<,B-5)5UPW+_`(A\>.6&V]U2[\;88SN"%-C63?D[+O(0OS<>E3JI]MR=42T4
M'X4I%!LT=8<`^YL?.KHL?_S#2?W16_N3.OBS+_1'*/\`9^X_A\C2)JP_#.\#
M..N-\;\TWXM=O*3(]X*;E%O5CF+9]<C(L[W'\9P_(%I<?KJV1-=>^1^6C(\C
MA1D;)[O%7%)11=5;\2UZ@V]''?#>./#SCEDTW`=T^96<AALS<6O>6+-Q3%%L
MJFGF-U\U%`X<VSDW3`C-9,7(\>._VJ!F!I=-\.C^@IG7[6?(_P#GE[5C?Q2?
MIB<E.9FWFPW(GBC4V.6;F\:;2\FSL,HW$#([&ILW:R?'NL>0C;%V?13*D'2C
M`0NO-/JX"JK':2)D1XI>@MZ>^SFU&-U^X.S=3OUN9<4<*?GVY^[;TO,,CR?(
M;&(W(LYY'9R)$>$BR77482$TR0@@D1FYU-;&]Z/1NVOXM>I'P+W[X28+N9MO
MBMWNO/9WWQ_;W(,D7`F*6MJW[*OGWT/YM]B%63)S+<&3!<(:^2VZK:L(J^<1
M^QGQ//J6<;,-QO;'EAZ>N;9O;X55P:.=F<+$\VQNZN6*V.#"2K%3K9%$LWV6
MP]UV)_1FO4S3N7JN4;AA\6YP[Y';MXOLMO-M+N!QHR?*K:+CM?=Y9/@W&--7
MLQT(\:/:R(T:%(IF'GW!:1V4!^V2BAHG7JB)MH::]+#[,IAF3&=!^/(:;?8>
M;)";=9=%#;<`DZH0&!(0JGA45%U[M(C3332(TTTTB----(G6/^F?E#WH3>O%
MG_'7?!'L2V=W-L++;*OR"Q%YBH7'\EG,3]N,J62:"V[&%2:@R#0B",[-=1XQ
M]D^G9K0IL.RAQ;"NE1YL&:PU*AS(KH/QI,9\$<9?8>;(FW6G0(3`P)1(5147
M6(/U8/1CXU>JO@=?$W!%_`-X\2:<_(+>7&HD?\H:A5ZF%=;`J`MS2>^J/+"=
M=;=9<13B/QR-Q3QH\<N%_P`11P3HXVT6R_)#BER@V>QR*E;AKG(P\OJ[ZFK&
M4[(T9MRCCRK1QMEM!%IJ9=2P9%$;;001$1$VF\BR&EQ.BM\FR.RB4]%15\NU
MMK2>^W&AP:^"P<B5)D/ND+;;;339F1$2(B)K1$]-#9J]]4KX@+D3ZFT:MEO<
M;MALQL*G`LLDL']$YAD&/TR83C+5,9I[$ACZ)COW,KV54XQOQ"<%#<5=9MLT
M]/WU1^>E,Q@OJ`<JMM]H=D9OM-YOLYQ"I[FM>SV']57ZNVSW)94FVC5;Z(;$
MN''81N6P9B?:JHJ9HN-7&393B-M)C.R6P>#5&!;?XK$;CP:NKC@V[+?0!%^R
MM)73W[&TF&/NRYTHW'WW"4C-5TB8^/78X57?/'TV=]=F,0CI+SNK@PMQL&A]
MB*=ADF$F[9Q:T"3ZXK-9]]H4#J3CBM@B+UZ:UZOA+/4CQ3%MO\T]-#?VZ:P3
M=C;_`#.[MMKZO*W?HF3;PI+B-Y!B3`SE91NSI)\8GV8'A]YJ1)<`%1M=;RZH
MA(J*B*BHJ*BIU147PJ*B_:B_BGXZUN_4Q^'`XX<VMQ9/)#9#,KOBIRD24S;)
MN!@K2A1W5W$+W(]I<TT-Z$\U9]Z#W6-9,A/N+T.1[ZBB:1-D1%14145%1414
M5%ZHJ+Y145/"HJ?8NO%UUIELW7G&VFFQ4G''3$&P%/M(S-4$13\5)41/QUJI
M;6\9?B=./-7&P7%N3W$CD!B-/$&#39!O,=]"R<([*JVS\T[54+DN8ZC0B2O3
M[&6ZI$HF9=J$MQ%#Z?OJZ\F94")SGY]T>`[8)/AS<AVEXM8R%!(R)B-(:D%5
MO[A3FV[J-6R?;6/,8;859$<S#O!5ZHB;$H&#@"XV8N-F*&V8$A`8$B*)`0JH
MD))T4215147JB]%UUV[V4U>RGQA$FQW&?;QJJR?,HE=7VMD\U$K^_)-JF@IW
M2DODVT3<V4K4%KL)5*6\#/3N0D3L,\>HX.,4%+CE8CJ5U#50*>`C[IOO)$K8
MK42/[KSBDXZY[3(=[ADI&74B5555UK\^L9Z`>UOJ<Y7C._>";BV6P?*'"8,6
M%4;A5,4Y5=>QZMXIE0W>18S\.6W85TKI\A;Q)3<B.VO:X+X-LBVB;#HD)")"
M2$)(A"2*BH2*G5"%4\*BIY14\*GE/&L)?Q"&[N.;7^E[O[4VMG$CWNZD2EVO
MQ*H,P.PO+G,+B'5#&K8?<C\IUEM\I#GL@:M--D9)T147%-@7"7XIW9:DB;=8
M-SBXYYSA5&#$*COMP7/GLI"O:`6D&3(F8-8S91M@*$*S;*4ZJH@^Z@^-78\<
MO1/Y*[I[Z8+R:]6GEI,Y799MG:LY%M[LQ0P`I-G\9R.,J'$N)-3&:B0+:1"<
M028[:R&ADV/S7S`*0*B9R.&N)6>!<3>.&%W33C%MBVRVW-'8LO-JTZU,KL7K
M8S[;C9>0,7`)"%?*+X7SUU8QZ^/W/7/G]1=M_%Z?67EML&FP::`6VV@%MML$
M01``%!`!%/`B(HB"B>$1$1/&L27K-\4^77-SB)D/%[BQDNV.)1MV5D4.[5SN
M*[9M/)AHBQ)9A8ZM>Q(#YN9.9099R&E0&`%6E0E72)C$^#R^Z3<_:/W9_=\8
MUM,7-O`H*BTO+1\(M;3U\RSGR720&V(<%AR3(=,C5!$0:;,E(E1$1.JKTUJ1
M<`/2^];WTRM@F.._&_>?A[?8/(RJ[SB:F=U&6.V,*_R`(06#,:5#)L9$14@L
M^VIM-D*BJ]/K=$F3?'C%\29OAA>5X!(Y-\0,!Q_-:>=CMV6'45I\Z--:PGJ^
MSCQ)%O4V#K!R8K[J>\V8OM&J$PXV2(J(F?7B3RBP?F)LI1[Z[<UMU68AD5MD
M-94M7[++$Z2&/VTFI<GB##CH?*378Q/1"[NXV2$B1%+IK1^^+P.5@O/+TY]S
M;:&XF+P8LA\YZ$*,HM1G6./S6W'%7M9)MDE=1'5#N;`S'J(JNMT;T\.,%KPV
MX9[!<<,BN(60Y1ME@M=293?5PD$&XR/Z[UM81$<$7/9DRG3,"=3W"Z]35574
M&>JGZ5&PWJL;&Q=J-W'['&,DQ>>[=[>;BT+;"W>*W)LDT8J#X$,VIF"J!/@$
MH(Z'0VG&GA!P43(7MCEF/YUMWA&88I:P[O',CQ6BMZ>UKWVY,.=`FUL9^.^P
M\T1`8&V8JBHJ_P!OG5,\@=P<<VJV0W7W#RRWKZ2AQ'`,KNY]C:26HL1H(-)-
M?`#==,`[WW0!EIM%[G'7!`$4B1-:BNS/I._$4\%*8=IN'W/39W-=E:OWHN.5
M&[7S".T\!LT6$W71+3&\JD5K0-J0_)1+((;?55%I>H]MPU=Z.WJN\W+*FJ/5
M9Y[5]ML?6SH4V[V*V"A-4U1FK49YN0=7?WD.LH2E5SSC?:^U-@S2("5&29+H
M2(E[OPXU;:IZ;E'FEC&.-#W8WEWCW1Q]#9=8)W'\MRV1*KG_`&W@`T1Q&W%%
M4115.G15Z+K*WN=R<VZVHWIV(V)RA;`<RY#3,K@8)\NP)P#D8A5#<6@3GE5/
M:58A=641%4U0O'C4H;8;9X3LWM]B.UVW-!`QC!\&HH&.XU15K(,1*ZLKF!88
M:;;!$1241[W7%ZFZZ9N&JD2JN(KU=_33Y!\YKGC3NSQ>Y)IQUWHXMY)DN4X;
M8R*9RR@7<_(6*Z*3,R4S)9<A,M1X3T=X#8F1YD68^P_',"TB9E;?&<<OV/EK
MV@IKF/T)/8M*R%/:Z&G0T]N4RZ'UT\%X^LGA?&M$/XM?AGQZQB\X6;C[&X!C
M.(<C]R-Y(N"R*+`:.#53\KHE$9L.YE4]0TPDN;`N0C1FY8QT<-'R%QPBZ:S7
M8G4?$P8]!AXG:W/ITY9!CI\D]N)=.[B-97)8[/;2T>I:MJ!3K-3HCOR[8MM*
M?5%54^V3>-7I`Y99<E:7G#ZBF]0<J.2>*M=NV5!%IQI=HMFQ(D<3\C\:<=D#
M(LF'40VK>5T>5P0?5M'VP<%$R]\>:+(\8V'V<QS+Y#LO*:/;3"ZK(9+R*CS]
MS!Q^!'L'7$4C5#.2VXI=3)>J_:NIBU^(B(B(B=$3PB)K]TB----(C3332(TT
MTTB----(C3332(TTTTB----(C3332(TTTTB1[F.[&VNWUC25&;YOCF+6>2R1
MAX_!N[./`DW,LB[1BUK3Y@4N02_8RRAN*GGM4?.I``Q<$#!4(#%#`D^PA)$4
M53^Q45%3^S6%KU4H6/RN0/I@K;1JE]W_`!OH@*L]N(;GRZ8#E[HBJOHI>RDE
MMEQ$_,]X&U_/0=6Z<M>97-O#-_.>N([5;P;:8]AW$K8W"-],3I;';ENVGY$W
M<,>[/PVVGID3!-L"#+G6V8C^^).B*Q!0.JHFQEIK!INKRBY:Y_N%P&Q+9_=[
M;;:ZOY5;"VVX>8)8X(UEUE2Y!`V[BY:+M(3F05PO0WK"04$8[P"K"(CB..F*
MM+'&->H[R(>XI<79F76^%T^[&]/+3,.+>5[OA2M)B5"QAV69K0CE8XZ5DH0[
M3(6\48A0H,^>RV$^>3XJX`M`XB;"6FL#L;D9SKRS;?U%=L\&S7#[W>7B5DM;
M.VHW,B8>(4^>8\_B[.82<6N:@;%V+]/,P5D5[DF%-<ZR187VA(U#54<1^:6Y
MF]6W.Y?*RVW=JCXY;;[)TSMB[884Y%<8W@K:!^=N6$HX\MV8<+"[1MN`_`8C
MD<AYWL!SZJ]$3-UK@[W)\=QBHDW^17M31TD(FQEVUI/C0JZ,3KP1VQ?ER'`8
M:4WW&VA0C15<,1^U>FL$G!OG/R,WSY![G;0Y?F&/Y-B&3<9Z7>_:?)I&+U6,
MVD&9?2;>`*G15F17$Y<?D"S#G0(]RE7<-L]R/1A0Q-;==MMP=Z<;]&'<W</*
MMT=OMS;B@W$EE]$YSAXY)#:K1W?@U$^@NBL<H>E39;BRDFUDV23!UPQF@"&\
MVG5$39]9>:D--OL.-O,/-@ZR\T8N-.M."A`XV8*HF!BJ$)"JB0JBHJHNO9K!
MMS-Y:[Z\3-UN,^73<\J:KBON[M?>8?/^CL/9G2,=WNC8BMA@@-SF9W1:C*)R
M!`C0D81&IGR\9IPQ-53@-^^7_,S8"EX(;&6B0LJWSY1,9G.SC-JRGQNIBX_,
MQS'H]\SB5/$RG(Z7'6[)]VR:9:D3+IMY^+4S28C&;G:")GHU"=]R0V&QC-(V
MW>0;M8+49K*D-0VL>FY!`:GC,?5!9B2!5WVXLITB%&HTIQE]Q2%``NY.L6\'
MLPY(9QQYH+?E;CE%B^\C%SE%1<Q<=L:2Q@3JJKMI$6ANS/'K2ZJHDVTK!8E3
M($>RE?)R"-HCZITUK\;AXKO+PWP_?_=:5AW%;FMQOR3D?99S9V%S<SZ/DG4/
MWV3P(S].P](I;!BTG8E/::9I(,:V9?5IE&F6V^]=(FV(BH2(0JBBJ(J*BHJ*
MBIU145/"HJ>45/"IK@X>48W87EMC,"^J9F14341^ZHXUA&>M:IF<'NPG;"`V
MZ4F(W+;7OCF\V`O#Y!236(#;WE!R$Y2<@-]MNMJ]R\&V$K^->?[48[(V_P`V
MQAFVR7-<<R*EQ[)L@L)TAZVA/UH3JVQG4V/_`"D24'TA"1QUQ>\FPH7)^4.:
M\?\`?'U4<[?I\!SB[V.VBP3-\1#'<99HLGN67,727`I,ML(\ZPE7C=*\8MC)
M4(R!$:)/8:+JJHF=;36!_BGR:]07=&@S/<+-H^(5FU&5<5W]V,)SR<NWL\\2
MW/&J2U9KXV-XMG5Q/N,3.,ZH$=O]$2&9$<6GE;=,FQA'AYS_`.963YGZ>V2;
MQ[@[=9O@W-C`=SYEYA]'A:8W+P?(-O:D;&#+J;Q+F>5BEO[+HRX,B&PK+D@1
M9<,6T4D39.TUAKXL\E^17):HD\F*W=S;J+MQCV;[LT&4\<8V-`650*G`I=E7
M0J]O(RM/I!W+#>K@?DM/4[$4OF5;;-0$3.W;ASSIY\\F,HVNW@KL(Q=[8?-<
MFW2I]PZ&RMMOZK\@:K&7KB'C;U4XWF+^82KF+.K8Z7\.SQJ&?R\EQQ`:!L#)
M$V'=-:;O)'UC>96R%K41=P\UD;,VV17&>.UK`[%M;IX%D^-U&1I#QVRP'*\2
MRJ2$N-'J'H8W?TD$:5](26U%@![A1I$W(M---(C3332(TTTTB----(C3332(
MTTTTB:KWKY?I>^F!^ON!^[S=6:;Z?IT>LQ^Q'%_@@:::1/?M3^EMZ'O[*$G^
M7G-1?EOW8.]/^]/MO^.-CIII$SM>CG_J>YC?KQSC^!CJU_AK]Q1S(_\`5\P_
MYDR#332)A_\`AY/TUZ']E)K]W:U'U-]TMZGG[85-_.P:::1,\GJ*?=K>GY^O
M3BI_'J?7"_$:?ZO>"G[1U%_*]GIII$RE^E#^A1@G]\YE_&Y6M5%G_7WE7^\)
M<_G*OTTTB3[RA^_4SW^Y^+O\ZTVJ_P`+^\P];']GZZ_D63III$M9](#]&GD=
M^P!N/_,Y:\^&?^@WH)?[=;W?N4#332)(_IB_>=<D/VO]\/W=[5&>EE^FUN;^
<O[E/_+M[III$QA\]/\U;$?W?NG_/:Z:::1/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
